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RESUMEN 
Objetivo: El objetivo general de este trabajo de investigación es evaluar la 
asociación entre el uso de benzodiacepinas (BZD) y las fracturas de 
cadera/fémur, bajo un punto de vista metodológico, comparando los resultados 
obtenidos con diferentes diseños de estudios, y analizando la consistencia de los 
métodos empleados, como parte del proyecto Europeo PROTECT 
(http://www.imi-protect.eu/). 
Metodología: Utilizando la misma fuente de datos BIFAP, una base de datos 
nacional de atención primaria, se realizaron dos diseños tradicionales, un estudio 
de cohorte y un caso-control anidado (NCC) para investigar la posible asociación 
entre BZD y fármacos relacionados y fracturas de cadera/fémur. Los resultados 
de estos diseños se compararon entre ellos y también con los obtenidos en dos 
diseños más novedosos de sólo casos: un estudio de casos cruzados (CXO) y 
uno de series de casos auto-controlados (SCCS). 
La población en el estudio de cohorte estaba formada por pacientes de 18 años 
o más, con al menos un año de registro con el médico, que no habían usado 
BZD o fármacos relacionados en los seis meses previos a la entrada del estudio 
(1ª receta de BZD), considerándose así "nuevos" usuarios, y sin fractura de 
cadera/fémur en los 12 meses antes de entrar para asegurar casos "incidentes" 
durante el periodo de estudio: 1/01/2001-31/12/2009. Para el NCC, los casos 
seleccionados en el estudio de cohorte se emparejaron con un máximo de cuatro 
controles por sexo, edad y tiempo de seguimiento dentro del periodo de estudio 
usando un muestreo por densidad de incidencia. Para los diseños de sólo casos, 
la población se seleccionó de toda la base de datos. Se consideró que tenían el 
evento de interés aquellos pacientes con un registro de una nueva fractura de 
cadera/fémur identificada con el código CIAP-2, L75 durante el periodo de 
estudio. La exposición se midió por prescripciones de BZD o fármacos 
relacionados. El tiempo de seguimiento total de cada paciente se dividió según 
su estado de exposición en periodos de uso actual, uso reciente, uso pasado o 
no uso (periodo anterior a la 1ª receta de BZD en el periodo de estudio, para los 
diseños de sólo casos). Una extensa lista de potenciales confusores (co-
medicación, co-morbilidades y variables de estilos de vida) se fueron añadiendo 
20 
 
progresivamente a los modelos, primero se incluyó sólo la edad y finalmente 
todas las co-variables en un modelo completo. 
Para evaluar el riesgo de tener una fractura de cadera/fémur asociada con BZD 
o fármacos relacionados en el estudio de cohorte, se hizo un análisis de riesgos 
proporcionales de Cox actualizando las variables confusoras cada 182 días. En 
el NCC y en el CXO se hizo una regresión logística condicional, y finalmente, 
una regresión de Poisson condicional en el SCCS. En este último diseño se 
investigó la posible dependencia de la exposición con el evento, separando un 
periodo de 30 días previo a la exposición de la categoría de referencia. Todos los 
análisis se hicieron con Stata v11®. 
Resultados: El uso actual de BZD y fármacos relacionados se asoció en todos 
los diseños con la fractura de cadera/fémur, sin embargo los estudios 
tradicionales (cohorte y NCC) dieron estimadores de riesgo más bajos (HR=1.17, 
1.07-1.28 y OR= 1.19, 1.06-1.32) que los obtenidos con los diseños de sólo 
casos (ORCXO = 1.47, 1.29-1.67 e IRRSCCS= 1.64, 1.48-1.81, respectivamente). El 
riesgo en el SCCS se obtuvo cuando el periodo de pre-exposición fue separado 
de la categoría de referencia. El uso concomitante de ansiolíticos e hipnóticos, 
presentó el mayor riesgo de fractura en todos los diseños, (HR=1.21, 1.01-1.43; 
ORNCC=1.48, 1.20-1.84; ORCXO=3.03, 2.30-4.00; IRRSCCS=2.22, 1.75-2.82) 
comparado con el uso de ansiolíticos o hipnóticos por separado. Respecto a la 
duración de tratamiento con BZD, no se observó riesgo en el primer mes de 
tratamiento (HR=0.98, 0.83-1.15; ORNCC=1.03, 0.82-1.30; IRRSCCS=1.11, 0.96-
1.29). En el estudio de cohorte se vio que altas dosis de BZD estaban 
relacionadas con un mayor riesgo, pero no se observó diferencia en cuanto a la 
vida media. 
Conclusiones: El uso de BZD y fármacos relacionados aumenta 
moderadamente el riesgo de fracturas de cadera/fémur, esto fue un hallazgo 
constante en los cuatro diseños empleados. Los diseños de sólo casos dieron 
estimadores de riesgo mayores que los obtenidos en los diseños tradicionales, lo 
que se podría interpretar como un mejor control por factores de confusión que 
son difíciles de medir en los tradicionales. El riesgo de tener una fractura de 
cadera/fémur fue mayor cuando ansiolíticos e hipnóticos se tomaban 
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concomitantemente. No se observó una tendencia clara de riesgo asociado a la 
duración del tratamiento, en particular, no se encontró efecto al principio del 
tratamiento. El uso de BZD estaba condicionado a la fractura de cadera/fémur lo 
que puede suponer un sesgo importante en el diseño SCCS. Este sesgo puede 
ser corregido cuando el periodo de pre-exposición asociado con un aumento de 
riesgo se identifica y se separa del periodo de referencia. 
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ABSTRACT 
Objective: The general objective of this research is to assess the association 
between benzodiazepines (BZD) use and hip/femur fracture under a 
methodological point of view. The main goal is to compare findings obtained by 
different study designs, and evaluate the consistency of methods employed. This 
research is part of the European project PROTECT (http://www.imi-protect.eu/). 
Methodology: From the same data source BIFAP, a national primary care 
database, two traditional designs, a cohort and a nested case-control (NCC) 
studies were performed to investigate the potential association between BZD and 
related drugs with hip/femur fractures and results from those designs were 
compared between them and with the ones obtained from the novel case-only 
designs: a case crossover (CXO) and a self-controlled case series (SCCS). 
The cohort study population was comprised by patients aged 18 years or older, 
registered at least for 1 year with the GP, having 6 months free of exposure 
before the start date (1st BZD prescription) to be considered "new" users, and 
without a hip/femur fracture within 12 months before entry to ensure "incident" 
cases during the study period: 1/01/2001-31/12/2009. For the NCC, all cases 
selected in the cohort study were matched by sex, age and time of follow up 
within the study period up to four controls using a risk-set sampling method. For 
the case-only designs, population was selected from BIFAP. Patients with a 
recorded diagnosis of a new event of hip/femur fracture during the study period 
were considered to have the outcome of interest and it was searched using the 
ICPC-2, code L75. The exposure was measured with prescriptions of BZD or 
related drugs, and the total person-time of each person was divided according 
their exposure status into periods of current, recent, past or non use (period 
before first prescription within the study period for the case-only designs). An 
extensive list of potential confounders (co-medications, co-morbidities and life-
style factors) was employed, and they were added to the analytical models 
progressively, first only age was included and finally all covariates into a full 
model. To evaluate the risk of having a hip/femur fracture associated with BZD or 
related drugs, in the cohort study a time varying analysis was done every 182 
days, using Cox proportional hazard models. In the NCC and the CXO designs a 
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conditional logistic regression was employed to examine the risk of hip fracture 
with BZD. And finally, a conditional Poisson regression model was utilized in the 
SCCS. The potential dependence of the exposure with the event was explored in 
this design, separating a pre-exposure time of 30 days from the baseline. All 
analysis were done using Stata, v11®. 
Results: Current use of BZD or related drugs was associated in all designs with 
the outcome of interest however traditional studies (Cohort and NCC) yielded 
lower estimates (HR=1.17, 1.07-1.28 and OR= 1.19, 1.06-1.32) than those 
obtained with the case-only designs (ORCXO= 1.47, 1.29-1.67 and IRRSCCS= 1.64, 
1.48-1.81, respectively). The risk in the SCCS was obtained once the pre-
exposure period was excluded from the baseline or reference period. The 
concomitant use of anxiolytics and hypnotics showed the highest risk across all 
designs (HR=1.21, 1.01-1.43; ORNCC=1.48, 1.20-1.84; ORCXO=3.03, 2.30-4.00; 
IRRSCCS=2.22, 1.75-2.82), compared with the use of anxiolytic or hypnotic 
separately. Regarding duration of treatment with BZD, no risk was observed 
during the first month (HR=0.98, 0.83-1.15; ORNCC=1.03, 0.82-1.30; 
IRRSCCS=1.11, 0.96-1.29). In the cohort study high doses were associated with a 
higher risk, but no difference was observed according to the half-life of BZD and 
related drugs. 
Conclusions: The use of BZD and related drugs moderately increases the risk of 
hip/femur fractures and this was consistently found across the four analytical 
designs performed. Case-only designs yielded estimates higher than the 
obtained in the traditional designs, allegedly because of a better control for 
confounding factors that are difficult to measure in traditional designs. The risk of 
having a hip/femur fracture was higher when anxiolytics and hypnotics were 
taken concomitantly. No clear trend of risk was observed with duration of use, in 
particular, a short-term effect was not observed. The exposure was heavily 
dependent on the event and this may introduce an important bias in the SCCS 
design. Such bias may be corrected when the pre-exposure period associated 
with an increased risk is well characterized and excluded from the period used as 
the reference. 
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1. INTRODUCTION 
1.1 HIP FRACTURES 
Hip fractures represent a major public health challenge in developed 
countries, due to the increasing age of the population. In 2000, there were almost 
one million patients with an episode of hip fracture in the European Union, and it 
has been predicted that this figure will increase more than two-fold in the coming 
fifty years (1). 
The increasing trend of the incidence of hip fractures, along with associated 
morbidity complications, dependence and mortality (2, 3) make this condition a 
major public health concern. In addition, hospital resources for injury-related 
admissions are one of the major causes of total healthcare costs in Europe (4). 
The burden of hip fractures, in terms of disability and healthcare budget, is higher 
than for common cancers, such as breast or prostate, and myocardial infarction 
(5). Osteoporosis affects millions of patients worldwide, and hip fractures are 
considered the most serious outcome.  
1.1.1 Definition. Types of hip fractures 
A fracture is a break, which occurs when the continuity of bone tissues or 
bony cartilage is disrupted or broken. There are many different types of fractures 
which include: 
- Simple or Closed: A fracture that does not produce an open wound in the 
skin. 
- Compound or Open: A fracture in which there is an external wound 
leading to the break in the bone. 
- Comminuted: A fracture in which the bone is splintered or crushed. 
- Complete: A fracture in which the bone is entirely broken across. 
- Incomplete: A fracture that does not entirely destroy the continuity of the 
bone. 
- Depressed fracture: A fracture in which a fragment is depressed. 
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- Greenstick: A fracture in which one side of a bone is broken, the other 
being bent. 
The hip joint is formed by the acetabulum of the pelvis and the proximal femur. 
The joint is surrounded by a capsule which reaches the trochanteric line 
completely covering the head and the femoral neck.  The femoral head is 
attached to the rest of the femur by a short section of bone called the femoral 
neck. The bump on the outside of the femur just below the femoral neck is called 
the greater trochanter (6). See Figure 1 for anatomy of hip joint. 
 
Retrieved from http://www.eorthopod.com.-Orthogate- A patient’s guide to hip fracture 
Figure 1- Hip joint anatomy 
Hip fractures occur in the proximal (upper) portion of the femur, just outside 
the area where the femoral head (ball) meets the acetabulum (socket) within the 
pelvis, typically resulting from a fall or minor trauma in old people with 
osteoporotic bone. Those fractures may be caused by twisting the hip while 
weight bearing, trips, or a fall from standing height. The actual fall is often 
secondary to the fracture. Most hip/femur fractures in younger people are the 
result of high-energy trauma like road motor-vehicle collisions.  
The anatomical relationship with the capsule is important from the point of 
view of classification of hip fractures, thus two main types of hip fractures are: 
-Intracapsular fractures are those located in the femoral neck. 
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-Extracapsular fractures are located in the trochanteric and subtrochanteric 
hip regions. 
Capital fractures are rare, and located in the femoral head. This distinction is 
important because in intracapsular fractures, such as fractures of the femoral 
neck, vascularization may be interrupted causing risk of avascular necrosis and 
pseudoarthrosis. This is the most common hip fracture, which occurs primarily in 
the elderly and is often associated with osteoporosis. It is also important to know 
the degree of displacement, which is correlated with the risk of complications and 
determines the type of treatment performed. 
In the extracapsular fractures, the break line is placed outside of the hip joint 
capsule. There are three types depending on the affected area: transcervical, 
intertrochanteric and subtrochanteric fractures. See Figure 2. 
 
Retrieved from https://www.stjohnprovidence.org/ProvidenceOrthopedics/HipFracture/ 
Figure 2- Types of extracapsular hip fractures 
Here it is important to know whether or not they are stable, given that the 
degree of stability increases inversely with the degree of comminution. A fracture 
is stable provided the end of the fractured bone is in its correct anatomical 
alignment, in other words, the transmission line loads from calcar to the diaphysis 
femoral is kept (7). 
Introduction 
 
30 
 
Simple radiographs may confirm the diagnosis of a fracture, thus there is 
another classification according to their appearance on radiographs:  
1. Intracapsular fractures 
1.1) Pauwels classifies fractures according to the obliquity or angle of the 
fracture: 
I -   30 degrees from horizontal 
II - 50 degrees from horizontal 
III - 70 degrees from horizontal 
1.2) Garden classification is based on the radiographic appearance of the 
fracture: 
I -  Incomplete or impacted fracture 
II -  Complete fracture without displacement 
III -  Complete fracture with partial displacement 
IV -  Complete fracture with full displacement, continuity of 
 fragments is disrupted 
In view of the differences between different observers in classifying the same 
fracture it is preferable and more practical to sort intracapsular hip fractures into 
non displaced (Garden I and II) and displaced (Garden III and IV) (8). 
2. Extracapsular fractures 
2.1 Intertrochanteric fractures are those located between the base of the 
femoral neck and lesser trochanter. Also pertrochanteric fractures are those in 
which the fracture line is at intertrochanteric line level. There are many 
classifications, e.g. the one by Boyd & Griffin:  
1. Simple fracture that extends along the intertrochanteric line from the 
greater to the lesser trochanter. 
2. Comminuted fractures, the main fracture being along the 
intertrochanteric line, but with multiple fractures in the cortex. 
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3. Fractures that are basically subtrochanteric with at least one 
fracture passing across the proximal end of the shaft just distal to or at the 
lesser trochanter.  
4. Fractures of the trochanteric region and the proximal shaft, with 
fracture in at least two planes, one of which usually is the sagittal plane 
and may be difficult to see on routine anteroposterior radiographs. 
 
Or the Evans classification based on direction of fracture (9): 
Type I: Fracture line extends upwards and outwards from the lesser 
trochanter (stable). 
Type Ia: Undisplaced two-fragment fracture 
Type Ib: Displaced two-fragment fracture 
Type Ic: Three-fragment fracture without posterolateral support, 
owing to displacement of greater trochanter fragment 
Type Id: Three-fragment fracture without medial support, owing to 
displaced lesser trochanter or femoral arch fragment 
Type Ie: Four-fragment fracture without postero-lateral and medial 
support (combination of Type III and Type IV) 
Type II: Fracture line extends downwards and outwards from the lesser 
trochanter (reversed obliquity/unstable). These fractures are unstable 
and have a tendency to drift medially. 
2.2 Subtrochanteric fractures are located in the area around the lesser 
trochanter from its upper edge up to 5cm below it. The most commonly used 
classification is that of Fielding who divided them into three groups: 
I- Fracture at the level of the lesser trochanter 
II- Fracture within 2.5 cm of the lesser trochanter 
III- Fracture between 2.5 and 5 cm of the lesser trochanter 
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1.1.2 Management and treatment of hip/femur fractures 
Depending on the type of fracture, the management and treatment will vary, 
as well as the recovery time. Patients with a hip/femur fracture have the typical 
symptoms of any fracture. Besides pain and local tenderness, they often show 
external rotation and shortening of the affected limb. Hip/femur fractures in adults 
mostly require surgery depending on the location, type of fracture and mainly on 
the general condition of the patient, associated pathology etc. Thus, steps to 
follow in the management of a hip fracture are: 
1) Pain relief with analgesics and immobilization 
2) Stabilization of the associated pathology  
3) Surgical intervention 
4) Rehabilitation 
In general, Garden Stage I fractures are the only ones that may not require 
surgical fixation. With this fracture, the person is on bed rest for 3 weeks and 
should perform only mild hip and knee exercise. After 3 weeks sitting and crutch 
ambulation is allowed, but full weight bearing must be avoided for 8 weeks (10).  
In the intracapsular fractures, there is a risk that the blood supply may be 
interrupted, which is vital to the femoral neck, resulting in vascular necrosis. As 
consequence, death of bone tissue occurs, resulting in pain and limited mobility. 
Therefore, the treatment of choice tends to be the replacement of the head and 
neck of the femur. Surgically treated by hemiarthroplasty (replacing half of the 
joint) or total hip arthroplasty (replacement of the entire joint) (6). 
Extracapsular fractures retain sufficient irrigation and they are surgically 
treated by open reduction and internal fixation. For internal fixation of those 
fractures, screws, pins and plates are often used and failure of the fixation device 
and mal-union are the most common complications. Among them, 
subtrochanteric fractures are the least common and most unstable traumatic 
fractures, also the most difficult to treat because of the high mechanical stresses 
in this area of the femur. They are normally the result of direct trauma of 
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considerable force, and are the most frequent femoral fractures in the younger 
population (11). 
1.1.3 Epidemiology of hip fractures 
In general, hip fractures increase exponentially with age regardless of sex, the 
average age in which hip fractures occur being about 80 years, in industrialised 
countries (12). Overall 80% of hip fractures occur in women, partly explained by 
their superior longevity over men. Factors such as race and ethnicity also affect 
the incidence rates of hip fractures, being higher in white than black or Asian 
populations (13). Although it might be related to urbanisation, because higher hip 
fractures rates have been seen in non rural areas compared to rural. Other 
conditions such as seasonality and climate seem to play a role, since in winter 
and temperate climates more hip fractures have been observed, but mostly 
indoors, which probably is associated with vitamin D levels (14). 
Most hip fractures which occur in people over 65 are generally due to falls 
from their own height. These kind of fractures are considered "low-trauma" 
fractures, defined as those resulting from falls from standing height and less 
severe trauma, whereas hip/femur fractures in young people are often considered 
as "high-trauma" fractures, defined as those caused by motor vehicle crashes 
and falls from greater than standing height (15), where there is often involvement 
of other organs and systems, and are therefore not subject of this study. 
Commonly, falls are the precipitating factor in the loss of mobility and 
independence among the elderly. In the 4 months following a fracture, an 
increase of mortality ranging from 12% to 35% was observed, in comparison to 
subjects of the same age who had not suffered fractures. And only 50% of these 
patients achieve a functional level comparable to the one they had prior to the 
fracture (16). A systematic literature review showed that patients who 
experienced hip/femur fractures had a substantial excess risk of death compared 
with the general population, that risk was greater during the first year after the 
fracture, ranging from 8.4% to 36 % (17). It was also observed that mortality was 
higher among men than women, although they were younger at the time of the 
fracture. So the cumulative mortality during the first year after a hip/femur fracture 
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compared with the general population was 37% in men and 26% in women. In 
general, overall mortality risk increased with age and with co-medication, but was 
higher in men (18). 
1.1.4 Risk Factors 
As the population over 65 years are the most affected by these types of 
fractures, there are numerous intrinsic risk factors associated with age and some 
also related to gender. Among typical  problems of aging, it is worth mentioning 
visual and hearing impairment, loss of reflexes, loss of bone mass, urinary 
incontinence, mental deterioration, and a wide range of conditions that may 
contribute to a greater or lesser extent to the falls suffering by the elderly. There 
are some fixed risk factors associated with hip/femur fractures such as (1) the 
ones presented in Table 1. 
Table 1- Fixed risk factors associated with hip/femur fractures 
Age 
• Female gender 
• Family history 
• Previous fracture 
• Race/ethnicity 
• Menopause/hysterectomy 
• Long term glucocorticoid therapy 
• Rheumatoid arthritis 
• Primary/secondary hypogonadism in men 
 
These are, at the same time, risk factors for developing osteoporosis. It is well 
known that people with this condition have bones that are more porous and 
fragile, and the risk of fracture is greatly increased, the hip/femur fracture being 
the most serious consequence. Approximately 6 % of men and 21 % of women 
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aged 50–84 years have osteoporosis affecting 27.6 million men and women in 
the European Union (EU) in 2010 (19). 
In that sense, progress has been made recently in Europe, mainly in the 
measurement of bone mineral density (BMD), diagnosis of osteoporosis, 
assessment of risk fracture, interventions to reduce the risk of fractures and 
creation of practice guidelines. According to the World Health Organization 
(WHO) criteria, osteoporosis is defined as a BMD of 2.5 standard deviations or 
more below the average value for young healthy women (a T-score of -2.5). This 
measurement has provided a diagnosis threshold, as well as an indication for 
pharmacological treatment (19). The problem is that not all countries have the 
same facilities and this measure is not available everywhere. And more 
importantly, there are factors other than BMD that contribute to fracture risk. 
These independent risk factors can be used to support BMD test results, or used 
to predict fracture risk in the absence of BMD tests. Thus, a fracture risk 
assessment tool FRAX® has been developed for use in primary care settings to 
support the identification of those at risk for fracture and the selection of 
appropriate treatment. These factors include age, bone mineral density, body 
mass index, prior fragility fracture, over use of oral glucocorticoids, parental 
history of fracture, current smoking, alcohol intake and rheumatoid arthritis. 
Clinical practitioners simply enter an individual’s risk factors into the FRAX® tool. 
Please see in Figure 3 below an example of the questionnaire of this web-based 
tool, available at www.shef.ac.uk/FRAX. 
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Figure 3- FRAX tool questionnaire. 
Apart from Osteoporosis, a wide range of pathologies have been investigated 
for their possible association with hip/femur fractures, either because they directly 
affect bone metabolism, or because they somehow alter the balance and 
facilitate the falls in these elderly patients.  
Among those pathologies would highlight neurological diseases: Parkinson’s 
disease (20, 21), Alzheimer's (22), multiple sclerosis (23), epilepsy (24); 
cardiovascular diseases (stroke (25, 26)) ; metabolic diseases: diabetes mellitus 
(27), hyperthyroidism (28), respiratory diseases: chronic obstructive pulmonary 
disease (29, 30), musculoskeletal disorders (rheumatoid arthritis, arthrosis, 
chronic inflammations, etc.) (31), renal disorders (32), gastrointestinal disorders 
(inflammatory bowel disease, malabsorption) (33) and haematological diseases 
(anaemia) (34).  
Besides the aforementioned intrinsic factors, physiological and pathological 
ones, there are other extrinsic factors to evaluate presented in Table 2. 
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Table 2- Extrinsic risk factors associated with hip/femur fractures 
Toxic 
habits 
Dietary habits Environment Life-styles Therapies 
Alcohol Low calcium intake Climate conditions Lack of 
exercise Drugs 
Smoking Vitamin D deficiency Pavements, rugs, poor lighting Immobilization 
Herbal 
medicines 
Drug 
abuse Eating disorders 
Lack of handrails, 
unsafe stairs Sedentary life Interactions 
 
It is important to draw attention to the pharmacological factors, because there 
is a high prevalence of co-medication among the elderly. Furthermore, with some 
particular drugs, such as oral corticosteroids, it has been shown that a relevant 
fraction of hip fractures was attributable to that treatment (35). The truth is that 
there are copious risk factors associated with hip fractures, however the drug 
treatment received largely affect that risk. As consequence, the role of 
pharmacoepidemiology is crucial in this assessment.  
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1.2 PHARMACOEPIDEMIOLOGY 
While it is true that in recent decades the life expectancy in the population 
has increased considerably, so there is a significant increase in the consumption 
of drugs. Nowadays, there are many more pharmacological options than there 
were before, and that has allowed people to live longer. It is definitely a step 
forward to be able to treat and combat diseases that previously could not be 
fought, but at the same time it is a double-edged sword, since no drug is free 
from damage. Adverse drugs reactions (ADRs) increase each year, as well as 
the incidence of significant morbidity and even mortality due to them. Also, 
medication errors contribute significantly to this burden of disease. 
In a recent study about emergency hospitalizations for adverse drug events in 
older Americans (36), 265,802 emergency department visits for adverse drug 
events occurred annually from 2007 through 2009 among adults 65 years of age 
or older. An estimated 37.5% of those visits required hospitalization and nearly 
half of the hospitalizations were among adults 80 years of age or older. 
Besides, there is an additional problem, 40% of adults older than 65 years of 
age take in general between 5 and 9 drugs, and around 18% take more than 10 
drugs. Poly-pharmacy has been associated with an increased risk of having an 
ADR nearly by seven fold in elderly patients compare to young people (37).  
There is a close relation between aging, multiple pathology, high drug 
consumption and prolonged treatments. In Spain, 37% of all hospitalizations in 
2005 were patients older than 65 years, and demographics projections indicate 
that in 2020, chronic pathologies will represent more than 60% of diseases (38). 
Hospital admissions due to adverse drug reactions could be avoidable and 
preventable with a deep knowledge of drug safety profiles. As a result, the need 
for pharmacoepidemiology will increase exponentially in the near future 
worldwide. 
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1.2.1 Concept and importance 
Pharmacoepidemiology is defined as the study of the use of and effects of 
drugs in large numbers of people (39). It aims to describe, explain, control and 
predict the effects and uses of pharmacologic treatments in a defined time, space 
and population. It is a evolving discipline between clinical pharmacology and 
epidemiology (40). 
The field of pharmacoepidemiology is relatively new and concerns itself 
primarily with the study and quantification of adverse drug reactions (ADRs) and 
patterns of drug use in a population. According to the Spanish Royal Decree 
577/2013, of 26th July, regulating pharmacovigilance of medicinal products for 
human use, an adverse reaction is defined as “any noxious and unintended 
response to a medicinal product". 
Adverse drugs events (ADEs), in contrast, describe an injury resulting from 
administration of a drug, which might be temporarily associated but not 
necessarily causally related, this term implies that the relationship may be 
coincidental or that the event is not caused solely by the drug itself but rather 
may relate to the circumstances surrounding use of the drug (41). 
ADRs have been divided into type A and B reactions. Type A reactions are 
expected exaggerations of a drug’s known pharmacologic effects. Thus, they 
normally are dose-dependent, predictable, and preventable. Most type A 
reactions are identified prior to drug marketing and are listed in a product’s 
labeling. Type B reactions are idiosyncratic and tend to be unrelated to the known 
pharmacologic action of a drug. They usually are not related to dose, 
unpredictable and uncommon, and potentially are more serious than type A 
reactions. They may be due to what are known as hypersensitivity reactions or 
immunologic reactions. Type B reactions are the more difficult to predict or even 
detect, and represent a major focus of pharmacoepidemiological studies of ADRs 
(42). See Table 3. 
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Table 3- Summary of features of Adverse Drug Reactions: type A and B 
Type A Type B 
Dose dependent Not related to dose 
Predictable Unpredictable 
Preventable Idiosyncratic 
Identified prior drug marketing Uncommon 
Listed in the product label Unexpected and serious 
 
Similarly, according to the Spanish Royal Decree 577/2013 of 26th July, 
regulating pharmacovigilance of medicinal products for human use, 
Pharmacovigilance is defined as “public health activity aimed at identifying, 
quantifying, assessing, and preventing the risks associated with the use of 
marketed medicinal products." That usually includes a continuous monitoring for 
unexpected effects and other safety-related aspects of marketed drugs. Hence, 
the main importance of pharmacoepidemiology is as a tool of pharmacovigilance. 
Clinical trials are carried out before a drug reaches the market, however, 
among limitations of premarketing trials could be cited the following: 
- Limited duration, usually short studies 
- Limited sample size 
- Limited comparison groups, especially for new drugs 
- Narrow defined population, often not covering special groups as children, 
females with child bearing potential, persons with multiple diseases, or 
limited life expectancy. 
- Ethical issues  
Therefore, knowledge of drugs after approval is limited as it is not possible to 
detect all potential risks and benefits during premarketing studies. Those effects 
occurring after chronic use or with a long latency period are unlikely to be 
detected as well as those with a frequency of less than 1/1000 (43). To address 
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the limitations of pre-marketing studies, spontaneous reporting systems are in 
place as a requirement for post marketing surveillance in all member states from 
the European Union. However, to determine causation in case reports of adverse 
reactions can be problematic due to numerous issues such as lack of information 
about co-medications and co-morbidities of the patient. 
Hypotheses can be tested with pharmacoepidemiological studies, and permit 
a better assessment of the risk/benefit balance of marketed drugs, because only 
after a drug is used widely by the general population can some effects be 
observed. They are needed for evaluating drug safety and effectiveness in 
situations where it is either infeasible or unethical to assign patients randomly to 
active treatment or placebo (41). 
1.2.2 Drugs associated with hip/femur fractures 
An extensive list of drugs has been investigated in relation with their potential 
association with hip/femur fractures. Among them, some drugs have been 
considered to have a strong relationship with these types of fractures and so it 
has been confirmed in many publications, whereas other drug associations have 
shown discrepancies between different published results. 
It is not surprising to see that the most widely investigated drugs among 
people suffering from hip/femur fractures were those employed to treat common 
pathologies of the elderly, as a result, the following drugs have been studied for 
their potential association with hip fractures, some of them increasing the risk of 
fractures, some decreasing the risk and some without presenting any association 
with fractures: 
- Drugs affecting central nervous system: Antidepressants (44, 45); 
antipsychotics (46), although lithium was associated with a decreased 
risk of fractures (47); anti-Parkinson drugs (48); anticonvulsants(49); 
Benzodiazepines and related drugs (50-52) 
- Glucocorticoids by systemic route (inhaled corticosteroids (53) have 
been shown not to increase the risk); bronchodilators(54) 
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- Cardiovascular drugs: Antihypertensive drugs (55); diuretics (56), in 
general, do not cause falls and thiazides, in particular, may help 
prevent fractures, however loop diuretics may affect fracture risk (57); 
antiarrythmics (58) treatment with amiodarone may have an increased 
risk of fracture, whereas digoxin may reduce fracture risk; 
anticoagulants (59); statins (60) seem to be associated with reduced 
fracture risk despite controversial results. 
- Thiazolidinediones (61); other antidiabetic drugs such as metformin 
and sulphonylureas were associated with a significantly decreased risk 
of any fracture (62), however no change in fracture risk was associated 
with the use of insulin or other antidiabetic drugs. 
- Hormone replacement therapy (HRT) showed a decline of incidence of 
hip fractures (63); thyroid hormones (64); antithyroid drugs (65); 
disease-modifying anti-rheumatic drugs (DMARDs) (66); aromatase 
inhibitors (59). 
- Proton pump inhibitors, recently it was seen that there was no 
increased risk of fracture contrary to first published articles (67-69); 
sedating antihistamines (70). Their association with fractures is 
controversial. 
- Non-Steroidal Anti-Inflammatory drugs(NSAIDs) (71); morphine/opiates 
(72). 
- Treatments for osteoporosis which are associated with a reduced risk 
of fracture: biphosphonates, raloxifene, (73, 74) although recent results 
are controversial (75). Similarly, some articles about vitamin D and 
calcium supplements have recently shown that they do not prevent hip 
fractures (76, 77). (Summary in Table 4). 
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Table 4- Summary of drugs whose association with risk of hip/femur 
fractures has been studied. 
 
Increase risk  No change risk  Decrease risk  
Central Nervous 
System 
Antidepressants, 
antipsychotics, anti-Parkinson 
drugs, anticonvulsants, 
benzodiazepines and related 
drugs 
 
Lithium 
Corticoids Oral glucocorticoids, bronchodilators 
Inhaled 
glucocorticoids  
Cardiovascular 
drugs 
Antihypertensives, loop 
diuretics, antiarrythmics: 
amiodarone, anticoagulants 
Diuretics in 
general 
Thiazides, digoxin, 
statins 
Antidiabetics Thiazolidinediones Insulin and other 
antidiabetic drugs 
Metformin and 
sulphonylureas 
Hormones 
Thyroid hormones, antithyroid 
drugs, Disease-Modifying 
Anti-Rheumatic drugs 
(DMARDs), aromatase 
inhibitors 
 
Hormone 
Replacement 
Therapy (HRT) 
Analgesics 
Non-Steroidal Anti-
inflammatory drugs (NSAIDs), 
morphine, opiates   
Other Sedating antihistamines Proton Pump Inhibitors (PPIs)  
Treatment for 
Osteoporosis 
 
Vitamin D and 
Calcium 
supplements 
Biphosphonates, 
raloxifen, etc. 
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1.2.3 Plausible mechanisms of action 
There are two plausible mechanisms of action directly related with a fracture, 
either falls or bone mass loss. Some drugs have been related with the bone 
mineral density, reducing bone mass and therefore increasing the risk of 
fractures. Glucocorticoids are well known drugs causing osteoporotic fractures, 
but it is observed also in women treated with aromatase inhibitors for breast 
cancer, in men receiving anti-androgen therapy for prostate cancer, in 
postmenopausal women treated with high doses of thyroxine, and in men and 
women treated with thiazolinediones for type 2 diabetes mellitus. Bone loss with 
fractures also occurs in patients treated with drugs targeting the immune system, 
such as calcineurin inhibitors, antiretroviral drugs, selective inhibitors of serotonin 
reuptake, anticonvulsants, loop diuretics, heparin and oral anticoagulants (59). 
However, drugs affecting the central nervous system, sympathetic activity, 
vasomotor response, cardiac function, or volume regulation are thought to be 
more related to falls. 
With the pathology of hip/femur fracture, there is an added factor which is the 
effect of age, as they mainly occur in the elderly. This group of people have a 
reduced functional reserve, and their secondary homeostatic responses may be 
impaired (39). Thus, elderly subjects may show an increased sensitivity to the 
side effects of many drugs. For example, individuals with chronic liver or lung 
disease may exacerbate postural changes in blood pressure with 
antihypertensive drugs, diuretics, etc. being common, postural hypotension 
among them. Or they sometimes exhibit extreme sensitivity to drugs that depress 
central nervous system function, such as benzodiazepines and opiates. 
Variability in pharmacokinetics and pharmacodynamics will contribute to 
variability in drug response, hence in drug effect (78). 
Among all possible drugs associated with hip/femur fractures, 
benzodiazepines and related drugs were selected in this research for their 
potential relation with hip/femur fractures and because they are one of the most 
common treatments employed in the general population. 
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1.3 BENZODIAZEPINES AND RELATED DRUGS 
1.3.1 Chemical characteristics 
Benzodiazepines (BZD) are composed of a benzene ring fused to a seven-
member 1,4 diazepine ring. Most contain a 5-aryl substituent ring. They differ in 
the chemical nature of the substituent groups at positions 1, 2, 3, 4 of the 
diazepine ring, position 7 of the benzene ring, and position 2 of the 5-aryl 
substituent ring (79). See the structure in Figure 4. 
 
Retrieved from Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 10th Edition 
Figure 4- The structure of the benzodiazepines 
A large number of non-benzodiazepine synthesized compounds compete for 
binding at specific sites in the central nervous system (CNS). These include 
pyrazolopyrimidines (e.g. zaleplon), imidazopyridines (e.g. zolpidem), 
cyclopyrrolones (e.g. zopiclone) and thiazoles (e.g. clomethiazole) among others. 
Although these compounds do not have the same chemical structure as 
benzodiazepines, their therapeutic actions are similar due to their agonist effects 
on the benzodiazepine receptor, and therefore they have been included in this 
research. 
1.3.2 Pharmacological properties. Mechanism of action 
All effects of the BZD result from actions of these drugs on the CNS. The main 
effects are sedation, hypnosis, decreased anxiety, muscle relaxation, 
anterograde amnesia and anticonvulsant activity.  All of the BZD have very 
Introduction 
 
46 
 
similar pharmacological profiles, but drugs differ in selectivity and clinical 
usefulness varies considerably. 
BZD are believed to exert most of their effects by interacting with inhibitory 
neurotransmitter receptors directly activated by γ-aminobutiric acid (GABA). 
These receptors are membrane-bound proteins that can be divided into two 
major subtypes: GABAA and GABAB receptors. BZD act only at the ionotropic 
GABAA, binding directly to a specific site that is distinct from that of GABA binding 
on the receptor chloride channel complex. BZD do not activate GABAA receptors, 
only modulate the effects of GABA. BZD-receptor ligands can act as agonists, 
antagonists or inverse agonists at the BZD receptor site, depending on the 
compound. Agonists will increase the amount of chloride current generated by 
GABAA-receptor activation, whereas inverse agonists will decrease it. And both 
effects can be blocked by antagonists such as flumazenil, which is used clinically 
to reverse the effects of high doses of BZD (79). 
Each GABAA receptor is believed to consist of homologous subunits, most of 
them are composed for: α, β, and γ subunits, and the subtype of each one (α1, α2, 
α3, β1, γ1, etc.) determines BZD pharmacology. Consequently, GABAA-receptor 
subunits are responsible for particular effects of BZD, as McKernan’s study 
revealed that the α1 subtype mediated the sedative, but not the anxiolytic effects 
of BZD (80). 
In addition to their action on the central nervous system, BZD have a dose-
dependent ventilatory depressant effect and they also cause a modest reduction 
in arterial blood pressure and an increase in heart rate as a result of a decrease 
of systemic vascular resistance (81). See GABAA-receptor structure in Figure 5. 
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Retrieved from http://en.wikipedia.org/wiki/File:NAchR_2BG9.png 
Figure 5- Structure of GABAA receptor 
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1.3.3 Pharmacokinetic features 
Most of the BZD are not adequate for administration by intramuscular route 
because it is painful and irregular plasmatic levels are reached, though 
midazolam is an exception. Some can be administrated by intravenous route 
under emergency situations, e.g. diazepam and midazolam, but the usual route 
of administration for BZD is oral. They are well absorbed taking from 30 to 240 
minutes according to the active ingredient. All BZD are completely absorbed, with 
the exception of clorazepate which is first decarboxylated in gastric juice and then 
absorbed. Some reach the systemic circulation only in the form of active 
metabolites (e.g. flurazepam). BZD and their active metabolites bind to plasma 
proteins, in varying degrees depending of their lipid solubility, ranging from 70% 
(alprazolam) to 99% (diazepam) (79). 
Accordingly, there is a rapid uptake of BZD into the brain and other highly 
perfused organs, followed by redistribution into tissues less well perfused such as 
muscle and fat. Concentration in the cerebrospinal fluid is similar to the 
concentration of free drug in plasma. They cross the placental barrier and are 
secreted into breast milk. 
Most BZD are metabolized extensively by enzymes in the cytochrome P450 
family, particularly CYP3A4 and CYP2C19, so drugs that act as inhibitors of 
those enzymes may affect the metabolism of BZD. In general their metabolism 
occurs in three stages: 
1- N-desalkylation: Modification and/or removal of the substituent at 
position 1 (or 2) of the diazepine ring. 
2- Hydroxylation at position 3 giving 3-hydroxyl active compounds. 
3- Conjugation with glucuronic acid, or glucuronidation, giving inactive 
products. 
The α-hydroxylated products (e.g. α-hydroxyalprazolam, α-hydroxytriazolam) 
are very active but are metabolized very rapidly by conjugation and no present 
accumulation of active metabolites (79). 
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Based on their elimination half-lives, which is the time taken for half of the 
dose of BZD to be eliminated or metabolised, the BZD may be divided into three 
categories: Short-acting <6 hours (e.g. midazolam, zolpidem, zoplicone); 
Intermediate acting from 6 to 24 hours (e.g. lorazepam, bromazepam); and Long-
acting >24 hours (e.g. flurazepam, diazepam) (82). 
1.3.4 Adverse effects and Interactions.  
Relatively common side effects of BZD are weakness, headache, blurred 
vision, vertigo, nausea and vomiting, epigastric distress, and diarrhoea; joint 
pains, chest pains, allergic reactions and incontinence may occur in some 
patients. Also, they may cause paradoxical or disinhibition effects although they 
are rare and dose-related.  
Chronic use poses a risk for development of dependence and abuse, and the 
use of high doses over prolonged periods can lead to more severe symptoms 
after discontinuing the drug, including agitation, depression, panic, paranoia, 
myalgia, muscle twitches and even convulsions and delirium (79). 
Main interactions are of pharmacodynamic nature when other depressors of 
CNS are administrated jointly. The interaction with ethanol may be especially 
serious, as it increases both the rate of absorption of BZD and the associated 
CNS depression. Antihistaminic sedative drugs, analgesics with sedatives, 
opiates or anaesthetics are other examples of this interaction. Also it has been 
described that BZD in combination with valproate may cause psychotic episodes.  
Pharmacokinetic interactions are of less magnitude than with other 
psycothropic drugs. Cimetidine, oral contraceptives, erythromycin, fluvoxamine, 
fluoxetine, dextropropoxyphene, ketoconazole, and ritonavir inhibit the 
metabolism of those BZD metabolised by the CYP3A4 increasing their plasmatic 
levels. These interactions may be significant in the elderly and patients with 
chronic liver disease (83). Lorazepam, lormetazepam and oxazepam are only 
conjugated and present a lesser range of interactions. 
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BZDs should be used with caution in patients with chronic obstructive 
pulmonary disease (COPD), or obstructive sleep apnea since they may 
compromise breathing. Similarly, patients with hepatic insufficiency the half-life of 
some BZD may be prolonged, and in general the intensity and incidence of CNS 
toxicity increase with age (82). 
1.3.5 Epidemiology of BZD and related drugs use 
The BZD and related drugs use varies between countries as different patterns 
of prescription exist worldwide, however, a higher use in women than in men has 
been observed as well as an increase of use with age (84-86). 
During the last decade the use of BZD and related drugs has increased in 
different parts of the world, exhibiting a rising trend of use. An example is the 
United States (87) where a high prevalence and increasing trend of BZD use was 
observed (41.8% in 2004 to 48.8% in 2009). In Europe, that trend was 
remarkably observed in Spain, where the use of anxiolytic and hypnotic drugs 
rose from 56.7 Defined Daily Doses (DDD) per 1,000 inhabitants per day in 2000 
to 89.3 in 2012, representing an increase of 57.4% (88). 
In contrast, certain European countries with a high prevalence of the use of 
BZD and related drugs now show a decline in its consumption due to regulatory 
actions that have been implemented. This is the case in France (89) and 
Denmark (90) whereas other countries, such as the Netherlands (NL), present a 
fairly stable use of these drugs (91). 
Regarding which BZD and related drugs are the most employed, again it 
depends on the country, but it could be said that those with short and 
intermediate half-life (<24h) are more used than those with long half-life (>24h) 
(92). Similarly, the use of anxiolytics or hypnotics as classified by Anatomical 
Therapeutic Chemical (ATC) classification system (N05B or N05C respectively) 
seems to follow a tendency, being the Mediterranean countries where 
consumption of anxiolytics is higher (93) (Figure 6). 
  
  
 
Retrieved from: Vicente Sanchez MP et al, Trends of use of anxiolytics and hypnotics in 
Spain from 2000 to 2011. Rev Esp Salud Publica 2013 May
Figure 6- Consumption of anxiolytic
different European countries in 2010.
1.4 ELECTRONIC HEALTHCARE 
The use of computerized 
developments in the field of pharmacoepidemiology, allowing efficient an
responses in line with the required timeframe in pharmacovigilance to make 
decisions. 
1.4.1 General characteristics
Healthcare records databases
well defined structure and purpose
administrative information
or claims, for clinical services and therapies
of health services, managed by
These databases include information at patient
prescriptions, specialist 
diagnoses, operations, ambulatory care, etc.
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There are many types of databases, such as disease registries, laboratory 
databases, census deaths, etc. But that information would need to be linked to 
drug exposure and diagnosis data to be useful for pharmacoepidemiological 
research. Hence, two main types of databases are contemplated, electronic 
medical records and record linkage of administrative health records (96). Medical 
record databases are generated from the electronic clinical records kept by 
medical practices. Usually general practitioners (GPs) enter information from the 
patient such as past medical history, smoking history, out-patient conditions 
diagnosed by the general practitioner, and procedures performed by the GP. 
Information on prescribed drugs is to generate prescriptions, not represent drugs 
dispensed. They may also enter conditions diagnosed by outpatient specialists or 
information from referral reports or hospital discharge letters. Some databases 
include laboratory results, and they may also record alcohol use and body mass 
index, although this is missing in many cases (97). 
Record linkage databases link patient's information that is stored separately. 
They are used mostly for payment, accounting, and fiscal functions related to 
healthcare services. Providers of those health services such as pharmacies, 
physicians, hospitals, and laboratories submit information about patients to be 
paid for their services. As a result, out-patient visits or hospitalizations include 
diagnoses data and pharmacy services contain details of drugs dispensed.  
In medical records databases, data are normally entered by the GP or primary 
care physician so drugs prescribed by specialists may be incomplete, whereas in 
record linkage databases, all drugs prescribed by any physician are recorded, as 
long as it is dispensed by a pharmacy that presents the bill to the administrative 
system (97). 
The main advantages of automated databases, in general, are the following 
(94): 
- Investigators have rapid and easy access to inpatient and outpatient or 
primary care records. 
- They usually cover large populations enough to detect an adverse effect 
that occurs with a very low incidence, e.g. rare events. 
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- They allow studies to be performed relatively quickly and cheaply since 
data have already been collected. 
- They may provide time trends, because information from several years is 
available. 
- Information is collected from routine clinical practice, so evaluation of 
drugs is within common conditions of use. 
- It is possible to analyze special populations at risk such as pregnant 
women, children, the elderly, diabetic patients, etc. who may be excluded 
from randomised trials. 
Similarly, the main disadvantages of automated databases, in general, are the 
following: 
- Incomplete data, information on potential confounding variables may not 
be collected (e.g. exercise, diet). 
- Private sector consultations can be missed. 
- The level of detail is limited because they were created for other purposes. 
Nowadays, electronic healthcare records databases are progressing 
considerably, and tend to obtain a full coverage of health data at patient level 
through data linkage with other databases such as death registries; census; 
disease registries; hospital; pharmacy; and laboratory databases. They aim to 
provide the most complete picture of a patient’s clinical profile, with the whole 
medical history and life styles collected for each individual registered, to achieve 
high quality pharmacoepidemiological studies. 
Some countries (Denmark, Sweden and Finland) have a unique personal 
identifier that is used in many different registers and this allows many registers to 
be linked. However in other countries some concerns exist about data 
confidentiality, therefore the quality and availability of these kinds of data is 
related to the specific type of health system in each country. 
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1.4.2 BIFAP Database 
In a country like Spain, with a public health system, the GP in primary care is 
the gateway to the national health services. They have information at individual 
level such as clinical history, diagnoses, operations, treatments and general 
health problems. Besides, most of the prescriptions from the National Health 
System are written by GPs. As a consequence, information managed in primary 
care contains all key elements for pharmacoepidemiological research: symptoms; 
diagnoses; exploratory data; demographic data; laboratory results; surgical 
procedures; and treatments prescribed. 
1.4.2.1 Definition, Rationale and Objectives 
In 2000, the Spanish Agency of Medicines and Medical Devices (AEMPS) in 
collaboration with the Spanish Centre for Pharmacoepidemiological Research 
(CEIFE) began the development of a national primary care database for 
pharmacoepidemiological research, called “Base de datos para la Investigación 
Farmacoepidemiológica en Atención Primaria” BIFAP. It might be defined as a 
public database with anonymised clinical information provided by primary care 
physicians of the Spanish National Health System (NHS). 
The idea of creating a national database for pharmacoepidemiological 
research was very interesting in order to contribute to the international effort in 
the assessing of drug safety. Also, information from foreign data sources can be 
of limited validity, since drugs marketed and their conditions of use may differ 
across countries. The effects of drugs might also vary according to genetic, 
environmental and sociological factors, so it would depend on the population 
involved (98). 
The main objective was to create an efficient data source to perform 
pharmacoepidemiological investigations in Spain and to detect and analyze 
signals raised by the Spanish Pharmacovigilance System. Thus, drug safety 
studies to test hypotheses of causal associations or to confirm signals detected in 
pharmacovigilance systems together with drug effectiveness studies (efficacy 
under normal conditions of use) were the intention for this database. 
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1.4.2.2 Coverage, structure and data collected 
At 2009, BIFAP included information of more than 3.5 million of patients, 
covering 6.9% of the Spanish population. From those, 3,180,161 patients 
contained valid information to participate in research studies, with a time of follow 
up in the database of 11,526,376 person-years. That database (2009) was 
employed for this doctoral research. 
Currently, BIFAP includes information of 4,187,465 million patients, covering 
8.6% of the Spanish population. Those data are provided voluntarily by 2,235 
primary care physicians (1,959 GPs and 276 paediatricians) of the NHS, with the 
collaboration of ten Autonomous Communities. From those, 3,963,538 patients 
contain valid information to participate in research studies, with a time of follow 
up in the database of 19,976,344 person-years. The population in BIFAP 
database is representative of the Spanish population and reflects a similar 
distribution of age and sex to the general population. Figure 7 below is from 
www.bifap.org the Spanish website; it shows general population data from the 
National Statistics Institute (INE) compared to the registered population in BIFAP, 
in the year 2011, regarding age and sex distribution. 
 
Figure 7- Comparative of the Spanish and BIFAP populations in 2011 
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The information contained in BIFAP is the following (98):  
1. Administrative data (admission/discharge dates) and demographics (sex 
and date of birth) 
2. Morbidity events: 
• Diseases/symptoms leading to patient consultation. 
• Starting date of first diagnosis of chronic and recurrent illnesses. 
• Significant results of complementary tests. 
• Events or disorders giving rise to admission, referral to the 
Emergency Service or to a specialist, and essential data derived 
from the latter (new diagnoses, interventions, results of specialized 
tests, etc.) 
3. Prescriptions: drug, quantity, dosage, date and instructions for use. 
4. Pregnancy and its outcome 
5. Deaths  
6. Other data of clinical or epidemiological interest (vaccinations, height, 
weight, smoking, alcohol abuse) 
Each healthcare practice participant has a software named OMI-AP 
(Organización y Management Informático - Atención Primaria) that allows 
diagnoses introduced by GPs to be linked to a given ICPC code. In addition, the 
physician can modify in real time the literal string offered by the OMI-AP software 
to better describe the disease of interest. In BIFAP, all literals with a frequency of 
more than 50 entries in the diagnosis table are included in "BIFAP thesaurus" as 
a extra level of granularity in the taxonomy by adding a fourth digit to the linked 
ICPC code (hereinafter ICPC BIFAP code). These codes represent about 90% of 
the total number of diagnoses included in BIFAP database. Those codes with a 
number "0" added to the ICPC code are diagnoses that did not meet previous 
criteria to be included in BIFAP thesaurus, giving a heterogeneous list of 
diagnoses which are expected to be correctly linked to the ICPC. To optimize this 
assignation, additional computational rules automatically redirect literals to the 
proper ICPC BIFAP code even in the case that this literal is originally linked to 
other ICPC code in the OMI-AP source. In addition to the table containing 
diagnosis, as commented before, free text GP notes linked to the episode 
(diagnosis) are stored in a different table (GP free-text comments table).  
  
Data are periodically exported (twice a year) to the 
(DPC) located in the Spanish Medicines Agency
process does not include any 
addition, a high level of encrypting is performed at origin. Once data are at the 
AEMPS they are processed for a second dissociation of personal data. In this 
step, also physicians and healthcare practices identifica
the researcher has no access to the identification data of patient, GP or 
healthcare practice. The BIFAP Unit however, may identify the GP and 
healthcare practice but not the patient.
patient, therefore, all data are completely anonymised (Figure 
Retrieved from Salvador Rosa, A. et al with permission.
Figure 8- Information flow in the BIFAP database: dissociation procedure.
data processing centre 
 (AEMPS). The exportation 
personal data that could identify patients
tion is dissociated, so that 
 A random code is assigned to each 
8).
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1.4.2.3 Quality Standards and Validation studies 
Data in the DPC are subject to automated controls to verify information 
received. From a qualitative and quantitative point of view, mean values of data 
received and population indicators are taken as reference, among other 
systematic quality controls in place to reach an up-to-standard level. Once that 
level is achieved a patient is considered valid for investigating purposes.  
A scientific committee with representation by the principal scientific societies 
in the field of primary care, including GPs, primary care paediatricians, specialists 
in bioethics, specialists in primary care computerization and 
pharmacoepidemiologists, supervise the activities carried out, provide counselling 
on specific aspects, contribute suggestions, and ensure adhesion to legislation 
and to current recommendations in matters of data protection (98). 
Several validation studies were performed within BIFAP database, with 
positive results (www.bifap.org). Some of them comprised correlation of the 
BIFAP registries with anonymous copies of clinical reports to ensure existing 
health records. Another type of validation involved a selected sample of patients 
by disease or medication code, verifying a concordance of diagnoses and 
prescribed drugs. For both methods a concordance of over 90% was needed to 
be considered adequate. Finally, another way to validate diagnoses collected in 
BIFAP is through revision of the patient’s clinical profile, including free text that 
GPs may add and confirming criteria used to assign a particular code or 
diagnosis. 
Moreover, study results obtained within the BIFAP database have been 
compared with gold standards, national statistics surveys, scientific publications, 
disease registries, and so on, giving perfectly comparable results. Thus, results 
from this database may well be compared with other data sources and with other 
databases from other countries, as it has been shown in different international 
studies where BIFAP took part. By all the above, BIFAP is considered as a valid 
tool for pharmacoepidemiological research. 
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1.4.3 Other databases  
The first databases employed for pharmacoepidemiological purposes were 
health maintenance organizations such as Group Health Cooperative of Puget 
Sound (1945) that covers part of the population of the state of Washington; 
universal care systems as Saskatchewan (1962) from Canada; or federal state 
programs like Medicaid (1965) which is a joint federal state program for financing 
medical care for qualifying poor persons in the United States (99). 
Then appeared databases where health information was collected by the 
primary care physician, especially in countries with public health systems. Thus, 
in 1987 a British automated healthcare database was created with the aim of 
generating useful clinical data for research purposes, named General Practice 
Research Database (GPRD). It comprises computerized medical records of GPs, 
and contains data from over 600 practices based throughout the United Kingdom, 
providing information on 12.5 million patients, of which 5 million are currently 
active. Data covers 8% of the British population. Recently it has changed the 
name, being now the Clinical Practice Research Datalink (CPRD) defined as the 
new English NHS observational data and interventional research service, jointly 
funded by the NHS National Institute for Health Research (NIHR) and the 
Medicines and Healthcare products Regulatory Agency (MHRA) (100). Data 
recorded in the CPRD include demographic information, prescription details, 
clinical events, preventive care provided, specialist referrals, laboratory results, 
hospital admissions and death. Validity of a wide range of drug exposure data is 
routinely tested. Furthermore, validation studies are conducted regularly by 
comparing CPRD data to written notes of general practitioners. Recent additions 
to the database include external record linkage to other national health services 
datasets, such as the national Hospital Episode Statistics (with extended data on 
all hospitalisations) and Death Certificates, increased availability of free text 
information via a new automated system, the possibility of genetic linkage 
studies, prospective data collections such as questionnaires, copies of patient–
based correspondence, the conduct of multi-country studies, and performing 
randomization studies within the database. 
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Similarly, sharing characteristics and content, another British healthcare 
records database is The Health Improvement Network (THIN) (101). It is 
collaboration between two companies, In Practice Systems Ltd. (INPS), 
developer of Vision software used by GPs in the United Kingdom (UK), and 
Cegedim Strategic Data: CSD Medical Research UK (formerly known as EPIC), 
provider of access to data for use in medical research. Data are collected during 
routine practice and regularly delivered to THIN database. THIN data collection 
prospectively started in 2003 – although all prior computerised data were 
extracted from each practice since they started medical record computerisation). 
It currently contains electronic medical records of almost 8 million patients (more 
than 3 million active patients) collected from over 386 general practices in the 
UK, some of them overlap with the ones employed by GPRD. THIN database 
consequently covers more than 5.7% of the population in the UK. Patient data 
are arranged in four standardised (Patient, Medical, Therapy and Additional 
Health Data and one linked (postcode variable indicators) files per practice. 
Further information is possible to obtain via the Additional Information Service 
(AIS) including: questionnaires completed anonymously by the patient or GP, 
copies of patient-based correspondence, a specified intervention (e.g. a 
laboratory test to confirm diagnosis) and death certificates. 
In the Netherlands (NL) there are other healthcare records databases that 
have been used for pharmacoepidemiological research, such as Mondriaan 
databases. The Dutch Mondriaan project is a private-public collaboration funded 
by the Dutch TOP Institute Pharma (102). Under the umbrella of Mondriaan, the 
participating databases currently include: the Netherlands Primary Care 
Research database (NPCRD), The Almere Health Care (AHC) database, The 
General Practitioners of Utrecht (HNU) database and The Leidsche Rijn Julius 
Health Centre (LRJG) database. The cumulative number of persons having data 
in Mondriaan reached around 1.4 million comprising mainly of GP data 
complemented by pharmacy dispensing data and linkages to survey data. The 
four databases within Mondriaan have different starting dates and scope of data. 
NPCRD is the Netherlands Information Network of General Practice and it holds 
a longitudinal data on morbidity, prescription, and referrals. The GPs record data 
on all patient contacts, including diagnoses, referrals and prescriptions. The AHC 
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is a GP and pharmacy database. The HNU is a GP database set up in 1995 and 
includes data dating till the end of 2005. The LRJG is a GP database with a 
linkage to additional survey records. Survey information is periodically up-dated 
through follow-up, including information on a wide range of health and lifestyle 
related variables. 
In the same way, The IPCI project (Integrated Primary Care Information) 
initially aimed to assess whether the electronic patient records of Dutch general 
practitioners contain sufficient data to perform studies in the area of post 
marketing surveillance. Due to the collection of data on the indication of therapy 
and the detailed information on measurements, contacts, referrals and exams, 
the usage of data has been extended to clinical epidemiology (incidence and 
natural history of disease) (103). 
As record linkage databases, a noteworthy other Dutch database broadly 
used: PHARMO Database Network, which compiles information from many 
databases to get global patient-level information as complete as possible. Among 
databases employed are: GP database, In and Out patient pharmacy, 
hospitalisations, mortality register, clinical laboratory, etc. In 1993, the PHARMO 
record linkage systems was established as an updateable working system 
covering a population of approximately 300,000 inhabitants. In 1999, the 
PHARMO Institute was established and first pharmacoepidemiological studies 
were performed. Since then, more than 750 scientific studies have been 
performed (104). 
The Danish national registries (105-107) maintained by the National Institute 
for Health Data and Disease Control (SSI), contain information on all hospital 
contacts since 1995, medication dispensing on a pharmacy level linked to 
individuals who redeemed the prescription from 1994 onwards, causes of death 
for the entire population and contact information of visits to GPs as well as 
specialist in private care. Likewise the Tayside Medicines Monitoring Unit 
(MEMO) is a validated record linkage database, community-based representing 
all socioeconomic groups. Its longitudinal data of dispensed prescribing and 
health outcomes over a 15-year period gives the capabilities for a variety of 
population-based research(108). 
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In general, the use of e-healthcare records databases is increasing nowadays 
for pharmacoepidemiology research, and it tends to improve day by day. 
 
  
 
JUSTIFICATION 
 
  
 
 
Justification 
 
65 
 
2. JUSTIFICATION 
The global aging population, especially in developed countries, is a matter of 
concern among health authorities. It has been estimated that the number of 
yearly hip fractures only in the EU, is expected to be more than double over the 
next 50 years (1). 
In recent years there have been an increasing number of studies describing 
that the secular trends in the incidence of hip fractures have levelled off (109-
111), or started to decline, since the late nineties (112) in some European 
countries. Allegedly this would be the result of the effectiveness of national 
campaigns to prevent both osteoporosis and falls (113). A call to update the data 
for as many countries as possible has been made (114) in order to check 
whether this favourable trend is consistent. 
Moreover, BZD and related drugs are one of the most commonly prescribed 
drugs worldwide, especially to the elderly. Their use represents a public health 
problem due to inappropriate use and dependence. Knowledge of their 
prevalence of use can be employed to guide research initiatives, intervention 
programs, and policy decisions. Globally, during the last decade the prevalence 
of use of BZD and related drugs was quite high and some policies were 
implemented to try to diminish their use (115, 116). An update of current situation 
of use of BZD and related drugs is needed and a comparison with other 
European countries is desirable. 
The association between risk of hip fractures and use of BZD has been 
investigated by several epidemiological studies (51, 117-119) but there are still 
some controversial issues. For instance, Cumming et al after reviewing eleven 
epidemiological studies found that results were not consistent: four case-control 
hospital-based studies and one study from nursing homes did not show an 
association between increased hip fracture risk and BZD use, whereas the 
remaining six found an association (50). 
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The reasons for the inconsistencies found may, in part, be explained by the 
diverse methodological approaches, mainly different designs; operative 
definitions of outcome, exposure, confounders and analytical strategies. 
Therefore, investigating the association of hip fracture with the use of BZD and 
related drugs, from the perspective of four different designs (cohort study, nested 
case-control study, case crossover and self-controlled case series) within the 
same database population, would allow evaluation of the consistencies and 
discrepancies that may arise attributable to study design. 
This research is part of the European project PROTECT 
(Pharmacoepidemiological Research on Outcomes of Therapeutics by a 
European Consortium) (http://www.imi-protect.eu/), work package two (WP2) 
which aims to define methodological standards for the design and analysis of 
pharmacoepidemiological studies using electronic healthcare records databases 
to allow more comparability. 
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3. HYPOTHESIS 
3.1 MAIN HYPOTHESIS: 
There is an association between the use of BZD and related drugs and the 
risk to develop a hip/femur fracture but the design chosen has an impact on the 
results obtained. 
3.2 SECONDARY HYPOTHESES: 
- The use prevalence of BZD and related drugs in Spain is high and has 
increased over time, while in other European countries the pattern is 
different. 
- There is a decreasing trend of hip/femur fractures in Spain and other 
European countries during the last decade. 
 
 
  
 
 
 
 
  
 
 
 
OBJECTIVES 
  
 
 
 
Objectives 
 
73 
4. OBJECTIVES 
4.1 GENERAL OBJECTIVE 
The primary general objective of this research is to assess the association 
between BZD use and hip/femur fracture under a methodological point of view. 
The main goal is to compare findings obtained by different study designs, and 
evaluate the consistency of methods employed. Hence, from the same data 
source BIFAP, two traditional designs, a cohort and a nested case-control (NCC) 
studies were performed to investigate the potential association between BZD with 
hip/femur fractures and results from those designs were compared between them 
and with the ones obtained from the novel case-only designs: a case crossover 
(CXO) and a self-controlled case series (SCCS). 
4.2 SPECIFIC OBJECTIVES 
4.2.1 Descriptive studies. 
1. Estimate the incidence rates and trends of hip/femur fractures in Spain, 
and compare with the ones from other European countries. 
2. Estimate the prevalence of BZD and related drugs use in Spain and 
compare with the ones from other European countries. 
4.2.2 Analytical studies: 
4.2.2.1 Cohort study  
3. Describe characteristics of BZD and related drugs users cohort. 
4. Calculate the incidence rates of hip/femur fracture associated with the 
exposure to BZD and related drugs overall and by age and sex. 
5. Estimate the relative risk of having a hip/femur fracture associated with 
BZD both crude and adjusted by potential confounding factors. 
6. Investigate whether the risk of developing a hip/femur fracture 
associated with BZD and related drugs varies or not with the type of 
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ATC group (anxiolytics or hypnotics); duration of treatment; half-life of 
the drugs, daily dose and individual drugs. 
4.2.2.2 NCC study  
7. Describe characteristics of cases and controls. 
8. Estimate the relative risk of having a hip/femur fracture associated with 
BZD and related drugs (crude and adjusted by potential confounding 
factors). 
9. Estimate the relative risk by duration of treatment and type of ATC 
group (anxiolytics or hypnotics). 
4.2.2.3 Case only designs 
10. Describe characteristics of cases selected in each design. 
11. Estimate relative risks of having a hip/femur fracture associated with 
the exposure to BZD and related drugs (crude and adjusted by 
potential time-varying confounding factors), in both CXO and SCCs. 
12.  Investigate whether the risk varies or not with the ATC group 
(anxiolytics or hypnotics) in both CXO and SCCS designs. 
13. Test whether exposure is event-dependent in the SCCS and examine 
whether the length of the “pre-exposure” window affects the relative risk 
estimate. 
4.2.2.4 Comparison across designs 
14. Compare the adjusted relative risks of current use of BZD and related 
drugs of having a hip/femur fracture across designs. 
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5. PATIENTS AND METHODS 
5.1 STUDY DESIGNS 
Two descriptive studies to assess the current situation of the incidence of 
hip/femur fractures and the prevalence of BZD and related drugs use in Spain 
were carried out using the database BIFAP. Following the same protocol, same 
descriptive studies were done in other six European databases from Denmark, 
Germany, the Netherlands, and the United Kingdom, as part of the European 
Project PROTECT WP2-working group 1 (WP2-WG1). Data from those studies 
were used to compare with the ones obtained in this research (120, 121). 
In addition, four analytical epidemiological designs have been conducted. Two 
using traditional designs, cohort and nested case-control studies, and two novel 
designs, a case crossover and a self-controlled case series. All studies were 
registered in the European Network of Centres for Pharmacoepidemiology and 
Pharmacovigilance (ENCePP) (122). 
5.1.1 Cohort Study 
A cohort study is an analytical observational study in which subjects do not 
have the outcome of interest at the start of the study and they are selected on the 
basis of their exposure. A cohort generally indicates a group of people who share 
a common characteristic. Once the cohort is selected, people are followed during 
a period of time to determine the occurrence of the outcome of interest and to 
compare the incidence of the outcome among exposed and unexposed subjects. 
It is an analytical study because it aims to identify and quantify associations, test 
hypotheses and identify causes. 
There are two main types of cohort studies based on when and how they are 
enrolled into the study: a) Prospective studies, where the outcome of interest has 
not occurred at the time of starting the study; b) Historical o retrospective studies, 
where the outcome of interest has already occurred when the researcher starts 
the investigation. In that case, disease-registries or electronic healthcare records 
databases are normally employed. As well, a cohort may be open or closed, 
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depending on whether subjects can be added to the cohort or not, once the 
cohort has been defined and the follow up has begun. The key difference 
between them is that in the closed cohorts, the time of follow up is the same for 
all subjects assuming no losses of follow up, and it allows calculate cumulative 
incidence of the outcome of interest, whereas in the open or dynamic cohorts, the 
time of follow up is different for every subject, and “person-time” should be used 
in the analysis. 
The major advantages of the cohort studies are the followings: 
- A temporal sequence between exposure and outcome can be established 
- They are useful to study rare exposures, i.e. a specific chemical product  
- A range of outcomes associated with the exposure can be studied 
- Information on confounding factors can be obtained 
- Useful for estimating the risk of disease, the incidence rate and/or relative 
risks. Time-to-event analysis is possible as well 
- Less prone to selection and information biases as compared to other 
designs 
In contrast, main disadvantages are: 
- Losses during the follow up time can impact in the risk estimates, in 
particular, if losses are differential with respect to the exposure status 
- Large study size is required, in particular when the outcomes are rare or 
present a long latency 
- High cost and time consuming 
- More complex analysis than other designs, in particular when time varying 
variables are to be considered. 
Traditionally, cohort studies have been considered highly inefficient to be used 
in pharmacoepidemiology due the low frequency of drug adverse reactions. The 
use of electronic healthcare records databases, however, has made them much 
more feasible, although the quality of information recorded may be an issue for 
specific purposes, and information about potential confounders might be not 
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recorded. In this research the study design was a retrospective cohort of BZD 
and related drugs users. 
5.1.2 Nested Case-Control (NCC) Study 
A case-control study is an analytical observational study in which subjects are 
defined by the outcome of interest, not by exposure. A group of individuals who 
have the outcome of interest (cases) and a group of individuals who do not have 
the outcome of interest (controls) are identified. Then both groups are compared 
to assess their exposure to a particular factor. 
In a "nested" case-control study, cases arise during a cohort study, and a 
sample of members of that cohort unaffected by the outcome of interest can be 
used as controls. This design offers advantages over a case-control study (123) 
because data on exposures is likely to have already been collected, hence less 
money and time need to be employed, and more important, cases and controls 
come from the same source population, in this research a cohort of users of BZD 
and related drugs. 
Both, cases and controls have to meet same inclusion/exclusion criteria 
except for the outcome itself. A precise case definition is required at the 
beginning of the study, and it has to be decided whether cases will be prevalent 
or incident. A problem with prevalent cases is that they may change exposure 
habits as consequence of the disease, and more severe cases might be 
underrepresented (124). In this research only incident cases were used. 
One common approach to select controls in this type of design is matching 
each case to a few set of controls on the basis of some factors that might be 
related with the outcome and the exposure, usually sex, age, place, or calendar 
time. As a consequence of matching the effect of those factors chosen for cannot 
be studied, so it is important to select them carefully. Normally a conditional 
logistic regression is performed to analyse matched case-control studies, to 
account for the matched nature of the population, and the outcome measure 
obtained is the odds ratio (OR) of exposure. When controls are randomly 
sampled from the same data source where cases came from, and they are 
Patients and Methods 
 
80 
 
selected by incidence density sampling, which implies sampling from those who 
are at risk at the time of case occurrence, the OR is an unbiased estimate of the 
rate ratio (125). 
In general, main advantages (124) of this design are the following: 
- They may be less expensive and time consuming than cohort studies. 
- Rare diseases or diseases with long latency or induction periods are more 
feasible to be explored. 
- It is possible to investigate multiple exposures within the same study 
- When a risk set sampling is used to select the controls, the OR is an 
unbiased estimate of the incidence rate ratio. 
- In "nested" case-control designs, information on exposures have been 
collected before cases had been diagnosed, and may be less prone to 
bias. 
As general limitations can be cited: 
- Prone to selection bias, especially when controls are not a random 
sample from the case source population. 
- Prone to information bias: recall and observer bias, although it depends 
on the data source. 
- Information on exposure and outcome is collected at the same time, 
therefore a causal relation is difficult to ascertain, especially in those 
studies which the selection of patients was based on interviews. 
- Rare exposures can be difficult to explore (huge sample size). 
- Disease incidence or prevalence cannot be estimate directly, but it may 
be calculated in the nested studies. 
Therefore, performing a "nested" case-control design may prevent some of 
the biases mentioned above. 
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5.1.3 Case Crossover (CXO) Study 
The case crossover method was developed by Maclure (1991), to investigate 
the effect of transient exposures on the risk of acute events, especially to 
investigate risk factors that might trigger a myocardial infarction (126). It arose 
from the difficulty of finding healthy controls representative of the general 
population, presence of selection bias in hospital controls and the need to 
response rapidly to serious acute events. 
Apart from studying immediate determinants of myocardial infarction, such as 
physical exertion, anger, cocaine use, sexual activity, etc (127); it has been 
applied as well to study drug adverse reactions as the risk of acute coronary 
events in patients with erectile dysfunction exposed to sildenafil (128); toxic 
epidermal necrolysis with nevirapine or the risk of flare of inflammatory bowel 
disease with antibiotic use, for instance (129, 130). 
The CXO follows the logic of a matched case-control study, retrospective 
study where events are fixed and exposure is random. The particularity is that 
controls come from the follow up time or person-time of cases before the event 
happens. Namely, controls are periods of time where person who developed the 
event of interest still had not developed at that time. This provides a set of 
matched variables corresponding to the event of interest and to control periods 
that may be analysed as a matched case-control study. 
The key feature of this design is that each case acts as its own control. It uses 
the difference in exposure rates just before the event (case) with those at other 
time (controls) to estimate an odds ratio of the outcome associated with 
exposure. In pharmacoepidemiology all control moments are selected prior to the 
outcome event, because changes in patient´s medical condition may alter the 
therapy they are being prescribed (131). Likewise, when the analysis employed is 
a conditional logistic regression with more than one control moment, distribution 
of exposures must be exchangeable between those periods to emulate a case-
control design where the order of controls is irrelevant (132). 
Concisely, assumptions required for this method are the following: 
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- Onset of the event must be acute 
- Exposure should be intermittent (only discordant pairs contribute to the 
estimate) and with stable prevalence over time 
- The effect of the exposure must be transient with no carry over effect 
- Probability of exposure should be the same in all control moments 
 
This method presents several advantages over other designs: 
- Only cases are necessary, therefore, costs are lower 
- All individual confounders that do not vary with time such as genetic 
factors, social status, sex, race, etc are implicitly controlled for 
- Comparisons are intra-subjects instead of inter-subjects 
- Simpler to design than a case-control as there is no possibility of selection 
bias to select controls 
- Provides a quantified, statistically valid effect estimate 
- Ethical benefits without selection of controls 
 
In contrast, main limitations of this method are: 
- Time varying confounders should be taken into account 
- Distribution of exposure should be exchangeable over time 
- Exposure need to be transient, not valid for chronic treatments 
- The need to infer the length of control periods might over or infra 
estimate the association 
5.1.4 Self-Controlled Case Series (SCCS) Study 
The self-controlled case series method was developed by Farrington (1995) to 
study the association between vaccination and adverse events arisen in the 90’s. 
This method was initially thought to avoid confounding factors not controlled by 
other designs such as cohort or case-control designs, because the exposure to 
vaccines was not uniform, and the population from which the cases arise may not 
be well known (133) or even with a high vaccine coverage it was hard to find 
appropriate non-exposed controls. Another key factor was the need to give a 
response as quick as possible after the event was known and the classical 
methods required a prolonged time span than was normally affordable. For those 
reasons the “case series” method was created. 
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Although initially this method was thought to investigate the effect of 
vaccination and acute potential adverse events, later on, it has been applied in 
other areas of pharmacoepidemiology (134, 135), to investigate transient 
exposures with acute and non-acute (136, 137) outcomes, employing only 
individuals who experienced the outcome of interest. 
The self-controlled case series method follows the cohort design approach, 
where an event may occur randomly during the observation period, and the follow 
up of each patient is divided according exposure status. It offers the possibility to 
investigate the association between time varying exposure and acute outcome 
events. Since only cases are sampled, the probability an event occurs is related 
to the individual’s time of exposure. The method is derived from a Poisson model 
by conditioning on the individual total number of events and its exposure history. 
It is self-matched and hence all age-independent confounders are implicitly 
controlled for (138). As a consequence of this conditioning, the effects of fixed 
covariates cancel out, so that the method has a particular advantage compared 
with cohort and case-control studies (139). 
Three key assumptions are required by this method to be applicable (140): 
1- Events arise in a non-homogeneous Poisson process, therefore rare non-
recurrent events may be analysed with this method. In case recurrent events are 
not independent, as may be the case of hip/femur fractures, but the occurrence of 
a first event is rare; the method can be applied using just the first event. So, 
considering a hip/femur fracture as a rare event, only first fractures will be used. 
2- The occurrence of an event must not alter the probability of subsequent 
exposure. To ensure this assumption, a “pre-exposure” time risk window can be 
created to examine whether the exposure depends or not on the occurrence of 
the outcome. 
3- The occurrence of the event of interest must not censor or affect the 
observation period. This assumption might be violated in case the event is death, 
and a single exposure has occurred. It could be considered the event as rare, 
and taking the observation period as the time from exposure to the end of the 
planned observation period. In summary, the key features of this method are the 
following:  
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- Only cases are required. 
- It is a conditional cohort method. 
- Follow-up is not censored at the time of the event. 
- It can be applied with independent recurrent events, or rare non-recurrent 
events. 
- Analysis is self-matched, removing the effect of fixed confounders. 
Consequently, main advantages of this method are: 
- All fixed variables such as socio-economic status, gender, severity of 
underlying disease, location, etc, are controlled by design. 
- Only cases are sampled, hence data collection and cost are reduced. 
- It provides consistent estimates of the relative incidence. 
- Temporal variations and age can be included in the model, having 
high efficiency comparative to cohort studies. 
- Independent recurrent events can be studied. 
- Dependent recurrent events, if the occurrence of the event is 
considered rare, can also be studied taking into account only the first 
event. 
In contrast, main limitations are the following: 
- The probability of exposure and the follow up time should be independent 
of the occurrence of the event, if not, the estimates may be biased (unless 
results are properly corrected for). 
- It only provides estimates of relative incidence, not absolute incidence. 
- It requires variability in the time or age of the event (not all events happen 
at the same time or age) 
- It cannot be used when the event only occurs a long time after the 
exposure. 
- The occurrence of an event must not censor or affect the observation 
period thus it is not good for mortality studies, although a modified form 
can be used. 
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5.2 DATA SOURCE 
Data employed in all designs came from the Spanish Base de datos para la 
Investigación Farmacoepidemiológica en Atención Primaria, BIFAP, which has 
been described previously (see Introduction, section 1.4.2). It is a national 
electronic healthcare records database from primary care, operated by the 
Spanish Medicines Agency (AEMPS), which aims to promote public health 
performing pharmacoepidemiological studies to evaluate the safety and 
effectiveness of medicines in Spain. 
This database collects data from practices or health centres; at 2009, included 
information of more than 3.5 million of patients, covering 6.9% of the Spanish 
population. Those data are provided voluntarily by primary care physicians 
(general practitioners or primary paediatricians) of the National Health System, 
with the collaboration of nine Autonomous Communities. From those, 3,180,161 
patients contained valid information to participate in research studies, with a 
follow up time in the database of 11,526,376 person-years. All information is 
anonymised, containing clinical data related to health issues, prescription 
records, and general characteristics data. 
For the two descriptive studies performed, data from the following data 
sources were used to compare with the Spanish ones, following same protocol: 
The Danish national registries (DKMA) (http://www.dkma.dk) (http://www.sst.dk), 
the German: Bavarian Association of Statutory Health Insurance Physicians 
database (Bavarian Claims) (http://subs.emis.de/LNI/Proceedings/) , the Dutch 
Mondriaan project (http://www.projectmondriaan.nl) with two databases: 
Netherlands Primary Care Research Database (NPCRD), and Almere Health 
Care group (AHC) http://www.zorggroep-almere.nl), and two databases from the 
UK, the Clinical Practice Research Datalink (CPRD) (formerly known as the 
General Practice Research Database, GPRD) (http://www.cprd.com) and The 
Health Improvement Network (THIN) (http://www.thin-uk.com). More detailed can 
be found in the articles (120, 121, 141) 
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5.2.1 Period of data collection 
The study period for all designs was considered from the 1st January 2001 
until 31st December 2009. The start date or left censoring date was the latest of 
the following: 1st January 2001; the date that a practice was enrolled into the 
database (BIFAP); the date that a patient was registered in a practice; or the date 
that a practice became up to research standards. 
In the same way, the end date or right censoring date was the earliest of the 
following: 31st December 2009; the date a patient died; the date a patient was 
transferred out of the practice; the date that the practice left BIFAP; or the latest 
recorded event date. 
5.3 STUDY POPULATION 
5.3.1 Descriptive study designs 
The study population consisted of all patients included in the period of valid 
data collection with the criteria of left and right censoring dates cited above. The 
only difference between the two descriptive studies was that the study period for 
the incidence of hip/femur fractures was from 1st January 2003 to 31st December 
2009, whereas for the prevalence of BZD and related drugs use the study period 
was from 1st January 2001 to 31st December 2009 due to the availability of data 
in the different European data sources to allow comparison between them. 
5.3.2 Cohort and NCC designs 
From all patients comprised in the period of valid data collection, those who 
had at least one year of enrolment with the GP, were aged 18 years or older, and 
had at least one BZD or related drugs prescription, were included in the cohort 
study. The date of the BZD or related drug prescription was considered the start 
date in the cohort study. Patients with a recorded prescription within six months 
before left censoring date were excluded to restrict the analysis to new users 
only. In addition, patients with a code of hip/femur fracture within the year before 
the start date were also excluded. The reason for that criterion is because it was 
established a minimum of 12 months as gap between fractures to be considered 
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as a new event. Besides, when the hip/femur fracture occurred the same day that 
the first BZD prescription, those patients were disregarded because temporality 
between exposure and event was ambiguous, thus, the cohort follow up started 
on the following day of BZD prescription, day 1 not on day 0. 
All patients identified were followed until one of the following events occurred: 
(a) occurrence of Hip/femur fracture, (b) death, (c) transfer out practice, (d) 
practice left the database, (e) end of the database collection and (f) end of study 
period, whichever came first. Cases identified in the cohort study were then used 
for the NCC design, being the date on which the hip/femur fracture occurred, the 
index date. For the NCC design a random sample around 10,000 patients from 
the cohort study was selected according to a risk set sampling (see section 
5.4.2). 
5.3.3 CXO and SCCS designs 
From all patients comprised in the period of valid data collection, those who 
had at least one year of enrolment with the GP, were ≥18 years old, and were 12 
months free of hip/femur fracture before the start date were included in the study 
population. All patients had to have a record/diagnosis of hip/femur fracture 
during the study period (1st Jan 2001-31st Dec 2009), and although in both 
designs it was required to have at least one BZD or related drug prescription 
during the study period, only for the SCCS was required to be free of those 
prescriptions within six months before the start date to restrict population to new 
users. This criteria was not applied for the CXO in order to give cases occurring 
at the beginning of follow up the same opportunity to be exposed to BZD (in both 
case and control moments), and therefore to avoid bias. As restricting to have a 
BZD prescription six months before the start date, for those who had a hip/femur 
fracture close to that date, would be necessarily unexposed. 
Patients could entry at any time they fulfilled the criteria above. It had not to be 
necessarily the first hip/femur fracture that occurred in that patient but the first 
occurred after satisfying those criteria. The start date was the date patients met 
the cited criteria. The index date was the date on which the hip/femur fracture 
occurred. 
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In the SCCS, all "cases"
date, until one of the following events occurred:
practice, (c) practice left the database, 
end of study period, whichever
the index date, and the exposure of the 
moments. 
A diagram with period of 
performed studies can be found in Figure 
Figure 9- Source population for all studies designs
 were followed starting on the day after of the start 
 (a) death, (b) transfer out 
(d) end of the database collection and (
 came first. For the CXO, hip/femur fracture was 
"cases" was explored at four control 
valid data collection and source population for all 
9. 
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5.4 OUTCOME DEFINITION 
Fractures of the acetabulum (socket) and other pelvic fractures (ilium, ischium, 
or pubis) are not considered to be hip fractures and have not been included in 
this study. However, femur fractures have been included since the nomenclature 
of health problems used by GPs taking part in BIFAP is the ICPC-2 classification 
which only use a code for “femur fracture” (L75), which includes all hip fractures: 
femoral head, femoral neck, intertrochanteric, subtrochanteric, etc. defined as a 
fracture of the proximal femur in the cervix or in the trochanteric region, So, the 
term “hip/femur” fracture was considered to be the operational outcome definition 
for this research. In addition, some authors have suggested to use all femur 
fractures in surveillance programs in order to avoid a misclassification of disease 
by miscoding (142). 
Thus, patients with a recorded diagnosis of a new event of hip/femur fracture 
during the study period were considered to have the outcome of interest, 
regardless of whether they had a history of past fractures. For a current fracture 
to be considered a new event, a minimum of 12 months should have elapsed 
between the two episodes. That was an inclusion criterion for all designs, except 
for the descriptive study of incidence rates of hip/femur fractures where patients 
with a history of past hip/femur fractures ever before the study period were 
excluded to increase the likelihood of including incident episodes only. 
The outcome was searched in BIFAP database using the International 
Classification of Primary Care: ICPC-2, code L75 "Fractura de fémur" and free 
text: "fractura cadera" or "fractura femur" or "fractura femoral". 
5.4.1 Case ascertainment and validation 
The same “case” definition was applied for all designs. A validation of cases 
ascertainment was performed in the four analytical studies. For instance, 
patients, who after reviewing their automated clinical records had a hip/femur 
fracture due to a major trauma such as road traffic accidents, were not included 
in any design. As a result of the validation process around 30% of cases were 
excluded, of them, about 15% were fractures due to major trauma; about 60% 
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were other diagnoses (no fractures)
about 25% were prevalent 
fractures was unknown. 
5.4.2 Selection of Controls for the NCC design
A risk set sampling method 
cases were compared with a set of patients at risk to develop a hip/femur fracture 
at the same moment the cases occurred. Those controls might become a case 
afterwards, so they could be re
became a case). Each case 
controls by sex, age (± 2 years age
defined as the time contribution of each patient
date (hip/femur fracture date). Index date was the
its matched controls. Matching by 
time. Then controls were selected progressively by follow
day up to a maximum of six months.
5.4.3 Cases and Controls da
The date of the first diagnosis of the hip/femur fracture within the study period 
was considered the index
contributed to one case moment and up to four co
moment was defined as the i
182, 273 and 365 days prior to the index
Figure 10- Case and control moments  defined in the CXO design
 and other fractures (e.g. pelvis fracture); 
cases (hip fractures before study period)
 
was employed to select the controls. Therefore, 
-sampled at different moments in time (until they 
of hip/femur fracture was matched 
-band), and follow up time (+/
 from the start date to the index 
 same date for each case and 
similar age was given priority against follow
-up time relaxing day by 
 
tes for the CXO design 
 date. Each case served as its own control, e.g., 
ntrol moments. The case 
ndex date. The control moments were defined at 91, 
 date as represented in Figure 10
and 
 or the date of 
to up to four 
-6 months) 
-up 
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5.5 EXPOSURE DEFINITION 
5.5.1 General criteria for all designs 
To ascertain the exposure of interest the Anatomical Therapeutic Chemical 
(ATC) classification system was used (http://www.whocc.no/atc_ddd_index/). In 
that system the active substances are divided into different groups according to 
the organ or system on which they act and their therapeutic, pharmacological and 
chemical properties. Drugs are classified in groups at five different levels. Thus, 
all drugs pertaining to ATC codes N05BA (Anxiolytics -Benzodiazepine 
derivatives), N05CD (Hypnotics and sedatives - Benzodiazepine derivatives), 
N05CF (Hypnotics and sedatives - Benzodiazepine related drugs) and N05CM02 
(Other hypnotics and sedatives - Clomethiazole) were included as exposure of 
interest. BZD primarily used in other indications (e.g. tetrazepam used as muscle 
relaxant, clonazepam used in epileptic patients) were not included in this study. A 
complete list of codes employed is available in Appendix A. 
The prescription of the drug of interest was the indicator of exposure for the 
descriptive study of prevalence of BZD and related drugs use. 
For the analytical designs, the complete person-time of patients was divided 
according to their exposure. Thus, duration of each prescription was estimated 
based on the prescribed amount and daily dose. In case of unknown data, the 
most recent previous prescription was used to estimate it. When that was not 
possible, population-mode specific for each presentation of pharmaceutical form 
was employed. 
A treatment episode (TE) was defined as a series of subsequent prescriptions 
and according to the method described in Gardarsdottir et al (143). In case a 
subsequent prescription is collected before the theoretical end date, with another 
ATC or different active ingredient, the patient is considered to have changed 
therapy and the remaining days from the prior prescription are disregarded 
(Fig.11, Method 1). However, if the subsequent BZD prescription collected before 
the theoretical end of the current one is from the same drug (active ingredient), 
the number of overlapping days is added to the theoretical end date of the repeat 
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prescription (Fig. 11, Method 2)
Retrieved from H. Gardarsdottir et al.
Figure 11- Method of Gardarsdottir et al
episodes 
A new TE was considered when an interval of 
between the theoretical end date of a prescription and the dispensing date of the 
subsequent prescription for the same patient.
Total person-time of each person was divided according their e
into periods of current, recent and past use (Figure 1
designs that started with a prescription of BZD or related drugs.
 
Figure 12- Person-time divided into exposure status for Cohort and NCC
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• Current use defined as the period from the start of a BZD or related 
drug prescription until 30 days after the estimated end date of the 
supply. 
• Recent use defined as the period up to 60 days after current use. 
• Past use defined as the period after recent use until the patient 
became a new user or the end of follow-up. This period was 
considered as the reference category. 
The period of Recent use after treatment was included because there is a 
natural uncertainty about the exact date that treatment is stopped, and this period 
represents a gradual shift from full exposure, followed by a washout period, and 
finally to an entirely unexposed state (Non use or Past use). 
Likewise, for cases and controls in the NCC, the exposure was defined as 
current use when a prescription lasted until the index date or ended within the 30 
days before (-1 to -30) index date, recent use when the most recent prescription 
ended within the 31 and 90 days before the index date, and past use when the 
most recent prescription ended before 91 days prior to the index date. 
For the case only designs, an extra period of Non use (Figure 13) was also 
considered because the start date of those studies was not necessarily 
coincident with a BZD or related drug prescription. 
• Non use defined as the period between the start date and the first 
BZD or related drug within the study period. This period together with 
the past use was considered as baseline or reference category. 
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Figure 13- Person-time divided into exposure status for CXO and SCCS
Among current users, 
factors:  
1. Duration of use
182, 183-365 and > 365 days
2. Type of BZD was divided 
a) Single use of 
b) Single use of 
c) Use of both, anxiolytics and hypnotics
Among those with only one active ingredient further stratifications according to 
individual drugs, dose and half
3. Individual BZD or related drugs
a) Anxiolytics -Benzodiazepine derivatives (N05BA):
• Lorazepam
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• Diazepam
• Alprazolam
• Others: Clobazam, Clotiazepam, Pinazepam, Oxazepam, 
Chlordiazepoxid
Ketazolam, 
b) Hypnotics and sedatives 
• Lormetazepam
the exposure was stratified according the following 
 was classified into five categories: 0-30, 31
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• Flurazepam 
• Loprazolam 
• Others: Midazolam, Triazolam, Brotizolam, Flunitrazepam, 
Quazepam, Temazepam and Nitrazepam. 
c) Hypnotics and sedatives - Benzodiazepine related drugs (N05CF): 
• Zolpidem 
• Others: Zopiclone and Zaleplon 
d) Other hypnotics and sedatives (N05CM02): 
• Clomethiazole  
4. Dose of current single users was classified with the Defined Daily Dose 
(DDD) as the number of DDDs per day. For instance, assuming that the 
DDD for diazepam is 10mg, a prescription of 30 tablets of diazepam 
5mg, lasting a period of 30 days, it would be a dose of 5mg/day, so to 
calculate the DDD, it would be 5/10=0.5 DDD. Thus, doses were 
considered: 
• Low doses <1DDD 
• Medium doses =1 DDD 
• High doses >1 DDD 
5. Half life was classified as (144, 145): 
• Short: <8h 
• Intermediate: 8-24h 
• Long: >24h  
A list of BZD and related drugs, DDD, Half-life and Recommended Daily Dose 
is available in Appendix A. 
From all these stratifications, individual BZD, dose and half-life were explored 
only in the cohort study. Stratification according type of ATC group (anxiolytic or 
hypnotic drug) was performed in all designs as follows: 
- For the Cohort study the stratification was done relating to the use of single 
anxiolytics or hypnotics in the current period, and for the SCCS was done within 
each time risk window (see below). 
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-For the NCC and CXO this stratification was done according to the BZD 
prescriptions within the previous 90 days. 
Finally, duration of use was performed in all but the CXO design, because in 
case a hip/femur fracture occurred at 1st January 2001, a period of time of at least 
15 months prior index date would be necessary to explore duration of use; 12 
months to explore duration and 3 months to have at least one control moment. In 
BIFAP data available before year 2000 are scarce, so it was decided not to 
perform this stratification for this design. 
5.5.2 Specific criteria for SCCS design. 
For the SCCS, the time risk windows chosen to investigate the exposure were 
similar to the duration periods: 1-30, 31-60, 61-182, 183-365 and >365 days. 
However, one key assumption of this design is that the exposure must not be 
affected by the occurrence of an event. That is not completely clear for this pair 
event-drug, because the prescription of a BZD or related drug might be altered by 
the occurrence of a hip/femur fracture, in both directions: 
- The GP may be prone to prescribe BZD after the occurrence of the 
event as anxiolytic or sedative effect; in that case results obtained 
could be biased downwards, and therefore underestimate. 
- On the contrary, the GP may avoid prescribing BZD after the 
occurrence of the event because the potential risk of falls; in that case, 
results obtained could be biased upwards, and therefore overestimate. 
In case the event restricts the exposure, events are unlikely to occur in the 
immediate pre-exposure period time, this effect would deplete the baseline 
incidence and hence exaggerate the relative incidence. Similarly, if the event 
increases the exposure, this effect over the baseline would understate the 
relative incidence. 
To investigate the possible event-exposure dependence, a sensitivity analysis 
was performed creating a "pre-exposure" period of 30 days (normal length of a 
BZD or related drug prescription) before each beginning treatment episode, to 
 remove this time from baseline and correct for the potential effect th
dependence might cause (Figure 1
Figure 14- Sensitivity analysis creating a pre
5.6 COVARIATES DEFINITION
Information of age, sex and life
mass index, smoking or alcohol abuse was extracted from patient’s record in 
BIFAP, for every design. In addition, 
potential confounders 
hip/femur fractures, and information about them was extracted as well
Among co-medications
included the following presented in T
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Table 5- Co-medication covariates 
Co-medications 
Oral Glucocorticoids 
Bisphosphonate use 
Raloxifene  
Strontium ranelate  
Parathyroid hormone  
Calcium & vitamin D  
Calcitonin 
Antidepressants 
Antipsychotics/lithium 
Anti-Parkinson drugs 
Anticonvulsants 
Inhaled glucocorticoids 
Bronchodilators 
Antihypertensive drugs 
Diuretics 
Anti-arrhythmics 
Sedating Antihistamines 
Hormone replacement therapy (HRT)  
Thyroid hormones 
Antithyroid drugs 
Disease-modifying anti-rheumatic drugs (DMARDs) 
Thiazolidinediones  
Other antidiabetics 
Antiemetic (Metoclopramide) 
Anticoagulants 
Morphine/opiates 
Non-steroidal anti-inflammatory drugs (NSAIDs) 
Statins 
Proton pump inhibitors (PPIs)  
Aromatase Inhibitors 
The exposure was measured by absence or presence of prescriptions of 
those drugs within six months (variable: “yes”/”no”; being “no” the reference 
category). To exclude sporadic use, two or more prescriptions of NSAIDs were 
needed to be considered exposed; and for Oral Glucocorticoids, prescriptions for 
more than 3 months at a dose of prednisolone of 5mg daily or more (or 
equivalent doses of other glucocorticoids) were required to be considered 
exposed, so no prescriptions or treatments for less than 3 months were 
considered not exposed (Reference category).  
Patients and Methods 
 
99 
Among co-morbidities, already described and referenced previously, were 
included the following presented in Table 6:  
Table 6- Co-morbidities as covariates 
Co-morbidities 
Previous fracture 
Rheumatoid arthritis 
Osteoporosis  
Paget’s disease 
Anaemia  
Epilepsies/seizures 
Syncope 
Ischaemic heart disease 
Cerebrovascular disease 
Malignant neoplasms  
Inflammatory bowel disease 
Obstructive airway disease 
Liver disease  
Chronic renal failure  
Mental disorders (without depression) 
     Dementia and/or Alzheimer's 
They were included totally or partially as potential confounders depending on 
the design. All of them were searched in BIFAP database using ICPC-2. The 
exposure was measured by absence or presence of recorded codes of these 
variables (“yes”/”no”; being “no” the reference category). Codes, descriptions and 
variable values for all potential confounders are described in Appendix B. 
5.7 DATA ANALYSIS 
All analyses were performed using Stata software, version 11® (StataCorp, 
College Station, TX). 
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5.7.1 Descriptive Studies Analysis 
5.7.1.1 Incidence of hip/femur fractures by sex and age per year 
Annual incidence rates (IRs) of hip/femur fractures were calculated for the 
whole study population. The numerator comprised all first ever recorded cases of 
hip/femur fracture and the denominator was the total number of person-years of 
follow up. Annual IR among people aged 50 years or older were calculated 
separately, as most fractures occurring before this age are primarily due to 
trauma and many studies use this age limit (146, 147). 
For the comparison of the IRs estimates with other European databases and 
over time, a direct sex and age standardization was carried out using the 
European Union population in 2008 (EUROSTAT) as the standard 
(http://epp.eurostat.ec.europa.eu/portal/page/portal/population/data/database).  
Age (in 10-year bands) and sex specific IRs over the study period were also 
calculated. Age of patients was computed at midyear within each calendar year 
of the study period. The incidence rate ratios (IRRs) and their 95% confidence 
intervals (95%CI) were calculated to assess the effect of sex on different age 
groups. 
To quantify the trend over the study period a linear regression analysis for 
both crude and standardized rates was performed, defining the annual IR as the 
dependent variable and the calendar year as the independent variable. The 
respective slope (β coefficient) was considered as the average change per year 
over the study period. This annual change was also expressed as a percentage 
of IR using the first year as reference. The null hypothesis of β=0 was tested 
using the t test. A p value <0.05 was considered significant. The 95% CI of the 
slope was also calculated. 
5.7.1.2 Prevalence of BZD and related drugs use 
Annual period prevalence was estimated by dividing the number of patients 
that received one or more prescriptions by the total number of person-years of 
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follow-up of all patients in every calendar year of the study period. Patients 
having more than one prescription in a particular year were counted only once. 
Due to the dynamic nature of the database, where patients have variable 
durations of follow-up time, person-years were considered as the most 
appropriate denominator. Prevalence rates (PRs) were standardized using the 
Eurostat 2008 population as before. Specific PRs were also provided by separate 
therapeutic groups (anxiolytics (N05BA) and hypnotics (N05CD, N05CF and 
N05CM02), age groups (in ten-year categories) and sex. 
5.7.2 Analytical studies 
5.7.2.1 Description of study populations 
In each design, study population was described in terms of age, gender, life 
styles factors, co-medications and co-morbidities. Proportions of subjects for 
each variable were calculated. Distribution by sex and age was also estimated by 
categorized age variable in 10 years band up to last category of 90+. Co-
medications were investigated within the 6 previous months and co-morbidities 
any time before. 
5.7.2.2 Incidence Rates of hip/femur fractures associated with BZD 
IRs of hip/femur fracture were calculated only in the Cohort study. Numerator 
was the total number of patients with a hip/femur fracture, and denominator was 
the person-years that each person contributed in the cohort. IRs were calculated 
separately by exposure status in current, recent and past users, overall and by 
sex and age in 10-years band. 
5.7.2.3 Measure of the crude association of potential risk factors with 
hip/femur fractures 
In the following analytical designs the independent association for life-style 
factors, co-medications and co-morbidities was examined: 
a) For the cohort study, crude Hazard Ratios (HRs) were calculated 
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using Cox regression analyses. 
b) For the NCC and CXO crude odds ratios (ORs) were calculated 
using conditional logistic regression. 
5.7.2.4 Risk of having a hip/femur fracture associated with BZD crude and 
adjusted by potential confounding factors 
For each study design different incremental models were run to evaluate the 
adjusted risk of having a hip/femur fracture associated with BZD, taking into 
account different confounding factors. 
In the Cohort study, a time varying analysis was done. All potential 
confounder variables were measured/updated whenever a patient changed 
between exposure status (current/recent/past) or at 182 days intervals in case a 
patient had a current or past period longer than 182 days. Besides crude 
analysis, five time dependent Cox proportional hazards models were run to 
calculate adjusted HRs and CI 95% as follows: 
1) Model ”age”: adjusted analysis by age (as continuous variable) 
2) Model A: adjusted analysis by age and sex 
3) Model B: adjusted analysis by model A plus well known risk factors for 
fracture such as previous fractures, glucocorticoids use, rheumatoid arthritis and 
lifestyle factors (bmi, smoking, alcohol abuse). 
4) Model C: adjusted analysis adding to model B risk factors immediately 
related to the outcome such as osteoporosis, Paget´s disease, biphosphonate, 
raloxifene, strontium ranelate, parathyroid hormone, vitamin D and analogues 
and calcitonin use. 
5) Model D: adjusted analysis adding to model C other drugs and diseases 
associated with fractures in the past, such as antidepressants, or ischaemic heart 
disease (see Table 5 and 6). 
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In addition, to examine which variables were those that most affected to the 
association of BZD with the event of interest stepwise models were performed. 
After backward and forward analyses, the resultant variables were included in a 
new model, and those ones that did not change more than 5% the estimator of 
the exposure variable were eliminated. Interaction terms between variables were 
also explored. Finally, the most parsimonious model was obtained with the 
following variables: age, sex, previous fractures, glucocorticoids, antidepressants, 
anti-Parkinson drugs and the interaction between antidepressants with anti-
Parkinson drugs. 
In the NCC study, conditional logistic regression analysis was used to 
estimate the risk of hip/femur fracture associated with the use of BZD and related 
drugs adjusting for confounding variables. The risk was calculated in terms of 
ORs with corresponding 95% CI. 
Co-morbidities were measured any time before the index date, and co-
medications were measured within 6 months before the index date. In addition, a 
sensitivity analysis measuring co-medication within the 30 days previous to the 
index date was performed in order to obtain a closer measure for co-medication. 
Regarding incremental models to adjust by potential confounders, only model 
B, C and D were run, since age and sex were matching variables for cases and 
controls. 
Similarly, stepwise models were executed to investigate variables that most 
affected to the association of BZD with the event. 
In the CXO study, conditional logistic regression analysis was used to 
estimate the risk in terms of ORs with corresponding 95%CI, similarly than the 
NCC analysis. The main difference with the only cases studies is that their 
analysis is within not between subjects so all intra-individual confounding factors 
are implicitly controlled for in both case only designs. Therefore, only co-
medication was included in the adjusted model, and variables were measured at 
index date and at each control moment, that is at -91, -182, -273 and -365 days. 
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Similarly, stepwise models were executed to investigate co-medication 
variables that most affected to the association of BZD with the event. 
In the SCCS study, conditional Poisson regression analysis was used to 
estimate the relative risk in terms of IRRs with corresponding 95%CI, to account 
for the matched nature of the data in accordance with standard practice for the 
SCCS method (148). This method has the benefit of allowing for exploration of 
changes in risk with duration of exposure, and it approaches cohort designs in 
terms of statistical power. 
In this study, only age was considered as potential confounder. Small age 
bands were created to allow adequate adjustment. A first age band was created 
for 18-29 years of age, and then 5-year age bands were created for patients up to 
59 years of age: 30-34, 35-39, 40-44, 45-49, 50-54, and 55-59. Then one-year 
age bands was created for patients from 60 to 95 years, after which the final age 
band summarised age for the oldest age group (>95 years). Thus, the 
observation period of each participant was divided into risk windows according to 
their exposure to BZD, and was further divided to control for age. 
Relative incidence rates were calculated by comparing the rate of hip/femur 
fractures experienced during risk periods with the rate of events during baseline 
time that is, periods of past use or not use (see Figure 14). For this analysis only 
the first event (hip/femur fracture) that occurred within the study period was taken 
into account. 
A sensitivity analysis was performed taking into account a new risk window up 
to 30 days just before the beginning of each treatment episode, estimating the 
IRRs in the same way than before. Besides, to inspect whether the length of that 
"pre-exposure" time risk window, affected the risk of developing a hip/femur 
fracture, the analysis was repeated with two additional and different lengths. 
Thus, one shorter than previously, with a length of 15 days, and one longer than 
initially, with a length of 60 days, were analysed. 
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5.7.2.5 Risk of having a hip/femur fracture associated with the type of BZD; 
duration of treatment; active ingredient; doses and half-life. 
To investigate whether the risk of having a hip/femur fracture was related to 
the type of BZD or related drug taken, current use was stratified according to the 
use of anxiolytics or hypnotics in all designs. Similar analyses than explained 
previously were carried out among current users:  
a) For the cohort design, a Cox or proportional hazards regression was used. 
In this analysis, the rate is allowed to vary continuously over time and hazard 
ratios (HRs) are the effects of different explanatory variables on the risk of having 
the event. 
b) For the SCCS same conditional Poisson regression analysis was 
employed, with and without adjusting by age but now considering for each period 
time of exposure if they were taking only anxiolytics, hypnotics or both. 
c) For the NCC and CXO, same conditional logistic regression analysis was 
used, exploring now the type of BZD or related drug taken within the previous 90 
days for both designs. 
Duration of treatment was explored for all but the CXO design as it has been 
explained before. Same mentioned analyses were performed for each one, 
dividing the length of treatment episode in 5 categories: 0-30, 31-60, 61-182, 
183-365 and >365 days, which were the risk time windows for the SCCS study. 
And finally, just for the cohort study, a Cox was defined for active ingredient, 
doses and half-life separately, using past use as category of reference. All these 
variables have been described in detail in section 5.5 among current users. 
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6. RESULTS 
6.1 DESCRIPTIVE STUDIES 
6.1.1 Incidence rates and trends of hip/femur fractures 
The standardized IRs of hip/femur fracture for the population aged 50 years or 
older were 2-3 times higher than the ones for the general population, ranging 
from 15-25 per 10,000 py in the UK, the NL, and Spain to 52 per 10,000 py in 
Denmark, and around 30 per 10,000 py in Germany (Table 7). Standardized IRs 
for the general population can be found in the Appendix C-Additional tables from 
descriptive studies. 
Time trends 
A significant trend in standardized IRs in people aged 50 years or older was 
only observed for the British CPRD (+0.7% per year; p<0.01) and the Danish 
database (-1.4% per year; p< 0.01) (Table 7). For the remainder of databases no 
significant trend was observed. 
Sex and age-specific IRs of hip/femur fracture 
The crude and age-standardized IRs were 2-3 times higher in women than in 
men for the whole population and for the population aged 50 years or older, over 
the study period and across all databases (Figure 15). The IRs of hip/femur 
fractures grew exponentially from the age of 50 years for both females and males 
(Figure 16), which was a constant feature for all databases (DBs) and for the 
whole study period. 
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Table 7- IRs and time trends: population ≥50 years old in all databases. 
 2003 2004 2005 2006 2007 2008 2009 Slope (95% CI) V
#
 
BIFAP          
No. fractures 1,298 1,643 1,638 1,629 1,558 1,350 1,027 -  
Person-years 475,139 588,242 616,300 589,588 554,287 472,785 369,872 -  
IR per 10,000py 27.32 27.93 26.58 27.63 28.11 28.55 27.77 0.15 (-0.14, 0.43) 0.5 
Standardized IR 26.94 27.13 25.60 26.42 26.49 27.05 26.33 -0.04 (-0.32, 0.24) (-) 0.1 
CPRD          
No. fractures 2,858 3,087 3,139 3,265 3,295 3,367 3,291 -  
Person-years  1,327,959 1,406,185 1,447,563 1,476,874 1,475,205 1,470,594 1,446,832 -  
IR per 10,000py 21.5 22.0 21.7 22.1 22.3 22.9 22.7 0.22 (0.12, 0.32)* 1.0 
Standardized IR 21.47 21.99 21.65 22.07 22.22 22.67 22.29 0.16 (0.04, 0.27)* 0.7 
THIN          
No. fractures 2,614 2,734 2,831 2,785 2,830 2,899 2,839   
Person-years  1,241,173 1,259,016 1,270,685 1,284,095 1,294,565 1,302,336 1,288,704   
IR per 10,000py  21.1 21.7 22.3 21.7 21.9 22.3 22.0 0.13 (-0.04, 0.30) 0.6 
Standardized IR 21.01 21.79 22.36 21.76 21.92 22.33 22.11 0.14 (-0.04, 0.32) 0.7 
AHC          
No. fractures 45 39 60 51 45 47 -   
Person-years  23,883 25,935 28,039 30,293 32,657 35,583 -   
IR per 10,000py  18.8 15.0 21.4 16.8 13.8 13.2 - -1.04 (-2.89, 0.80) (-) 5.5 
Standardized IR 26.84 21.75 32.43 25.85 20.24 19.75 - -1.33 (-4.43, 1.77) (-) 5.0 
NPCRD          
No. fractures 157 101 77 82 124 107 74   
Person-years  103,010 64,504 62,856 52,701 76,946 60,608 45,969   
IR per 10,000py  15.24 15.66 12.25 15.56 16.12 17.65 16.10 0.37 (-0.38, 1.13) 2.4 
Standardized IR 14.43 15.02 11.74 14.86 14.42 17.76 16.40 0.5 (-0.30, 1.31) 3.5 
DKMA          
No. fractures 9,031 9,277 9,206 9,041 8,905 9,036 8,814   
Person-years  1,810,178 1,831,556 1,843,587 1,861,768 1,878,628 1,901,823 1,912,890   
IR per 10,000py  49.9 50.7 49.9 48.6 47.4 47.5 46.1 -0.72 (-1.03, -0.42)* (-) 1.4 
Standardized IR 53.39 54.27 53.51 52.02 50.88 50.97 49.54 -0.74 (-1.07, -0.42)* (-) 1.4 
BAVARIAN          
No. fractures - - - 12,868 11,787 12,928 - - - 
Person-years$  - - - 3,885,264 3,938,210 3,988,146 - - - 
IR per 10,000py  - - - 33.12 29.93 32.42 - - - 
Standardized IR - - - 31.08 27.82 29.94 - - - 
95% CI: Confidence Interval; * p < 0.05 ; V
#  
% Variation: (Slope/2003 IR)*100 
$  
Incidence per 10,000 Insured persons in BAVARIAN, not enough data to assess time trends   
 A) Males 
B) Females 
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A) Males 
B) Females
Figure 16- IRs of hip/femur fracture by age groups in 
across databases in 2008.
 
0
50
100
150
200
250
300
0-9 10-19 20-29
In
c
id
e
n
c
e
 
o
f H
ip
/fe
m
u
r 
fra
c
tu
re
 
pe
r 
10
,0
00
py
DKMA
AHC
BAVARIAN
BIFAP
CPRD
THIN
NPCRD
0
50
100
150
200
250
300
0-9 10-19 20-29
In
c
id
e
n
c
e
 
o
f H
ip
/fe
m
u
r 
fra
c
tu
re
 
pe
r 
10
,0
00
py DKMA
BIFAP
BAVARIAN
CPRD
THIN
AHC
NPCRD
males and 
 
 
30-39 40-49 50-59 60-69 70-79 80+
Age groups
30-39 40-49 50-59 60-69 70-79 80+
Age groups
 
 
females 
 The median standardized IRR of females vs males was strongly dependent o
age: for age groups less than 50 years
consistently below 1, but then increased gradually reaching the maximum at the 
age 70-79 and then declined (
 
 
Figure 17- Box-plot showing 2008 IRRs of hip/femur fracture in females vs. 
males in the participating databases a
(Boxes represent the 25-75 percentiles; the bar within the box represents the median value).
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6.1.2 Prevalence of BZD and related drug use 
Prevalence rates (PRs), crude as well as age- and sex-standardized ones, are 
presented in Figure 18. Crude rates showed the highest prevalence of use in the 
BIFAP database (around 1,600 per 10,000 person-years) and the lowest in the 
German (Bavarian) and the British (CPRD and THIN) databases (around 570 per 
10,000 person-years). The standardization did not substantially change the 
observed differences. 
Prevalence rates by ATC group: anxiolytics (N05B) or hypnotics (N05C) 
The prevalence of BZD and related drugs classified as anxiolytics showed in 
the BIFAP database a PR of use 4-times higher than hypnotics during the whole 
study period (i.e. 1439.3 vs. 363.2 per 10,000 person-years for 2008), a PR 1.4 
times higher in the Bavarian database (i.e. 347.8 vs. 266.4 per 10,000 person-
years for 2008) and 1.2 times higher in the Mondriaan-AHC database (i.e. 666.7 
vs. 457.0 per 10,000 person-years for 2008). While in the Danish (DKMA), and 
the UK databases (CPRD and THIN), PR for hypnotics outweighed that of 
anxiolytics, around 1.2 to 1.5 times higher (i.e. 436.7 vs. 523.6, 302.8 vs. 355.6, 
and 291.5 vs. 359.6 per 10,000 person-years, respectively for 2008). Almost no 
differences were observed between anxiolytic or hypnotic drugs for the 
Mondriaan-NPCRD database (Figure 19). 
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Figure 18- PRs of BZD and related drugs use by year in all databases 
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A) Anxiolytics (N05BA)
B) Hypnotics (N05C) 
Figure 19- PRs of BZD and related drugs use 
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The prevalence of BZD
age in all databases both in females and in males, although the slopes were 
higher in females (Figure 
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Figure 20- PRs of BZD 
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This was observed in all age categories from 20 years and older. For all 
databases, the age-specific prevalence rates were about 1.5 to 2 times greater 
for women than for men, and this difference was particularly notorious in patients 
over 50 years of age. 
6.2 ANALYTICAL STUDIES 
6.2.1 Cohort study 
From BIFAP, following the incl
5.3.2, a initial study cohort was selected. Then, after a case ascertainment and 
validation process, a final study cohort was reached (Figure 2
 
Figure 21- Flow chart of 
Cohort and NCC populations
usion and exclusion criteria explained in section 
1). 
inclusion and exclusion criteria as well as final 
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6.2.1.1 Characteristics of the Cohort study population 
Final cohort of BZD or related drugs users was composed of 558,599 patients. 
Age ranged from 18-107 years old, with a mean=52.0 ± 17.1 and 66% were 
women. Information about life-styles factors, distribution by sex and age in 10-
years band categories was collected and presented in Table 8a and co-
medication and co-morbidities are presented in Table 8b, together with the crude 
hazard ratio (HR) for hip/femur fracture estimates with those covariates. 
Table 8a- Life-style characteristics and crude hazard ratio (HR) for 
hip/femur fracture estimates in the cohort 
Cohort Population N=558,599 (100%) HR 95%CI 
Mean Age (SD) years 52.0 (17.1)     
Age range (min - max) 18-107     
Age group (years)* 
18 - 29 75,264 (13.5)     
30 - 39                              18-39 105,270 (18.9) 0.42 0.31-0.57 
40 - 49 107,332 (19.2)     
50 - 59                              40-59 98,620 (17.7) 1.00ⱡ   
60 - 69 71,976 (12.9)     
70 - 79                               60-79 62,765 (11.2) 9.39 8.00-11.02 
80 - 89 31,475 (5.6)     
90+                                     80+ 5,897 (1.1) 50.26 42.84-58.96 
Sex 
Male 192,519 (34.5) 1.00ⱡ    
Female 366,080 (65.5) 1.75 1.59-1.92 
Smoking 
Yes 84,224 (15.1) 1.00ⱡ   
No 173,543 (31.1) 0.2 0.17-0.24 
Ex Fumador 8,240 (1.5) 0.37 0.26-0.53 
Unknow 292,592 (52.4) 0.5 0.46-0.55 
Alcohol Use  
Yes 17,380 (3.1)     
No / Unknown 541,219 (96.9)     
Body Mass Index (BMI) 
 < 18.5 kg/m2, % 3,838 (0.7) 1.61 1.14-2.28 
18.5-24,9 kg/m2, % 69,796 (12.5) 1.00ⱡ   
25-30 kg/m2, % 92,072 (16.5) 0.99 0.88-1.12 
>30 kg/m2, % 74,693 (13.4) 0.75 0.65-0.86 
Unknown % 318,200 (57.0) 0.74 0.67-0.83 
* Different age groups were created to calculate proportions N (%), and hazard ratios (HRs) in bold type; 
SD=Standard Deviation; ⱡ Reference category  
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The complete list of co-medications and co-morbidities was examined. As a 
result, the drugs most used in this population were: proton pump inhibitors; 
antihypertensive drugs [including angiotensin-converting enzyme (ACE) 
inhibitors, angiotensin II antagonists, beta blocking agents, calcium channel 
blockers and other antihypertensive drugs]; and non-steroidal anti-inflammatory 
drugs (NSAIDs), considered as exposed only if the patient had two or more 
prescriptions of those drugs; followed by statins, diuretics, antidepressants, and 
bronchodilators. 
The following medication was taken by more than 2% of the population, but in 
lower percentages than the ones mentioned before: other antidiabetics 4.7%; 
morphine/opiates 4.2%; antipsychotics/lithium 3.4%; vitamin D plus Calcium and 
analogues 3.1%; thyroid hormones 2.7%; anticoagulants 2.5%; anticonvulsants 
2.2%; and antiemetic 2.0%. 
In the same way, the most prevalent diseases in this population were: 
malignant neoplasms; anaemia; syncope; ischaemic heart disease (IHD); 
previous fractures; osteoporosis; cerebrovascular disease (CVA); and chronic 
obstructive pulmonary disease (COPD). The rest of morbidities explored were 
suffered by less than 2% of the population (see Table 8b). 
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Table 8b- Co-medications and co-morbidities and crude hazard ratio (HR) 
for hip/femur fracture estimates in the cohort 
Cohort Study Population N=558,599 (100%) HR 95%CI 
Oral Glucocorticoids* 2,671 (0.5) 3.09 2.55-3.73 
Bisphosphonates 9,855 (1.8) 2.69 2.32-3.11 
Raloxifene 3,907 (0.7) 0.5 0.28-0.88 
Strontium ranelate 478 (0.1) 1.95 1.04-3.62 
Parathyroid hormone 65 (0.0) 5.88 2.44-14.15 
Vitamin D+Calcium and analogues 17,153 (3.1) 2.15 1.47-3.15 
Calcitonin 1,450 (0.3) 3.44 2.38-4.96 
Antidepressants 39,868 (7.1) 1.87 1.72-2.04 
Antipsychotics / Lithium 19,050 (3.4) 2.62 2.32-2.95 
Anti-Parkinson drugs 2,991 (0.5) 6.27 5.27-7.45 
Anticonvulsants 12,498 (2.2) 2.76 2.44-3.12 
Inhaled glucocorticoids 9,175 (1.6) 1.54 1.22-1.95 
Bronchodilators**  34,043 (6.1) 1.73 1.53-1.95 
Anti-arrhytmics 3,209 (0.6) 3.62 2.86-4.57 
Sedating antihistamines 3,891 (0.7) 2.35 1.78-3.11 
Antihypertensive drugs† 93,745 (16.8) 3.06 2.83-3.31 
Diuretics 43,976 (7.9) 3.82 3.51-4.15 
Hormone Replacement Therapy (HRT) 6,789 (1.2) 0.21 0.10-0.45 
Thyroid hormones 14,966 (2.7) 1.19 0.99-1.43 
Antithyroid drugs 946 (0.2) 2.05 1.19-3.53 
Disease-modifyng anti-rheumatic drugs 2,730 (0.5) 1.64 1.13-2.38 
Thiazolidinediones 845 (0.2) 2.25 1.30-3.88 
Other antidiabetics 26,009 (4.7) 2.77 2.48-3.09 
Antiemetic (Metoclopramide) 11,307 (2.0) 1.54 1.23-1.92 
Anticoagulants 14,119 (2.5) 3.55 3.14-4.02 
Morphine / opiates 23,164 (4.2) 2.73 2.45-3.05 
NSAIDs (≥ 2 prescriptions ) 62,915 (11.3) 1.15 1.04-1.26 
Statins 45,161 (8.1) 1.39 1.25-1.55 
Proton pump inhibitors (PPI) 97,741 (17.5) 2.55 2.35-2.76 
Aromatase Inhibitors 806 (0.1) 3.48 2.33-5.20 
Osteoporosis 22,494 (4.0) 3.11 2.51-3.85 
Paget's disease 432 (0.1) 2.96 0.74-11.84 
Previous fractures  24,635 (4.4) 3.41 2.79-4.17 
Rheumatoid arthritis 2,886 (0.5) 1.92 0.92-4.04 
Anaemia 34,196 (6.1) 2.05 1.56-2.69 
Epilepsies/ seizures 5,013 (0.9) 1.63 0.90-2.95 
Syncope 28,322 (5.1) 1.73 1.31-2.28 
Ischaemic heart disease (IHD) 26,919 (4.8) 2.22 1.93-2.54 
Cerebrovascular disease (CVA) 17,294 (3.1) 5.32 4.44-6.38 
Malignant neoplasms 34,367 (6.2) 2.66 2.19-3.23 
Inflammatory bowel disease (IBD) 2,396 (0.4) 1.65 0.74-3.67 
Obstructive airway disease (COPD) 15,383 (2.8) 3.01 2.33-3.89 
Liver disease 8,699 (1.6) 1.87 1.17-2.97 
Chronic renal failure 4,688 (0.8) 6.35 4.64-8.67 
Mental disorders_no_depression 8,005 (1.4) 1.08 0.62-1.86 
Dementia and/ or Alzheimer's 5,732 (1.0) 11.25 8.90-14.20 
*Exposed to oral glucocorticoids for > 3 months 
**Including Beta-2-adrenoceptors agonist and Anticholinergics 
† Including angiotensin-converting enzyme (ACE) inhibitors, angiotensin II antagonists, beta blocking agents, 
calcium channel blockers and other antihypertensive drugs  
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6.2.1.2 Incidence rates of hip/femur fractures associated with BZD. 
Total person-time of the whole cohort was 1,695,045 person-years (py), with a 
mean of follow up time of 1,491.9 ± 782.9 days (4.1 years), ranged from 1 day to 
3,285 days (8.99 years). There were 2,459 valid cases of hip/femur fracture 
(0.44%), giving an incidence rate (IR) of 14.5 per 10,000 py, (95%CI: 13.94-
15.09). The mean time to a fracture (among cases) was 884.3 ± 705.4 days 
(range: 1 day to 3,114 days). 
The highest overall crude IR was observed among current users of BZD 24.4 
cases per 10,000 py, (95%CI: 23.10-25.73) decreasing to 8.7 cases per 10,000 
py (95%CI:
 
8.10-9.28) for past users. Similarly, women exhibited higher IRs than 
men in all exposure categories, being the highest IR among current users, and 
decreasing in recent and past periods of use (Figure 22). Regarding age 
distribution, the number of incident cases of hip/femur fracture increased 
exponentially with age regardless the exposure, while it is true that among 
current users and recent users the incidence of hip/femur fracture was higher 
than in past users. Low IRs were observed under 50-59 age category, but then 
increased sharply in the elderly. 
IRs of hip/femur fractures across exposure categories (current, recent or past 
use) by sex are presented in Figure 22; and IRs according to age distribution are 
represented in Figure 23. 
  
 Figure 22- IRs of hip/femur fractures across exposure categories
Figure 23- IRs of hip/femur fractures across exposure categories 
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 by sex. 
 
by age. 
Overall
Females
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6.2.1.3 Crude association of potential risk factors with hip/femur fractures 
In univariate Cox regression models (Table 8a) crude hazard ratios (HRs) of 
having a hip/femur fracture were higher in females and older people as it was 
expected. Those with a low body mass index (BMI <18.5 kg/m2) were the ones 
that showed risk associated to hip/femur fractures, taking as reference category 
BMI between 18.5 and 24.9 kg/m2. Smoking was not associated with the risk of 
having the event of interest. 
Among co-morbidities, diseases that showed the highest HRs were dementia 
and/or Alzheimer's with 11.25 (95%CI: 8.90-14.20) followed by chronic renal 
failure and cerebrovascular disease, with 6.35 (95%CI: 4.64-8.67) and 5.32 
(95%CI: 4.44-6.38) respectively. Then, with a hazard ratio around 3, were 
previous fractures, osteoporosis, Paget’s disease (although it was not statistically 
significant due to the low proportion of patients with this disease) and COPD. 
Complete information can be found in Table 8b. 
Among co-medications, drugs presented the highest crude HRs were anti-
Parkinson drugs and parathyroid hormone with 6.27 (95%CI: 5.27-7.45) and 5.88 
(95%CI: 2.44-14.15) respectively, followed by diuretics; anti-arrhythmic drugs; 
anticoagulants; aromatase inhibitors; calcitonin; glucocorticoids; and 
antihypertensive drugs, ranged between 3.06 and 3.82. Complete information 
can be found in Table 8b. 
6.2.1.4 Crude and adjusted HRs of having a hip/femur fracture associated 
with the duration of treatment with BZD; type of BZD; individual drugs; 
doses and half-life. 
Adjusted risk of hip/femur fractures by all potential confounding factors was 
explored according to recency (current, recent or past use). Also, among current 
users the effect of duration of treatment, type of BZD taken, individual drug, dose 
and half-life was examined. Five different models of adjustment were performed 
(see section 5.7.2.4). In Table 9 it is shown the two models with the major 
changes: "age-adjusted" model and the “fully-adjusted” (model D) together with 
Results 
 
125 
the crude estimates. A table with the rest of adjusting models can be found in the 
Appendix D. 
Table 9- Crude and adjusted HRs of hip/femur fracture 
COHORT 
    
Crude 
"Age-adjusted" 
model 
“Fully-adjusted” 
model D 
  Cases P_y HR (95%)CI HR (95%)CI HR (95%)CI 
PAST 851 980,993.2 1 - - 1 - - 1 - - 
RECENT 268 164,513.1 1.89 1.64 2.17 1.38 1.20 1.58 1.26 1.09 1.44 
CURRENT 1,340 549,538.7 2.83 2.60 3.09 1.39 1.28 1.52 1.17 1.07 1.28 
By Duration    
Current 0-30d 184 117,683.0 1.80 1.53 2.11 1.14 0.97 1.34 0.98 0.83 1.15 
Current 31-60d 179 100,432.9 2.06 1.75 2.43 1.28 1.08 1.50 1.10 0.93 1.29 
Current 61-180d 267 117,810.3 2.59 2.26 2.98 1.25 1.09 1.44 1.04 0.91 1.20 
Current 181-365d 212 67,096.9 3.64 3.13 4.23 1.54 1.32 1.79 1.27 1.09 1.48 
Current >365 498 146,515.6 3.93 3.52 4.39 1.59 1.42 1.78 1.33 1.18 1.48 
Type of BZD by ATC  
Current both 159 56,050.1 3.29 2.77 3.90 1.63 1.37 1.93 1.21 1.01 1.43 
Single use of anxiolytics 894 418,895.8 2.48 2.26 2.73 1.37 1.24 1.50 1.17 1.07 1.29 
Single use of hypnotics 287 74,592.8 4.46 3.90 5.11 1.36 1.19 1.56 1.16 1.01 1.33 
By Individual drugs  
Anxiolytics (N05BA) 838 377,824.1 2.58 2.34 2.84 1.39 1.26 1.53 1.20 1.09 1.33 
Lorazepam 453 134,490.5 3.90 3.48 4.37 1.58 1.41 1.77 1.34 1.19 1.50 
Bromazepam 171 96,793.9 2.05 1.74 2.41 1.11 0.95 1.31 1.01 0.86 1.19 
Diazepam 92 60,637.8 1.76 1.42 2.18 1.36 1.10 1.69 1.23 0.99 1.53 
Alprazolam 56 41,301.8 1.57 1.20 2.06 1.31 1.00 1.72 1.06 0.81 1.39 
Others  66 44,600.1 1.72 1.33 2.21 1.27 0.99 1.64 1.08 0.84 1.40 
Hypnotics (N05CD) 166 43,777.9 4.40 3.72 5.20 1.35 1.14 1.60 1.22 1.03 1.44 
Lormetazepam 150 36,888.9 4.70 3.95 5.59 1.47 1.23 1.75 1.32 1.11 1.57 
Flurazepam 3 1,969.8 1.76 0.57 5.48 0.80 0.26 2.49 0.74 0.24 2.29 
Loprazolam 3 2,270.2 1.53 0.49 4.75 0.43 0.14 1.32 0.42 0.13 1.29 
Others  10 2,649.0 4.37 2.34 8.15 1.07 0.58 2.01 0.91 0.49 1.70 
Hypnotics (N05CF) 58 24,166.3 2.79 2.14 3.64 1.07 0.82 1.40 0.98 0.75 1.29 
Zolpidem 57 22,092.1 2.99 2.28 3.91 1.17 0.89 1.53 1.08 0.82 1.41 
Others     1 2,074.2 0.56 0.08 3.97 0.19 0.03 1.35 0.17 0.02 1.21 
Other N05CM02 54 3,857.3 16.28 12.36 21.44 2.17 1.64 2.86 1.31 0.97 1.78 
By Half Life  
Short  <8h 125 33,015.9 4.40 3.64 5.31 1.38 1.14 1.66 1.09 0.90 1.32 
Intermediate 8-24h 850 323,139.3 3.05 2.77 3.36 1.40 1.27 1.54 1.22 1.10 1.34 
Long  >24h 141 93,470.2 1.75 1.47 2.10 1.31 1.10 1.57 1.16 0.97 1.39 
By Dose (last Rx)  
Low dose (< 1DDD) 630 248,270.9 2.95 2.66 3.27 1.42 1.28 1.57 1.21 1.09 1.35 
Medium dose (=1DDD) 135 56,427.9 2.78 2.32 3.33 1.19 0.99 1.42 1.06 0.89 1.28 
High dose (>1DDD) 76 31,462.5 2.80 2.22 3.55 1.75 1.38 2.21 1.42 1.12 1.80 
Missing 275 113,464.2 2.83 2.47 3.25 1.35 1.17 1.55 1.18 1.03 1.35 
P_y= person-years; Rx= Prescription; Others (N05BA): Clobazam, Clotiazepam, Pinazepam, Oxazepam, Chlordiazepoxide, 
Prazepam, Clorazepate, Ketazolam and Halazepam; Others (N05CD): Midazolam, Triazolam, Brotizolam, Flunitrazepam, 
Quazepam, Nitrazepam, and Temazepam; Others (N05CF): Zopiclone and Zaleplon; N05CM02: Clomethiazole 
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Use of BZD or related drugs: Crude HRs estimates showed a strong 
association with the current use of these drugs (2.83; 95%CI: 2.60-3.09). After 
adjusting by age and by all covariates (full model D), risk estimates of hip/femur 
fractures associated with current and recent users were similar, (1.17, 95%CI: 
1.07-1.28) and (1.26, 95%CI: 1.09-1.44) respectively. 
Duration of treatment: Crude HRs exhibited an increased risk of hip/femur 
fractures with the duration of treatment, short treatments 1.8 (95%CI: 1.53-2.11) 
and for long treatments (>365 days), 3.93 (95%CI: 3.52-4.39). Adjusted HRs 
showed same trend than crude estimates, however, the risk of having a hip/femur 
fracture dropped dramatically and became non-significant for duration periods 
shorter than six months (see Table 9). 
Type of BZD classified by ATC subgroup: The crude risk was almost two fold 
higher with hypnotics than with anxiolytics, being 4.46 (95%CI: 3.90-5.11) and 
2.48 (95%CI: 2.26-2.73), respectively, and the risk of taking both types of BZD 
was in-between (3.29, 95%CI: 2.77-3.90). Whereas after adjusting by age, the 
highest risk was exhibited by the use of both, anxiolytics and hypnotics as well as 
after adjusting by all covariates (full model D). No difference was observed 
between the single use of anxiolytics and the single use of hypnotics in the 
adjusted estimates. 
Individual BZD or related drug: Crude estimates for individual drugs 
demonstrated that anxiolytics presented lower risk than hypnotics in general, 
being lorazepam the drug with the highest risk among them (HR=3.90; 95%CI: 
3.48-4.37), followed by bromazepam, (HR= 2.05; 95%CI: 1.74-2.41). Though 
after adjusting with the full model, bromazepam showed no risk, and diazepam 
marginal increased risk (1.23; 95%CI: 0.99-1.53). Lorazepam exhibited still the 
highest risk of all individual drugs, (HR=1.34; 95%CI: 1.19-1.50). 
Among hypnotics (N05CD) the most used drug was lormetazepam showing a 
crude HR of 4.70 (95%CI: 3.95-5.59) and a full adjusted HR of 1.32 (95%CI: 
1.11-1.57). From other hypnotic groups, zolpidem (N05CF) showed no risk after 
full adjustement (HR=1.08; 95%CI: 0.82-1.41), while zopiclone and zaleplon 
hardly had any exposed cases. The highest risk was seen with clomethiazole 
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(N05CM02), being 3 times higher than the risk group of N05CD, but it is 
remarkable the HR sharply fell after adjustment from 16.28 (95%CI: 12.36 -21.44) 
to 1.31 (95%CI: 0.97-1.78). While the risk observed with lormetazepam was 
present after adjusting (1.32; 95%CI: 1.11-1.57). 
Half-life of BZD: In crude estimates, BZDs with shortest half-lives (<8h) 
presented the higher risks, while those with long half-lives (>24h) the lowest. This 
trend disappeared once estimates were age- or fully-adjusted, where the highest 
risk was presented by BZD with intermediate half-lives. 
Dose of BZD: No dose effect was detected in the crude estimates. In contrast, 
BZD at high doses (>1DDD) showed the highest risk after age- and full-
adjustment. 
In addition half-life and doses of single use of anxiolytics and hypnotics was 
explored separately. No risk was found associated with half-life either. Regarding 
dose, high doses of anxiolytics and low doses of hypnotics accounted for the 
highest risk associated with hip/femur fractures. The analyses of doses using last 
instead of first prescriptions yielded similar results. Tables for the mentioned 
additional analyses can be found in the Appendix D. 
6.2.1.5 Stepwise analysis 
After running the most parsimonious model obtained only with the following 
variables: age, sex, previous fractures, glucocorticoids, antidepressants, anti-
Parkinson drugs and the interaction between antidepressants with anti-Parkinson 
drugs, the estimates observed were slightly higher than those obtained with the 
full model "D", changing the estimate for recent users from 1.26 (95%CI: 1.09-
1.44) to 1.30 (95%CI: 1.13-1.49) and for current users from 1.17 (95%CI: 1.07-
1.28) to 1.24 (95%CI: 1.13-1.35). This analysis was only performed for the main 
exposure to BZD and related drugs, using past use as reference category. 
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6.2.2 NCC study 
The cases and controls for this study were selected from the cohort study. 
See flow chart in Figure 21 with the source population and criteria applied for the 
final population. 
6.2.2.1 Characteristics of cases and controls at index date 
Final NCC study population was comprised of 12,289 patients (2,459 cases 
and 9,830 controls). Cases and controls were matched by sex, age and follow-up 
(time between start and index date). About 44% of patients were between 80-89 
years old, with a mean=78.5 ± 12.5 and 78% were women. Distribution by sex 
and age in 10-years band categories is presented in Table 10a. About half of 
patients had less than 2 years of follow up, and 37% between 2-4 years. 
Table 10a- Age, sex and follow up time for cases and controls 
NCC population Cases N=2,459 Cases (100%) Controls N=9,830 Controls (100%) 
Age in years at index date     
18-29 y 11 0.45 44 0.45 
30-39 y 39 1.59 156 1.59 
40-49 y 53 2.16 212 2.16 
50-59 y 97 3.94 388 3.95 
60-69 y 198 8.05 792 8.06 
70-79 y 651 26.47 2604 26.49 
80-89 y 1071 43.55 4284 43.58 
³ 90 y 339 13.79 1350 13.73 
Mean (SD) of age  78.55 (12.54) - 78.53 (12.52) - 
Sex     
Female 1927 78.37 7702 78.35 
Male 532 21.63 2128 21.65 
Time window (Median, IQR)† 1.94 (0.84-3.64) 1.93 (0.84-3.65) 
<2 years 1255 51.04 5014 51.01 
2-4  years 907 36.88 3633 36.96 
5-7 years 286 11.63 1143 11.63 
8> years 11 0.45 40 0.41 
 
SD=Standard deviation; IQR=interquartiles; (†) Cases and Controls are matched by sex, age and follow up (Eme 
between start and index date) 
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The complete list of co-medications and co-morbidities was examined as well. 
Broadly, cases showed a higher prevalence of drug use than controls, with the 
exception of antihypertensive drugs; diuretics; antipsychotics/lithium; other 
antidiabetics; non-steroidal anti-inflammatory drugs; statins; and bronchodilators 
which presented a similar prevalence, and raloxifen and HRT which presented a 
lower prevalence among cases than controls (see Table 10b). 
Similarly, the prevalence of co-morbidities was higher in cases than controls, 
showing big differences for previous fractures (19.8 vs. 9.7%) and dementia 
and/or Alzheimer's (10.7 vs. 6.5%). Other frequent co-morbidities presented in 
this population were osteoporosis; anaemia; syncope; malignant neoplasms; 
cerebrovascular disease; ischemic heart disease and chronic obstructive 
pulmonary disease. 
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Table 10b- Co-medication and co-morbidities from cases and controls and 
crude association with hip/femur fractures 
NCC study population Cases N Cases % ControlsN Controls% CrudeOR 95% (CI) p-value 
Co-medication 
       
Glucocorticoids* 52 2.11 122 1.24 1.71 1.24-2.37 0.001 
Bisphosphonates 201 8.17 650 6.61 1.27 1.07-1.50 0.005 
Raloxifene 10 0.41 91 0.93 0.43 0.22-0.83 0.012 
Strontium ranelate 12 0.49 36 0.37 1.34 0.69-2.60 0.383 
Parathyroid hormone 6 0.24 8 0.08 3.19 1.06-9.56 0.039 
Vitamin D+Ca 279 11.35 1016 10.34 1.12 0.97-1.29 0.134 
Calcitonin 34 1.38 77 0.78 1.78 1.19-2.68 0.005 
Antidepressants 795 32.33 2022 20.57 1.88 1.70-2.08 < 0.001 
Antipsychotics / Lithium 312 12.69 805 8.19 1.64 1.42-1.89 < 0.001 
Anti-Parkinson drugs 140 5.69 229 2.33 2.56 2.06-3.19 < 0.001 
Anticonvulsants 308 12.53 742 7.55 1.77 1.53-2.04 < 0.001 
Inhaled glucocorticoids 67 2.72 330 3.36 0.80 0.61-1.05 0.111 
Bronchodilators* 313 12.73 1225 12.46 1.03 0.90-1.17 0.708 
Anti-arrhytmics 74 3.01 220 2.24 1.36 1.04-1.77 0.026 
Sedating antihistamines 49 1.99 170 1.73 1.16 0.84-1.59 0.375 
Antihypertensive drugs* 1200 48.80 4917 50.02 0.95 0.87-1.04 0.270 
Diuretics 784 31.88 3144 31.98 0.99 0.90-1.10 0.901 
HRT 7 0.28 29 0.30 0.96 0.41-2.26 0.931 
Thyroid hormones 125 5.08 473 4.81 1.06 0.87-1.30 0.568 
Antithyroid drugs 13 0.53 53 0.54 0.98 0.53-1.80 0.951 
DMARDs 28 1.14 63 0.64 1.79 1.14-2.81 0.011 
Thiazolidinediones 14 0.57 30 0.31 1.87 0.99-3.52 0.054 
Other antidiabetics 372 15.13 1310 13.33 1.16 1.03-1.32 0.019 
Antiemetic  78 3.17 213 2.17 1.47 1.13-1.92 0.004 
Anticoagulants 309 12.57 914 9.30 1.41 1.23-1.62 < 0.001 
Morphine / opiates 405 16.47 977 9.94 1.80 1.59-2.05 < 0.001 
NSAIDs  477 19.40 1662 16.91 1.19 1.06-1.33 0.003 
Statins 412 16.75 1969 20.03 0.80 0.71-0.90 < 0.001 
PPI 1197 48.68 4191 42.63 1.30 1.19-1.42 < 0.001 
Aromatase Inhibitors 23 0.94 57 0.58 1.63 1.00-2.66 0.050 
Co-morbidities 
       
Osteoporosis 417 16.96 1302 13.25 1.36 1.20-1.54 < 0.001 
Paget's disease 10 0.41 38 0.39 1.05 0.52-2.11 0.885 
Previous fractures  487 19.80 957 9.74 2.30 2.04-2.59 < 0.001 
Rheumatoid arthritis 38 1.55 116 1.18 1.31 0.91-1.90 0.146 
Anaemia 418 17.00 1229 12.50 1.46 1.29-1.66 < 0.001 
Epilepsies/ seizures 44 1.79 107 1.09 1.66 1.17-2.38 0.005 
Syncope 374 15.21 1180 12.00 1.33 1.17-1.51 < 0.001 
IHD 305 12.40 1261 12.83 0.96 0.84-1.10 0.559 
CVA 306 12.44 820 8.34 1.58 1.37-1.81 < 0.001 
Malignant neoplasms 371 15.09 1134 11.54 1.37 1.20-1.55 < 0.001 
IBD 18 0.73 36 0.37 2.02 1.14-3.56 0.016 
COPD 216 8.78 692 7.04 1.29 1.10-1.53 0.002 
Liver disease 62 2.52 178 1.81 1.41 1.05-1.88 0.023 
Chronic renal failure 118 4.80 406 4.13 1.16 0.94-1.44 0.158 
Mental disorders  65 2.64 148 1.51 1.78 1.32-2.39 < 0.001 
Dementia / Alzheimer's 264 10.74 635 6.46 1.77 1.52-2.06 < 0.001 
*same variables and conditions for all studies (see Table 8b)   
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6.2.2.2 Crude association of potential risk factors with hip/femur fractures. 
Crude odds ratios (ORs) of co-medication and co-morbidities were estimated 
and presented in Table 10b. Among co-morbidities, diseases that showed the 
highest ORs were previous fractures (2.30, 95%CI: 2.04-2.59) intestinal bowel 
disease (2.02, 95%CI: 1.14-3.56), mental disorders without depression (1.78, 
95%CI: 1.32-2.39), dementia and/or Alzheimer's (1.77, 95%CI: 1.52-2.06), 
epilepsies/seizures (1.66, 95%CI: 1.17-2.38) and cerebrovascular disease (1.58, 
95%CI: 1.37-1.81). Among co-medications, drugs presenting the highest ORs 
were parathyroid hormone and anti-Parkinson drugs with 3.19 (95%CI: 1.06-9.56) 
and 2.56 (95%CI: 2.06-3.19) respectively, followed by antidepressants; 
thiazolidinediones (although no statistically significant); morphine/opiates; 
disease-modifying anti-rheumatic drugs; calcitonin; glucocorticoids; 
antipsychotic/lithium; and aromatase inhibitors, ranged between 1.63 and 1.88. 
The rest of co-medication and co-morbidities with an OR less than 1.5 can be 
found in the Table 10b. 
6.2.2.3 Risk of hip/femur fracture associated with BZD and related drugs 
Crude and adjusted (model D) ORs of having a hip/femur fracture associated 
with the use of BZD and related drugs, are shown in Table 11. Risk estimates for 
specifics aspects of current use such as duration of treatment and type of BZD by 
ATC group were presented as well. Different groups of potential confounding 
factors were included in their respective conditional logistic models (models B, C 
and D). Tables with the rest of the models can be found in the Appendix E. 
A sensitivity analysis measuring co-medication 30 days previous to the index 
date was also performed and presented in Table 11. 
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Table 11- Risk estimates of hip/femur fracture associated with BZD, and by 
duration and type of ATC group in the NCC. 
NCC Cases(%) Controls(%) NCC Crude* Full model Sensitivity full** 
    OR (95%CI) OR (95%CI) OR (95%CI) 
Past use (ref.) 851 (34.6) 3,949 (40.2) 1.00   1.00   1.00   
Recent use 268 (10.9) 934 (9.5) 1.39 1.18-1.63 1.30 1.10-1.54 1.36 1.15-1.61 
Current use 1,340 (54.5) 4,947 (50.3) 1.30 1.17-1.43 1.14 1.02-1.26 1.19 1.06-1.32 
By Duration         
Current 0-30d 184 (13.7) 786 (15.9) 1.06 0.86-1.32 1.03 0.82-1.30 1.06 0.84-1.33 
Current 31-60d 179 (13.4) 686 (13.9) 1.26 1.02-1.56 1.19 0.95-1.48 1.22 0.98-1.53 
Current 61-182d 267 (19.9) 1,058 (21.4) 1.20 1.02-1.41 1.04 0.88-1.24 1.09 0.92-1.29 
Current 183-365 212 (15.8) 660 (13.3) 1.51 1.27-1.80 1.30 1.08-1.56 1.37 1.14-1.65 
Current >365d 498 (37.2) 1,757 (35.5) 1.34 1.17-1.53 1.14 0.99-1.31 1.20 1.04-1.38 
By ATC drug         
Use of both 161 (12) 407 (8.2) 1.87 1.53-2.28 1.40 1.13-1.73 1.48 1.20-1.84 
Anxiolytics 894 (66.7) 3,476 (70.3) 1.23 1.10-1.37 1.11 0.99-1.25 1.17 1.04-1.31 
Hypnotics 285 (21.3) 1,064 (21.5) 1.28 1.09-1.49 1.10 0.94-1.30 1.13 0.96-1.33 
*Crude: adjusted only for matching factors (age, sex and index date) 
**Sensitivity Analysis: Full model but co-medication variables were measured at 30 days from 
index date. 
Recency of use of BZD or related drug: The full-adjustment for all potential 
risk factors hardly changed the OR associated with current use as compared with 
the crude one (adjusted only for the matching factors), indicating that the 
matching factors (in particular age) were the most relevant confounding factors. 
To note, recent users presented slightly higher ORs than current users. 
Duration of treatment: No clear trend was observed with duration of treatment. 
In particular, there was no short term effect.  
Type of BZD classified by ATC: In this design, the highest risk of having a 
hip/femur fracture was associated with the use of both anxiolytic and hypnotics. 
Risk estimates for the use of anxiolytic or hypnotic separately were quite similar. 
The sensitivity analysis in the NCC, showed no material differences (Table 
11). 
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6.2.2.4 Stepwise analysis 
A more parsimonious model was obtained with only the following variables: 
previous fractures, glucocorticoids, antidepressants, anticonvulsants and 
morphine/opiates. The analysis yielded similar ORs estimates than those 
obtained with the full model: current use, 1.14 (95%CI: 1.03-1.26) and recent use, 
1.29 (95%CI: 1.09-1.52). 
6.2.3 CXO study 
6.2.3.1 Characteristics of the CXO study population at index date 
From 5,705 patients available in BIFAP who fulfilled the required criteria, 293 
were unable to participate in the study because it was not possible to find a 
control moment for them. Thus, the final CXO study population was comprised of 
5,412 patients with a recorded diagnosis of hip/femur fracture, and at least one 
control moment; from them, 95% had two, 90% had three and 85% had four 
control moments respectively. From those cases, 1,368 had not a prescription of 
BZD or related drug before the recorded code of hip/femur fracture. And only 
1,820 discordant pairs were included in the analysis. Mean age of patients were 
78.3 ± 13.1 years old, and 78% were women. The index date was the hip/femur 
fracture date, and the four controls moments were at -91, -182, -273, -365 days. 
A flow chart with the source population, inclusion and exclusion criteria, case 
ascertainment and final populations for case only designs is presented in Figure 
24. 
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Figure 24- Flow chart of CXO and SCCS final populations
The sample size for the SCCS design was lower than for the CXO due to the 
additional requirement of no BZD use six months befo
gender, mean age in years
fracture is presented in Table 1
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Table 12- Gender distribution, and co-medication used by CXO population. 
CXO Population N=5,412 100% 
Age, mean (S.D.) 78.27 (13.11) 
Gender    
Female 4,224 78.05 
Male 1,188 21.95 
Co-morbidities (anytime before)   
Osteoporosis 844 15.59 
Paget’s disease 24 0.44 
Previous fractures 1,010 18.66 
Rheumatoid arthritis  80 1.48 
Anaemia 879 16.24 
Epilepsy/Seizures 94 1.74 
Syncope 665 12.29 
Ischaemic heart disease (IHD) 661 12.21 
Cerebrovascular disease (ACV) 617 11.40 
Malignant neoplasms 731 13.51 
Inflammatory bowel disease (IBD) 30 0.55 
Chronic Obstructive Pulmonary Disease (COPD) 423 7.82 
Liver disease 136 2.51 
Chronic renal failure 254 4.69 
Mental disorders (without depression) 139 2.57 
Dementia and/or Alzheimer's 566 10.46 
SD=Standard deviation 
Regarding the most used drugs, 40% of this population was using 
antihypertensive drugs at index date (hip/femur fracture); 37% were taking proton 
pump inhibitors; and around 25% were using diuretics and antidepressants. In 
less proportion, but more than 8% of the population were using other 
antidiabetics; statins; morphine/opiates; bronchodilators; non-steroidal anti-
inflammatory drugs; anticoagulants; antipsychotics / lithium; anticonvulsants and 
vitamin D plus calcium and analogues (Table 13). 
  
  
 
Table 13- Co-medication and its crude association with hip/femur fracture in the CXO population 
 
Co-medication use* 
Case M 
N(%) 
Control M1 
N(%) 
Control M2 
N(%) 
Control M3 
N(%) 
Control M4 
N(%) 
∑ control (date1-4) 
N(%) 
OR 95% CI 
Glucocorticoids 97(1.8) 85(1.6) 77(1.5) 71(1.5) 71(1.5) 304(1.5) 1.72 1.17-2.54 
Bisphosphonates 304(5.6) 308(5.7) 285(5.5) 258(5.3) 241(5.2) 1,092(5.5) 1.26 0,97-1,65 
Raloxifene 22(0.4) 19(0.4) 23(0.5) 19(0.4) 20(0.4) 81(0.4) 1.11 0,41-3,01 
Strontium ranelate 11(0.2) 15(0.3) 15(0.3) 14(0.3) 12(0.3) 56(0.3) 0.48 0,15-1,49 
Parathyroid hormone 9(0.2) 3(0.1) 6(0.1) 4(0.1) 3(0.1) 16(0.1) 14.24 1,65-122,94 
Vitamin D/Calcium  451(8.3) 434(8.0) 431(8.4) 393(8.1) 380(8.3) 1,638(8.2) 1.12 0,93-1,34 
Calcitonin 54(1.0) 49(0.9) 42(0.8) 44(0.9) 37(0.8) 172(0.9) 1.39 0,89-2,16 
Antidepressants  1,332(24.6) 1,297(24.0) 1,182(23.0) 1,063(21.8) 969(21.1) 4,511(22.5) 1.72 1,49-1,98 
Antipsychotics 481(8.9) 441(8.2) 394(7.7) 364(7.5) 312(6.8) 1,511(7.5) 1.54 1,30-1,83 
Anti-Parkinson drugs 262(4.8) 260(4.8) 234(4.6) 217(4.5) 200(4.4) 911(4.6) 1.97 1,28-3,02 
Anticonvulsants 463(8.6) 465(8.6) 404(7.9) 358(7.4) 335(7.3) 1,562(7.8) 1.52 1,23-1,88 
Inhaled glucocortic. 113(2.1) 132(2.4) 122(2.4) 109(2.2) 104(2.3) 467(2.3) 0.67 0,46-0,96 
Bronchodilators 526(9.7) 537(9.9) 490(9.5) 459(9.4) 429(9.3) 1,915(9.6) 1.11 0,92-1,34 
Anti-arrhythmics 131(2.4) 122(2.3) 108(2.1) 97(2.0) 94(2.0) 421(2.1) 1.90 1,17-3,09 
Sedating Antihistamines 67(1.2) 73(1.4) 60(1.2) 49(1.0) 47(1.0) 229(1.1) 1.22 0,84-1,78 
Antihypertensives 2,615(40) 2,240(41.4) 2,119(41.2) 1,989(40.8) 1,855(40.3) 8,203(41.0) 0.95 0,84-1,09 
Diuretics 1,385(25.6) 1,422(26.3) 1,311(25.5) 1,231(25.3) 1,146(24.9) 5,110(25.5) 1.11 0,97-1,27 
HRT 10(0.2) 6(0.1) 10(0.2) 9(0.2) 11(0.2) 36(0.2) 1.16 0,38-3,50 
Thyroid hormones 205(3.8) 198(3.7) 197(3.8) 175(3.6) 156(3.4) 726(3.6) 1.53 1,03-2,26 
Antithyroid drugs 23(0.4) 21(0.4) 27(0.5) 20(0.4) 18(0.4) 86(0.4) 1.07 0,44-2,62 
DMARDs 42(0.8) 47(0.9) 43(0.8) 49(1.0) 38(0.8) 177(0.9) 0.80 0,42-1,50 
Thiazolidinediones 22(0.4) 19(0.4) 19(0.4) 18(0.4) 17(0.4) 73(0.4) 2.02 0,76-5,38 
Other antidiabetics 718(13.3) 764(14.1) 737(14.3) 695(14.3) 646(14.1) 2,842(14.2) 0.68 0,54-0,85 
Antiemetics 83(1.5) 81(1.5) 70(1.4) 59(1.2) 50(1.1) 260(1.3) 1.24 0,93-1,64 
Anticoagulants 509(9.4) 452(8.4) 396(7.7) 384(7.9) 342(7.4) 1,574(7.9) 1.96 1,62-2,37 
Morphine/opiates 613(11.3) 552(10.2) 491(9.5) 439(9.0) 378(8.2) 1,860(9.3) 1.88 1,61-2,20 
NSAIDs 514(9.5) 567(10.5) 535(10.4) 490(10.1) 487(10.6) 2,079(10.4) 0.85 0,74-0,98 
Statins 680(12.6) 735(13.6) 680(13.2) 648(13.3) 612(13.3) 2,675(13.4) 0.87 0,70-1,06 
PPIs 2,015(31.2) 1,986(36.7) 1,794(34.9) 1642 1498 6920(34.6) 1.56 1,40-1,74 
Aromatase Inhibitors 34(0.6) 37(0.7) 39(0.8) 35 30 141(0.7) 0.77 0,35-1,69 
 
M=moment; M1= moment 1 etc. 
*Exposure: at least a prescription within the previous 91 days. Reference category: non-use in the 91 days window. (Glucocorticoids and NSAIDs were measured as in the rest of 
designs). 
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6.2.3.2 Crude association of potential risk factors with hip/femur fractures. 
As a case only design, this study based its analysis on comparison within 
individuals hence all intrinsic potential confounding factors were controlled for by 
design. Thus, the association with the outcome was not measured for any of the 
co-morbidities because they were considered conditions that do not vary within 
each patient (in a limit time span). Instead, co-medications were considered time-
varying variables. Crude odds ratios (ORs) of co-medication were estimated and 
presented in Table 13. Among drugs that showed the highest ORs were 
parathyroid hormone with an OR of 14.24 but very wide 95%CI: 1.65-122.94, 
because the number of patients who took this drug was very small; 
thiazolidinediones, 2.02 although was not statistically significant 95%CI: 0.76-
5.38; anti-Parkinson drugs 1.97 (95%CI: 1.28-3.02); anticoagulants 1.96 (95%CI: 
1.62-2.37); anti-arrhythmics 1.90 (95%CI: 1.17-3.09); morphine/opiates 1.88 
(95%CI: 1.61-2.20); antidepressants 1.72 (95%CI: 1.49-1.98); and 
glucocorticoids 1.72 (95%CI: 1.17-2.54); followed by proton pump inhibitors, 
antipsychotics/lithium; thyroid hormones and anticonvulsants, ranged between 
1.56 and 1.52. The rest of co-medications with an OR less than 1.5 can be found 
in the Table 13. 
6.2.3.3 Risk of hip/femur fracture associated with BZD and related drugs 
There was only one adjusted model for this design, including all co-
medications, named as full model. Table 14 summarizes crude and adjusted risk 
estimates of having a hip/femur fracture associated with BZD or related drugs 
use. Risk estimates by type of ATC group were presented as well. A table with 
the complete model for the CXO design can be found in the Appendix F. 
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Table 14- Risk estimates of hip/femur fracture associated with BZD use, and 
type of BZD by ATC group in the CXO design 
CXO 
Crude Full model* 
OR 95% CI OR 95% CI 
No use/past use Reference   Reference   
Recent use 1.88 1,62-2,18 1.69 1,46-1,97 
Current use 1.70 1,50-1,92 1.47 1,29-1,67 
Type of BZD by ATC group 
Both 3.62 2,77-4,75 3.03 2,30-4,00 
Anxiolytics 1.42 1,23-1,63 1.24 1,07-1,43 
Hypnotics 2.09 1,64-2,67 1.82 1,42-2,33 
*Full model: adjusted by all co-medication 
The ORs observed for current and recent use of BZD and related drugs 
indicated a relevant association between the exposure and the outcome, in the 
crude and adjusted estimates. 
Regarding the type of BZD by ATC group, patients who took both, anxiolytics 
and hypnotics, had higher risk than those who took them separately. 
6.2.3.4 Stepwise analysis 
A more parsimonious model was built with the following variables: 
antidepressants, antipsychotics; anticoagulants; morphine/opiates; and proton 
pump inhibitors. The analysis was run for the main exposure, giving similar 
results than the full model. Current use, OR=1.45 (95%CI: 1.28-1.65) and recent 
use, 1.71 (95%CI: 1.47-1.98). 
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6.2.4 SCCS study 
A common flow chart with the source population, inclusion and exclusion 
criteria, case ascertainment and final populations for case only designs was 
presented in Figure 24. 
6.2.4.1 Baseline characteristics of the SCCS study population 
Final SCCS study population was composed of 4,450 patients who had a 
recorded diagnosis of hip/femur fracture and at least one prescription of BZD or 
related drug within the observation period (1/01/2001-31/12/2009). Patients had a 
median duration of the observation period of 1,956 days (5.4 years). 
Age ranged from 18-106 years old, with a mean age of 74.5 ± 13.6 years old 
and a mean age at first exposure of 76.4 ± 13.6 years old. About 77% were 
women. From all cases, 35% had a hip/femur fracture during the exposure to 
BZD or related drug, with a median duration of exposure to BZD of 360 days. 
Distribution by sex and age in 10-years band categories and co-morbidities at 
baseline are presented in Table 15. 
Osteoporosis; previous fractures; malignant neoplasms; ischemic heart 
disease; cerebrovascular disease; chronic obstructive pulmonary disease and 
anaemia, were the most frequent co-morbidities for this study population. 
Regarding co-medication of these patients collected at baseline, the most 
used drugs were antihypertensives (21.6%); diuretics (12.8%); and proton pump 
inhibitors (11.8%). Followed by other antidiabetics; antidepressants; non-steroidal 
anti-inflammatory drugs; statins; and bronchodilators, in a proportion between 5-
10%. Information about all co-medication can be found in Table 16. 
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Table 15- Baseline characteristics and co-morbidities of SCCS population 
Total SCCS population N=4,450 100% 
Age 
18 - 29 57 1.28 
30 - 39 100 2.25 
40 - 49 134 3.01 
50 - 59 254 5.71 
60 - 69 540 12.13 
70 - 79 1,531 34.4 
80 - 89 1,563 35.12 
90+ 271 6.09 
Sex 
Male 1,038 23.33 
Female 3,412 76.67 
Co-morbidities 
Osteoporosis 385 8.65 
Paget's disease 12 0.27 
Previous fractures 383 8.61 
Fractures during BZD exposure 1,543 34.67 
Rheumatoid arthritis 47 1.06 
Anaemia 230 5.17 
Epilepsies/ seizures 49 1.10 
Syncope 133 2.99 
IHD 341 7.66 
CVA 317 7.12 
Malignant neoplasms 372 8.36 
IBD 13 0.29 
COPD 248 5.57 
Liver disease 60 1.35 
Chronic renal failure 81 1.82 
Mental disorders_no_depresion 49 1.10 
Dementia and/ or Alzheimer's 174 3.91 
* Observation period is from start date until the end of observation: patient died, leave 
the practice or the practice leave the database (end of data collection) or end of the 
study period. 
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Table 16- Co-medication at baseline of SCCS population 
Total SCCS population N=4,450 100% 
Co-medication  
Glucocorticoids 33 0.74 
Bisphosphonates 92 2.07 
Raloxifene 10 0.22 
Strontium ranelate 0 0.00 
Parathyroid hormone 1 0.02 
Vitamin D+Ca  179 4.02 
Calcitonin 37 0.83 
Antidepressants 316 7.10 
Antipsychotics/ Lithium 132 2.97 
Anti-Parkinson drugs 87 1.96 
Anticonvulsants 105 2.36 
Inhaled glucocorticoids 85 1.91 
Bronchodilators  235 5.28 
Anti-arrhytmics 52 1.17 
Sedating antihistamines 24 0.54 
Antihypertensive drugs 962 21.62 
Diuretics 570 12.81 
HRT 14 0.31 
Thyroid hormones 62 1.39 
Antithyroid drugs 9 0.20 
DMARDs 27 0.61 
Thiazolidinediones 2 0.04 
Other antidiabetics 340 7.64 
Antiemetic 41 0.92 
Anticoagulants 156 3.51 
Morphine/ opiates 156 3.51 
NSAIDs  311 6.99 
Statins 271 6.09 
PPIs 526 11.82 
Aromatase Inhibitors 11 0.25 
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6.2.4.2 Relative IRs of hip/femur fractures associated with BZD and related 
drugs, and with the type of BZD by ATC group. 
Crude and adjusted by age incidence rate ratios (IRRs) of hip/femur fracture 
comparing exposed/unexposed periods were estimated. To investigate the effect 
of taking one type of BZD or another on the risk of having a hip/femur fracture, 
exposure was divided according ATC groups in single use of anxiolytics, single 
use of hypnotics or use of both. Results were presented in Table 17. 
Crude analysis: 
- No risk of having a hip/femur fracture was observed in current use 
periods to BZD: 1.02 (0.94-1.11), while a small increased risk was 
observed in recent use periods: 1.14 (95%CI: 1.00-1.30). 
- Estimates across exposure time period windows subdividing the 
current use in five risk strata illustrated that no risk appeared in the 
SCCS analysis up to six months of treatment. 
- Only the use of both, anxiolytics and hypnotics exhibited a risk 
associated with hip/femur fractures: 1.48; 95%CI: 1.18-1.86. 
Adjusted analysis by age: 
- No association was observed over current or recent use periods. 
- No association was observed in any time window of current use. 
- Similarly, no risk was found as it was stratified by type of BZD. 
 
  
  
 
Table 17- Risk of having a hip/femur fracture associated with BZD use, and type of drug by ATC group in the SCCS 
SCCS Model Crude  Model Adjusted by age 
Exposure Cases          Py IRR IC(95%) IRR IC(95%) 
Past/Non use (ref) 2,615 5,169,764 1.00     1.00     
Recent use 292 476,812 1.14 1.00 1.29 0.97 0.85 1.10 
Current 1-30d 213 409,985 0.92 0.80 1.07 0.79 0.68 0.92 
Current 31-60d 201 362,943 0.99 0.85 1.15 0.85 0.73 0.99 
Current 61-182d 314 614,880 0.93 0.82 1.06 0.75 0.66 0.86 
Current 183-365d 246 437,601 1.11 0.95 1.29 0.83 0.71 0.96 
Current >365d 569 1,120,123 1.28 1.12 1.47 0.73 0.63 0.84 
Current use 1,543 2,945,532 1.02 0.94 1.11 0.79 0.72 0.86 
Type of BZD by ATC 
        
Use of Both 187 314,002 1.48 1.18 1.86 1.02 0.81 1.30 
Use of Anxiolytics 1,023 1,985,997 1.01 0.91 1.11 0.80 0.72 0.88 
Use of Hypnotics 333 645,533 0.96 0.82 1.13 0.72 0.61 0.84 
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6.2.4.3 Potential exposure-event dependence and impact of different length 
periods of pre-exposure. 
To examine whether the exposure was dependent on the event, a pre-
exposure time risk window was created with a length of 30 days, because it was 
considered as normal length for a BZD prescription. The rationale to do that was 
explained in section 5.5.2 (Specific criteria for the SCCS design). A significant 
risk was now observed across all exposure period time windows of approximately 
1.44 of median value, even after controlling by age. The markedly highest risk 
was exhibited by the new created pre-exposure time window, with 6.47 (95%CI: 
5.91-7.09) adjusted by age, and the lowest by recent use, with 1.21 (95%CI: 
1.03-1.42). 
In addition, a shorter window of 15 days and a longer window of 60 days were 
created. Changes in the length of the pre-exposure time risk window, had a 
relevant impact on the risk of having a hip/femur fracture associated to all 
exposure time periods. Thus, risks obtained with pre-exposure time of 60 days 
were higher than those obtained with 30 days, and these in turn were higher than 
those obtained with 15 days, along the different exposure categories. Likewise, 
risk associated with recent use increased when pre-exposure period was 
considered. 
Examining the risk associated with pre-exposure, the highest risk was 
observed with a length of 15 days, giving a value of 8.32 (95%CI: 7.54-9.18). 
Table 18 represents a comparison between IRRs in the model adjusted by age 
with different lengths in the pre-exposure risk period. 
Complete tables for each pre-exposure time window (crude and adjusted) can 
be found in the Appendix G. 
 
  
 
Table 18- Comparison of IRRs of hip/femur fracture changing the length of pre-exposure time risk window to 15 days, 30 
days and 60 days. 
    Model Adjusted by age Model Adjusted by age Model Adjusted by age 
Exposure IRR15* IC(95%) IRR30 IC(95%) IRR60 IC(95%) 
Past/non use 1.00     1.00     1.00     
Recent use 1.13 0.97 1.32 1.21 1.03 1.42 1.25 1.05 1.49 
Pre-Exposure 8.32 7.54 9.17 6.47 5.91 7.09 5.06 4.64 5.52 
Current 1-30d 1.26 1.09 1.46 1.40 1.21 1.62 1.52 1.31 1.77 
Current 31-60d 1.35 1.16 1.57 1.49 1.28 1.74 1.62 1.39 1.89 
Current 61-182d 1.24 1.08 1.41 1.37 1.20 1.57 1.49 1.30 1.71 
Current 183-365d 1.38 1.18 1.60 1.53 1.32 1.79 1.67 1.43 1.95 
Current >365d 1.26 1.08 1.47 1.42 1.22 1.65 1.55 1.33 1.81 
Current use 1.29 1.18 1.41 1.43 1.31 1.57 1.56 1.42 1.72 
*IRR15, 30 60, this sub-index indicates the length of the risk window in days 
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6.2.4.4 Post hoc analysis to explore the risk in 
Two unexpected findings were observed, 
exposure, and a lower risk in the recent period whereas it was found constantly 
higher than current use along the other designs
time were created. Therefore, 
hoc analyses were performed
a) Exploring the risk at seven days before the exposure
pre-exposure periods, one created from baseline only, and the other crea
recent use periods. See Figure 2
Figure 25- Two pre-exposure 
Both pre-exposure periods showed important increased risks
(95%CI: 13.69-17.05) when patient were in 
(95%CI: 4.09-6.55) as they were within a recent period. There was no risk in the 
recent period resulting from the exclusion of the week before the exposure
the risk in current use drop to 1.12 (95%CI: 1.02
 
the pre-exposure period
an elevated risk just before the 
 and before this pre
in order to explore those findings further 
: 
, but separating two 
5 for clarification. 
periods created at 7 days before the exposure
a past or non use period, and 5.17 
-1.23). See Table 19
 
 
-exposure 
two post 
ted from 
 
 
 being 15.28 
. And 
 for results. 
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Table 19- IRRs with two different pre-exposure periods at 7 days 
    Adjusted Model 
Exposure         Cases         Py IRR IC(95%) 
Past/non use 2,192 5,113,236 1.00     
Pre-Exp -baseline 7d 423 56,528 15.28 13.69 17.05 
Recent use 212 441,528 1.03 0.89 1.19 
Pre-Exp -recent 7d 80 35,284 5.17 4.09 6.55 
Current 1-30d 213 213 1.11 0.96 1.29 
Current 31-60d 201 201 1.18 1.02 1.38 
Current 61-182d 314 314 1.07 0.94 1.23 
Current 183-365d 246 246 1.19 1.02 1.39 
Current >365d 569 569 1.08 0.93 1.25 
Current use 1,543 1,543 1.12 1.02 1.23 
 
b) Exploring the risk at baseline (past/non use) before the exposure, dividing 
the time before the exposure in periods of 7 days up to no risk was found. Then, 
remove this time from baseline and repeat the analysis. 
The baseline time before the exposure was studied up to 210 days. A 
decreasing curve was observed, with lower risks as long as pre-exposure 7-day 
interval moved away the starting of current use (Figure 26). 
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Figure 26- Risk at baseline before the exposure 
Note, the scale starts at exposure time (0) and then 30 intervals of 7 days before that day are presented. The 
red line indicates the value of IRR=1. 
 
From the 27th interval (IRR= 0.9; 95%CI: 0.46-1.72) onwards no risk was 
observed. Hence the whole period between that interval and the exposure was 
removed from baseline creating a separate category called "182-day pre-
exposure time”. Crude and adjusted IRRs as well as the risk stratified by type of 
BZD (anxiolytics or hypnotics) for this post-hoc analysis can be found in Table 20. 
Crude post-hoc analysis: 
- Estimates across exposure time period windows dividing the exposure 
in five risk strata exhibited high risk of hip/femur fracture associated 
with the use of BZD. 
- Estimates across exposure categories aggregated in current, recent or 
past use demonstrated the highest risk at 7 days before the exposure 
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within a recent period (9.37; 95%CI: 7.38-11.90), whereas the rest of 
the recent period showed the lowest risk (1.71; 95%CI: 1.47-1.99). 
- The risk associated with current use of BZD and related drugs was 
2.10 (95%CI: 1.91-2.31). 
- The use of both, anxiolytics and hypnotics exhibited the highest risk 
associated with hip/femur fractures: 3.12; 95%CI: 2.49-3.91. 
Post-hoc analysis adjusted by age: 
- Estimates across exposure time periods windows , aggregated in 
current, recent or past use, and stratified by type of BZD, were in the 
same line as commented before, but the magnitude of the estimates 
were slightly lower after adjusting by age. Thus, the risk associated 
with current use was 1.64 (95%CI: 1.48-1.81), with recent use 1.47 
(95%CI: 1.26-1.71) and the risk at 7 days before exposure within 
recent use was 7.51 (95%CI: 5.91-9.56). 
- Similarly, the use of both, anxiolytics and hypnotics exhibited the 
highest risk associated with hip/femur fractures: 2.22; 95%CI: 1.75-
2.82. 
 
 
 
  
 
Table 20- Risk of having a hip/femur fracture associated with BZD use, and type of drug by ATC group. Post-hoc analysis. 
SCCS Analysis without baseline risk Crude Model Model Adjusted by age 
Exposure Cases Py IRR IC(95%) IRR IC(95%) 
Past/Non use (ref) 1,315 4,109,390 1.00 
  
1.00 
  
182-day pre-exposure 1,300 1,060,374 3.95 3.63 4.29 3.68 3.38 4.01 
Recent use 212 441,528 1.71 1.47 1.99 1.47 1.26 1.71 
Pre-exp 7d-Recent 80 35,284 9.37 7.38 11.90 7.51 5.91 9.56 
Current 1-30d 213 409,985 1.86 1.60 2.17 1.60 1.37 1.87 
Current 31-60d 201 362,943 2.00 1.71 2.34 1.71 1.46 2.00 
Current 61-182d 314 614,880 1.92 1.67 2.21 1.56 1.36 1.80 
Current 183-365d 246 437,601 2.31 1.98 2.70 1.75 1.49 2.06 
Current >365d 569 1,120,123 2.71 2.35 3.13 1.62 1.38 1.89 
Current use 1,543 2,945,532 2.10 1.91 2.31 1.64 1.48 1.81 
Type of BZD by ATC 
        
Use of Both 187 314,002 3.12 2.49 3.91 2.22 1.75 2.82 
Use of Anxiolytics 1,023 1,985,997 2.06 1.85 2.30 1.65 1.47 1.85 
Use of Hypnotics 333 645,533 1.95 1.66 2.29 1.48 1.25 1.75 
 
 In addition, representing those patients who started a treatment episode of 
BZD and related drugs within two months around the hip/femur fracture date 
(from -60 days to +60 days
(36%) patients started before the hip/femur fracture and 754 (64%) started after 
the fracture, showing a peak around 10
Figure 27- People started a BZD treatment b
 
6.3 COMPARISON OF RISK OF HIP
BZD AND RELATED DRUGS AC
A comparison of the 
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To allow better comparison, results from the SCCS design were presented 
aggregated in just one current category of use. 
the full adjusted model in each design, and for the 
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*Cohort (HRs); NCC and CXO (ORs); S
sensitivity analysis for the NCC and the post
of vertical axis starts at the relative risk null value which is equal to 1
Figure 28 Comparison of risk of hip/femur fracture associated with BZD use 
in all designs 
Current use of BZD or related drugs was associated in all designs with the 
outcome of interest however traditional studies (Cohort and NCC) yielded lower 
estimates (1.17, 95%CI: 1.07
obtained with the case-only designs (1.47, 95%CI: 1.29
1.48-1.81 respectively). 
To investigate the effect of taking one type of BZD or another on the risk of 
having a hip/femur fracture, exposure was divided according ATC groups in 
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Crude and adjusted estimates of the use of both types of BZD showed the 
highest risk across all designs, compared with the use of anxiolytic or hypnotic 
separately. Regarding the risk of the use of anxiolytics or hypnotics, once 
obtained adjusted estimates, in the cohort and NCC studies were fairly similar 
(1.17-1.16 and 1.17-1.13, anxiolytic-hypnotics respectively); whereas for the case 
only designs, results were contradictory. In the SCCS, the risk of hip/femur 
fracture associated with anxiolytic use (1.65, 95%CI: 1.47-1.85) was higher than 
the risk obtained with hypnotic use (1.48, 95%CI: 1.25-1.75) in contrast with the 
CXO where the risk of hypnotics use (1.82, 95%CI: 1.42-2.33) outweighed by 
large the risk of anxiolytics (1.24, 95%CI: 1.07-1.43). 
In common, all designs exhibited risk associated with the use of BZD and 
related drugs, although risk estimates in the traditional designs were lower than 
those obtained in the case only designs. For instance, comparing the results from 
the cohort with the ones from the SCCS, there was a big difference in the 
magnitude: 1.17 (95%CI: 1.07-1.28) and 1.64 (95%CI: 1.48-1.81) respectively. 
Similarly, the ORs from NCC and CXO were 1.19 (95%CI: 1.06-1.32) and 1.47 
(95%CI: 1.29-1.67) for current use in full models, respectively. In addition, in all 
designs was observed that, taking both anxiolytics and hypnotics showed the 
highest risk. 
Regarding differences observed, apart from the magnitude of the estimates, it 
was the big variation found in the CXO with the use of hypnotics and anxiolytics, 
whereas in the other designs those estimates were much more similar. 
 
  
 
Table 21- Risk of hip/femur fracture by ATC: Anxiolytics/Hypnotics in all designs, crude and adjusted. 
  
Cohort  Crude  
Cohort 
Adjusted* 
NCC Crude ** NCC Adjusted* CXO Crude  CXO Adjusted* SCCS Crude SCCS Adjusted* 
  HR 95%CI HR 95%CI OR 95%CI OR 95%CI OR 95%CI OR 95%CI IRR 95%CI IRR 95%CI 
Past/non 
use 
1.00     1.00     1.00     1.00     1.00     1.00     1.00     1.00     
Recent 
use 
1.89 1.64 2.17 1.26 1.09 1.44 1.39 1.18 1.63 1.36 1.15 1.61 1.88 1.62 2.18 1.69 1.46 1.97 1.71 1.47 1.99 1.47 1.26 1.71 
Current 
use 
2.83 2.60 3.09 1.17 1.07 1.28 1.30 1.17 1.43 1.19 1.06 1.32 1.70 1.50 1.92 1.47 1.29 1.67 2.10 1.91 2.31 1.64 1.48 1.81 
 Type of BZD by ATC 
   
Use of 
Both 
3.29 2.77 3.90 1.21 1.01 1.43 1.87 1.53 2.28 1.48 1.20 1.84 3.62 2.77 4.75 3.03 2.30 4.00 3.12 2.49 3.91 2.22 1.75 2.82 
Anxiolytics 2.48 2.26 2.73 1.17 1.07 1.29 1.23 1.10 1.37 1.17 1.04 1.31 1.42 1.23 1.63 1.24 1.07 1.43 2.06 1.85 2.30 1.65 1.47 1.85 
Hypnotics 4.46 3.90 5.11 1.16 1.01 1.33 1.28 1.09 1.49 1.13 0.96 1.33 2.09 1.64 2.67 1.82 1.42 2.33 1.95 1.66 2.29 1.48 1.25 1.75 
*Cohort and NCC adjusted by full model; CXO adjusted by co-medication; SCCS adjusted by age. The NCC results come from the sensitivity 
analysis and the SCCS results come from the post-hoc analysis. 
**Crude: adjusted only for matching factors (age, sex and index date) 
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7. DISCUSSION 
One research question in the same source population has been analysed 
with four different methodological designs. Results of this research are going to 
be discussed initially for the descriptive studies, as an overview of the current 
situation of the incidence of hip/femur fractures and the exposure to BZD and 
related drugs, in Spain compared with other European countries. Then, an 
evaluation of findings from analytical designs, with a comparison between them 
is going to be presented. Strengths and limitations of all studies will be 
addressed, as well as the contribution of this study to the scientific community. 
7.1 DESCRIPTIVE STUDIES 
7.1.1 Incidence of hip/femur fractures 
The main findings of this study were as follows: 1) Denmark showed age- 
and sex- standardized IRs of hip/femur fractures two times higher than those 
observed in the UK, the NL and Spain while Germany yielded IRs in between; 
2) in all countries, IRs were about 2-3 times greater in females than in males 
and grew exponentially with age regardless sex; both patterns were constant in 
all databases; and 3) significant trends in standardized IRs over time were 
observed only in two databases (slight increasing trend in the British CPRD and 
a decreasing trend in the Danish databases), both among the general 
population and among the population aged 50 years or older. 
Denmark showed the highest IRs throughout the study period with figures 
rather similar in the population aged 50 years or older (45 per 10,000 py) (149). 
The two UK databases participating in the present study yielded almost 
identical results and were similar to the ones reported for England (10.2 per 
10,000 py) using hospital admission rates (150). The IRs from the Spanish 
database in people aged 50 years or older are also similar to the ones reported 
by Hernández et al (110) using hospital discharge data from Cantabria in 2002 
(25,9 per 10,000 persons) and to the ones reported in Catalonia (151) using GP 
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records in 2009 (22.3 per 10,000 py). The two databases from the NL provided 
standardized IRs that fluctuated greatly over the study period probably due to 
the small numbers of hip/fractures that they had, yielding lower values than 
those based on hospital registries (152). Apparently until 2009 there was an 
under-registration of ICPC codes in the NL that improved significantly after a 
national campaign, making more similar the IRs of hip/femur fractures between 
the hospital registries and NPCRD database in 2010-11 (121). Finally, IRs from 
the Bavarian claims database were marginally lower than in other studies (109, 
153), that might be due to differences in data sources employed (national 
hospital discharge diagnosis opposed to outpatient diagnosis). Therefore, in 
general, the data provided in the present study seem to be consistent with 
results from previous studies using different data sources. 
The IRs of hip/femur fractures increased exponentially with age for both 
males and females, as observed in other studies, which may be partly 
explained by the progressive bone mass reduction with ageing (154), but also 
by the accumulation of other risk factors, such as disability and increasing risk 
of falls, as well as increasing use of drugs acting at the central nervous system 
(e.g. antidepressants, hypno-sedatives, anti-Parkinson drugs, opioids), the 
cardiovascular system (e.g. antihypertensives, diuretics) or drugs affecting the 
bone mineral density (e.g. corticosteroids, glitazones, SSRIs). 
The female to male IR ratios steadily increased with age among the 
population over 50 years but declined at older ages (≥80 years) probably 
indicating that males approximate females in bone mineral density and major 
risk factors at very old ages (155). This pattern was consistent across most 
databases and over the whole study period, and is in accordance with 
previously published results (147, 156, 157). Conversely, men presented higher 
IRs than women under the age of 50 years old, most probably due to the 
greater incidence of trauma-related fractures among males (158). 
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Time trend analyses showed no decreasing trend in the standardized IRs 
over time in most databases, with the exception of the Danish database. Thus, 
the general picture is of a rather stable situation which appears to date back to 
the nineties, as shown by previous reports in the same countries (2, 150). 
Denmark was the only country which showed a steady decline over the study 
period, in particular among the population 70-79 years old, in both males and 
females. This tendency is shared by other Nordic countries (159), as well as by 
the US (160); Australia (161); Canada (162) and Scotland (163). This decline in 
the Nordic countries might be attributable to a better management of 
osteoporosis (earlier screening, diagnosis and treatment of patients at risk) 
(164) and a combination of healthier diet, increase of physical activity, and 
educative measures to prevent falls (165). 
7.1.2 Prevalence of BZD and related drugs use 
The main findings of this study were as follows: 1) Spain exhibited the 
highest PRs compared to the other European countries, and it was the only one 
that presented an increased trend of BZD and related drug use over the study 
period (2001-2009); 2) PRs of BZD use were about 2 times greater in females 
than in males and grew steadily with age; both patterns were shared by all 
databases; and 3) decreasing trends of use were observed in Denmark, 
Germany and the Netherlands. 
Remarkable differences were found in prevalence rates (PRs) of BZD and 
related drugs use, which were not attributable to differences in age or sex 
distribution in the participant populations. Most published studies included 
psychotropic drugs, not only BZD and related, applied different exposure 
definitions, and obtained information from questionnaires (84, 91, 166), making 
difficult a proper comparison between studies (167). Diverse prescription habits 
(168, 169) and attitudes of patients towards mental health help-seeking might 
explain those differences. A European study performed to explore this issue, 
showed that Spanish participants were keener to seek mental aid than for 
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instance the German ones (170). And this factor of seeking help for emotional 
problems is one of the most important independent predictor for BZD and 
antidepressant prescriptions (84). 
The increasing trend observed in Spain was consistent with results from 
other studies (83, 171). Recent research suggests that the current economic 
crisis might be negatively affecting population mental health (172). Therefore, a 
further increase in the PRs of BZD use could be anticipated. In contrast, 
databases from Denmark, Germany and one from the NL (NPCRD), yielded a 
decreasing trend of use of BZD and related drugs. Such trend might reflect 
initiatives taken by official bodies (115) and the scientific community (173, 174), 
in order to rationalize the use of BZD in those countries. 
With regards to the differences in use of anxiolytics and hypnotics found, 
several explanations are plausible. Firstly, the prescription of anxiolytics or 
hypnotics is influenced by marketing preferences and physician habits rather 
than by real pharmacological differences. Thus, in Spain lorazepam is generally 
the BZD most prescribed and, although classified among anxiolytics, it is widely 
used at low doses to induce sleep, in particular among the elderly (175); its 
special hepatic metabolism (glucuronidation pathway) which does not generate 
relevant active metabolites nor has relevant pharmacokinetics interactions with 
other (drugs or herbal) medicines (176) is usually referred to as an advantage in 
several practice guidelines. Therefore, indication for this type of drug is not 
always followed strictly and patients with insomnia are treated in a similar 
percentage with anxiolytics and hypnotics (177). Moreover, anxiety and 
insomnia seem to be intertwined over time (178) and the choice of the BZD may 
depend on the most predominant disorder as well as the physician experience 
(179). 
As an overview of the situation in Spain, the incidence rate of hip/femur 
fractures remained rather stable taking up an intermediate position among the 
other European countries analyzed. However, the prevalence of use of BZD 
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and related drugs in this country was the highest compared to the other 
European countries, and it was the only one which exhibited an increasing 
trend. 
7.2 ANALYTICAL STUDIES  
7.2.1 Cohort study 
In this study, crude IRs of hip/femur fracture increased exponentially with 
age regardless the exposure, and it was higher in females than in males in all 
exposure categories. Current use of BZD and related drugs accounted for the 
highest overall crude IR (24.38 per 10,000 py) and it was decreasing with past 
use. IRs obtained were higher than the obtained for the general population in 
the descriptive study of incidence of hip/femur fracture performed, (about 10.44 
per 10,000py)(121), possibly due to the population was a cohort of users of 
BZD and related drugs, instead of general population. 
Potential risk factors of hip/femur fractures identified in this study are in line 
with the ones described in the literature. Thus, having a low body mass index, 
dementia and/or Alzheimer's, cerebrovascular disease, osteoporosis or 
previous fractures, among others, were associated with an increased risk of hip 
fractures (25, 180, 181). Similarly, medication such as anti-Parkinson drugs, 
parathyroid hormones, diuretics, anticoagulants, glucocorticoids, 
antihypertensives, etc were associated with an increased risk as well (182). The 
increased risk associated with some drugs used in the prevention of 
osteoporotic fractures (e.g. parathyroid hormone, biphosphonates, vitamin D 
and calcium) should be interpreted as a confounding by indication. 
Cox proportional hazards incremental models with time-dependent 
covariates were employed to estimate the risk of hip/femur fracture associated 
with BZD and related drugs use. Taking the past use as reference category, 
and comparing crude with the age-adjusted model, HRs demonstrated that the 
age was a factor strongly related with the outcome. However, the rest of 
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covariates in the subsequent models did not seem to act as relevant 
confounding factors. Even after performing an stepwise analysis, the only 
variables which seemed to affect more the association between hip/femur 
fracture and the use of BZD and related drugs, were age, sex, previous 
fractures, oral glucocorticoids, antidepressants and anti-Parkinson drugs. One 
reason could be that all those variables are related to age hence once age is 
controlled for the estimates are indirectly adjusted for the rest of covariates as 
well. Another explanation would be that in this study, a cohort of current users 
are compared with themselves when they are not using the drug of interest, so 
the intrinsic characteristics of the past users are the same and therefore many 
co-morbidities and chronic treatments are adjusted by design. Once all 
covariates were included in the model, HRs for current use of BZD (1.17, 
95%CI: 1.07-1.28) were comparable than those obtained in another cohort 
study (183) with similar characteristics (1.24, 95%CI: 1.06-1.44). 
Contrary to what was expected, the risk observed immediately after the 
treatment with BZD, that is, in the washout or recent period, was similar to the 
one obtained for current use when the model was age or fully-adjusted. Albeit a 
residual increased risk might be due to some treatments which are prescribed 
to take them on request, and patients classified as unexposed could be 
misclassified for this reason, the risk should be similar in both periods, not 
higher. This finding was common to all designs except for the SCCS, where, it 
was further investigated and an explanation is presented below, being 
applicable to all. 
Regarding duration of treatment, crude estimates showed an increasing 
trend of risk with longer periods of treatment, whereas no short-term effect was 
observed, in particular when adjusting by all covariates. The short-term effect of 
BZD and related drugs has not been observed in a consistent manner across 
the different studies published so far. Some studies found the higher risk at the 
beginning of the treatment (183, 184) others found fluctuation of risk along the 
periods of use (185) and others after 14 days (186). From a pharmacological 
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point of view, it is reasonable to think that at the beginning of the treatment the 
patient may be more vulnerable to the adverse effects of the drug, and 
therefore more prone to sedation, confusion, dizziness, which may impair body 
balance and the risk of fall and subsequently the risk of hip/femur fractures. 
After continual use for a few weeks patients may develop some tolerance to 
these adverse effects reducing such a risk. 
However, the lack of short-term effect may also have a plausible 
explanation: at the beginning of treatment patients received lower doses of 
BZD, and they escalated to higher doses afterwards leading to higher risks. 
This idea is supported by standard guidelines for the rational use of BZD where 
is indicated that dosage should be adjusted in the elderly, usually to half the 
recommended adult dose (187). Also, some authors have pointed out (186) that 
clinicians and patients could be more vigilant or alert at the beginning of 
treatment, and such vigilance may decrease as time goes by. 
Concerning doses, findings from this study are consistent with previous 
reports (117, 145, 184, 186, 188, 189) showing that high doses of BZD and 
related drugs were associated with higher risk of hip fractures. 
The effect of half-life has been largely studied giving controversial results. In 
this study no differential effect was shown according to drug half-life. Many 
previous studies found higher risk of falls and hip fractures with the use of long-
acting BZD (99, 180, 190) and it seems to be plausible because of the potential 
accumulation of those drugs might cause prolonged drug activity. However, it 
has been shown in many others (92, 117, 183, 191, 192) that a high risk of hip 
fractures was still present for the short-acting BZD and related drugs. 
There could be several explanations for this finding; one would be that the 
use of hypnotics with short-acting half-life could increase the rate of falls 
occurring over night as Ray et al (118) already pointed out. Also, it has been 
suggested (51) that short-acting BZD could imply more rapid tolerance, and 
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more cognitive impairment resulting in higher risk of hip fractures. Another 
possible explanation would be a potential confounding by indication, because 
patients with more severe conditions would be more frequently prescribed 
short-acting BZD to avoid the high risk implicit with long-acting drugs (191). 
With respect to the risk observed with individual drugs, lorazepam was the 
anxiolytic with the highest risk and lormetazepam the highest among hypnotic 
drugs, followed by the non-BZD drug clomethiazole. However, results relating to 
this aspect are very disparate, for instance the risk found for flurazepam by 
Sylvestre and Tamblyn (189, 193) was 2.83 (95%CI: 1.45-4.34) and 2.2 
(95%CI: 1.39-3.47), respectively; and for diazepam and zolpidem by Finkle 
(119) were 1.97 (95%CI: 1.22-3.18) and 2.55 (95%CI: 1.78-3.65). In contrast, in 
this study an increased risk was not observed with flurazepam or zolpidem, and 
the risk associated with diazepam was marginally non-significant. The high risk 
observed with clomethiazole, and the remarkable fall after adjustment is 
suggesting that physicians are particularly prone to prescribe this drug to the 
elderly. This could indicate the different pattern of use of BZD and related drugs 
in different countries, as only three cases were taking flurazepam and the use 
of “z” drugs is lower compare to other countries. In addition, differences in 
potential confounders might yield substantial changes in the estimates. 
Finally, as regards the type of BZD or related drug, classified as anxiolytic, 
hypnotic or both, the highest risk after adjusting for all covariates was found in 
patients taking both anxiolytics and hypnotics, similarly to findings from other 
authors (184). An explanation for this might be patients with more severe 
underlying conditions are prescribed both types of drugs instead of just one, as 
a result the risk of hip fractures in those patients would be higher. 
The risk for anxiolytics and hypnotics separately was quite similar. Most 
published articles did not examine the risk by type of BZD, making for difficult 
comparison, only Guo et al (194), found similar results but were not statistically 
significant: anxiolytics 1.41 (95%CI: 0.90-2.19) and hypnotics 1.15 (0.78-1.69). 
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7.2.2 NCC study 
The crude association of potential risk factors with hip/femur fractures in this 
study with cases and controls were similar to the ones found in the cohort study 
and is also in line with other published studies (184). Apart from the ones 
mentioned in the cohort study discussion, intestinal bowel disease, mental 
disorders and epilepsies/seizures were independently associated with hip 
fractures, as it was seen in previous reports (24, 195, 196). Similarly, 
medication such as morphine/opiates (72), disease-modifying anti-rheumatic 
drugs (66), calcitonin (197) and aromatase inhibitors (59), were also associated 
with an increased risk of hip/femur fractures. 
Conditional logistic regression was employed to estimate the risk of 
hip/femur fracture associated with the use of BZD and related drugs. Despite 
age and gender were used as matching variables, a difference in the ORs 
estimates was observed between crude and full adjusted model, indicating that 
some co-morbidities and co-medications were acting as potential confounders. 
Similarly to the cohort study, as a more parsimonious model was obtained, only 
the following variables were included: previous fractures, oral glucocorticoids, 
antidepressants, anticonvulsants and morphine/opiates. This probably indicates 
that only a few covariates were having an independent role in the estimates 
obtained.  
A fully-adjusted odds ratio (AOR) of 1.14, 95%CI: 1.02-1.26 was found for 
the current use of BZD and related drugs, and it was comparable to the ones 
obtained by Zint et al (184): 1.2 (95%CI: 1.1-1.2) and Sgadari et al (198): 1.10 
(95%CI: 0.98-1.20) with similar designs. 
BZD usage and the other covariates were measured within 180 days before 
index date, to be comparable with the cohort study, but in addition a sensitivity 
analysis was done measuring the exposure to BZD and co-medication within 30 
days before index date. As a result an AOR of 1.19, 95%CI: 1.06-1.32 was 
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obtained for the current use of BZD, which was slightly higher than the previous 
one but still comparable with the same published reports. 
Regarding duration of treatment, crude and adjusted estimates suggested 
neither short-term effect nor a trend with the continuous use of BZD, in contrast 
with the cohort study where an increasing trend was observed. However, in the 
NCC cases were matched with controls on follow-up and this might hinder the 
possibility of observing a trend. 
Also many discrepancies can be found in the literature. Thus, Chang et al 
(51) found a risk particularly high during the first month (AOR = 5.6, 95%CI: 2.7-
11.8) of exposure to BZD; Zint et al (184) found an AOR = 2.1 (95%CI: 1.5, 2.8) 
for BDZ use initiated within 14 days preceding the index date; Wang et al (185) 
found fluctuation, with a significant increased risk during the initial 2 weeks of 
use (60% increase) and after more than 1 month of continuous use (80% 
increase) but not for 2-4 weeks of continuous use. 
Possible explanations for increasing or decreasing the risk with duration of 
treatment have been discussed previously. While it is true that most published 
studies observed risk at the beginning of the treatment, particular 
characteristics of the design (e.g. selection of controls from hospital) or the 
number of covariates included in the logistic regression model to adjust for may 
yield very different results. 
A summary with studies which have explored duration of BZD and related 
drugs use is presented in Table 22. 
 
  
Table 22- Published studies which have explored duration of BZD use 
Author Title Design Population Results Observations 
Chang, C. 
M. et al, 
2008 
BZD and risk of hip fractures in older 
people: a nested case-control study in 
Taiwan 
NCC 
217 cases, 
214 controls 
AOR 1st 
month=5.6 (2.7-
11.8) 
Using nonusers as reference group, use of BZD was significantly associated with hip 
fractures (AOR,1.7, 95% CI, 1.2-2.5). Such risks appear to be particularly high during the 
first month (AOR = 5.6, 95% CI = 2.7-11.8) of exposure. 
Zint, K. et 
al. 2010 
Impact of drug interactions, dosage, 
and duration of therapy on the risk of 
hip fracture associated with BZD use in 
older adults 
NCC 
17,198 
cases, 
85,198 
controls 
AOR 1st 
month=2.1 
(1.57-2.8) 
While the adjusted relative risk (RR) for overall BDZ use and hip fracture was 1.16 (95% 
confidence interval 1.10, 1.22), for BDZ use initiated within 14 days preceding the index 
date was 2.1 (1.5, 2.8).  
van der 
Hooft, C. S. 
et al. 2008 
Inappropriate BZD use in older adults 
and the risk of fracture 
NCC 
200 cases, 
2,678 
controls 
AOR (14-90 
days)=2.15 
Daily dose and longer duration of use (>14 days) is associated with higher risk of 
fracture, irrespective of he type of benzodiazepine prescribed. 
Wang, P. S. 
et al 2001 
Hazardous BZD regimens in the 
elderly: effects of half-life, dosage, and 
duration on risk of hip fracture 
C-C 
1,222 cases, 
4,888 
controls 
AOR (14 days) 
=1.6; AOR 
(>28days)=1.8 
Significantly increased adjusted risks of hip fracture were seen during the initial 2 weeks 
of use (60% increase) and after more than 1 month of continuous use (80% increase) 
but not for 2-4 weeks of continuous use.  
Berry, S. D. 
et al 2013 
Non-BZD sleep medication use and hip 
fractures in nursing home residents 
CXO 15,528 OR=2.2 
The risk for hip fracture was elevated among users of a non-BZD hypnotic drug (OR, 
1.66; 95% CI, 1.45-1.90). The association between non-BZD hypnotic drug use and hip 
fracture was some greater in new users (OR, 2.20; 95% CI, 1.76-2.74).  
Neutel, C. I. 
et al 2002 
Medication use and risk of falls CXO 227 OR=11.4 
The highest OR was for BZD at OR = 1.8 (unadjusted). Residents starting a new 
BZD/antipsychotic were at very high risk (OR = 11.4) for experiencing a fall.  
Hoffmann, 
F. et al 
2006 
New use of BZD and the risk of hip 
fracture: A case-crossover study 
CXO 1,630 
OR (first 
5days)=3.4 
Odds ratio (OR) of hip fracture was highest during the initial 5 days of new use (OR: 
3.43; 95% CI 1.15-10.20) and then declined to a non-significant OR of 1.59 (95% CI 0.96-
2.63) after 30 days.  
Wagner, A. 
K. et al. 
2004 
BZD use and hip fractures in the 
elderly: who is at greatest risk? 
Cohort 
125,203 
(2,312 cases) 
IRR (14 
days)=2.05 
Exposure to any BZD (IRR, 1.24; 95% CI, 1.06-1.44), during the first 2 weeks after 
starting a BZD (IRR, 2.05; 95% CI, 1.28-3.28), during the second 2 weeks (IRR, 1.88; 95% 
CI, 1.15-3.07), and for continued use (IRR, 1.18; 95% CI, 1.03-1.35). 
Ray, W.A. 
et al. 2000 
BZD and the risk of falls in nursing 
home residents 
Cohort 2,510 RR (7days)=2.96 
The rate of falls was greatest in the 7 days after the BZD was started (RR, 2.96 [2.33-
3.75]) but remained elevated (1.30 [1.17-1.44]) after the first 30 days of therapy.  
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Finally, as regards the type of BZD or related drug, classified as anxiolytic, 
hypnotic or both, the highest risk of having a hip/femur fracture was found 
taking both types of drugs, for crude and full AOR estimate. This result was 
similar to the one found in the cohort study, but with a higher difference 
between taking both (AOR = 1.40, 95%CI: 1.13-1.73) and taking separately 
anxiolytics (AOR = 1.11, 95%CI: 0.99-1.25) or hypnotics (AOR = 1.10, 95%CI: 
0.94-1.30). Prescription of both drugs might be related to patients with more 
severe conditions, as it has been said before, with the corresponding increase 
of risk. Similarly, Herings et al (117) found an OR = 2.5; 95%CI: 1.3-4.9 with the 
concomitant use of several BZD. 
Between anxiolytics and hypnotics taken separately there was no difference 
in the main analysis, alike the cohort study. 
7.2.3 CXO study 
The crude association of co-medication as potential risk factors with 
hip/femur fractures yielded similar results than the two previous studies. 
Odds ratios (ORs) of hip fracture were estimated using conditional logistic 
regression models by comparing the exposure to BZD and related drugs during 
1 to 90 days before the hip fracture (hazard period) with the exposure during 
four backward consecutive 90-days time windows (91 to 182, 183 to 273, 274 to 
365 and 366 to 457 days before the hip fracture, control periods). A crude OR 
of 1.70, 95%CI: 1.50-1.92, and a full AOR of 1.47, 95%CI: 1.29-1.67 was found 
for the current use of BZD and related drugs. Other CXO studies showed high 
risk estimates as well, hence, Neutel et al (199), found a crude OR = 1.7, 
95%CI: 1.0-2.9, for exposure to BZD, similar to the crude estimate obtained. In 
the same way, Berry et al (200) found an AOR = 1.66, 95%CI: 1.45-1.90 
associated with the use of non-BZD hypnotics. 
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Concerning the type of BZD or related drug, the highest risk was observed 
taking both type of drugs, anxiolytics and hypnotics, similarly than in the other 
designs. As falls and fractures are dose-related adverse effects, the use of 
several drugs is equivalent to the use of a higher dose. Yet again, this could 
partly be related to the higher severity of the underlying conditions of these 
patients. 
Looking at the type of drugs separately, the risk associated with hypnotics 
was higher than for anxiolytics for crude and AOR, whereas in the other designs 
this risk was similar or slightly higher with anxiolytics. No clear explanation can 
be provided for this finding. A published case crossover study (200) found a risk 
of hip/femur fracture of 2.20, 95%CI: 1.76-2.74, in new users of hypnotics (Z 
drugs), which is aligned with the magnitude of the result obtained for hypnotics 
separately. 
7.2.4 SCCS study 
In this study, crude incidence rate ratios (IRRs) of hip/femur fracture 
associated with BZD and related drugs was observed only after the first six 
months of treatment and in the recent use category, which was a period up to 
two months after the current exposure to BZD. Once the analysis was adjusted 
by age, no risk was found in any exposure category, or in the recent use. 
This drug-event pair has been explored in the study of Madigan et al (201), 
to evaluate the heterogeneity of databases, as part of the Observational 
Medical Outcomes Partnership (OMOP) project. In seven out of ten DBs they 
found no risk of hip fracture associated with BZD use, when a SCCS was 
employed. 
Such a lack of effect may be related to the strong dependence of event and 
exposure. As it has clearly been shown, patients who sustained a hip/femur 
fracture were frequently prescribed a BZD or a related drug after such event (as 
new treatment, not as treatment continuation). This dependence between the 
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exposure and the outcome represents a violation of one of the key assumptions 
that this design must fulfil, as consequence, to overcome this problem a pre-
exposure period over which there was an increased risk was identified. First, a 
"pre-exposure" period of 30 days was created taking that time from the baseline 
(past/non use) or recent use periods, as a new different category, and results 
changed radically. Separating this period, risk associated with exposure to BZD 
was found in all current use windows. Usually, the reference category is the one 
with the lowest risk, in this case was past/non use, because the hypothesis was 
to investigate the possible association between the exposure to BZD and 
hip/femur fractures, so it was assumed the unexposed periods, after a washout 
time, as reference category. Since that period with high risk was included in the 
baseline, all results were underestimated, because the risk was higher in the 
denominator yielding necessarily lower estimates. 
Gibson et al (148) used a pre-exposure time as well, obtaining similar 
results, the highest risk was observed in that pre-exposure time, and then was 
progressively decreasing in recent and past use. The outcome was not the 
same, because their outcome was motor vehicle crashes, not hip/femur 
fractures, but design and results are comparable. 
After exploring the length of this pre-exposure time window, it was seen that 
the shorter windows (7 or 15 days) presented higher risk than the longer ones 
(30 and 60 days). This is the mirror image of the high number of new users of 
BZD and related drugs found after a hip/femur fracture. Implications of this 
finding are critical, because it reveals dependence between the exposure and 
the event, and the results without separating this time from the reference 
category were biased. Similar situation with a SCCS design and hip/femur 
fracture as an outcome was observed by Lai C et al (202) where they examined 
prescriptions of alpha blockers following hip/femur fractures. 
Further exploring the baseline risk before the exposure, it was found that 
apart from the intense risk just before the exposure, there was some risk up to 
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182 days before. Once this period was removed, the results in the SCCS were 
similar to the ones found in the CXO, IRR=1.64 (95%CI: 1.48-1.81) and 
OR=1.47 (95%CI: 1.29-1.67), respectively. 
Another finding observed was that contrary to the rest of the designs, and 
after creating the pre-exposure time, not before, the risk observed in recent use 
was lower than the risk observed in current use. This finding was further 
explored post-hoc. When the risk in recent periods was investigated, windows 
of seven days just before the exposure showed a remarkable risk, leaving the 
rest of the period without it. This finding may partly explain the constant high 
risk observed in recent periods across designs. Most of the patients take 
intermittently BZD and related drugs, being frequent periods of current-recent-
current-recent- and so on. Consequently, if the exposure is conditioned by the 
event, as it has been shown with this design, it would be reasonable to obtain 
higher risk during recent periods than during current use. 
7.2.5 Comparison across designs and literature review 
All designs showed an increased risk associated with current use of BZD 
and related drugs as a group. However, they differ in the magnitude of HRs: 
traditional designs presented lower values than case-only designs. Interestingly, 
traditional designs are consistent with each other and so case-only designs 
(after adjusting for the pre-exposure in the SCCS). This is a major finding of the 
present research. 
The lack of a gold standard does not allow identification of which of these 
estimates was closer to the true HR value, though it should be noted that 
traditional designs might still have some residual confounding due to factors 
difficult to adjust for, such as severity of underlying diseases, or frailty. Such 
factors may increase the risk of fall and fractures and, for this reason, 
physicians could be reluctant to prescribe them BZD and related drugs, or use 
them at lower doses. As a result, it could lead to an underestimation of HR. In 
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case-only designs, these personal factors are implicitly controlled for by design 
and then a greater HR could be obtained. 
The experience of comparing different designs using the same source 
population is very limited. The OMOP project (201), studied this drug-event pair 
employing a SCCS and a cohort design within the same data source, and 
compare the results across ten DBs. In general, results were similar to the ones 
obtained in this research, before taking into account the pre-exposure period, 
that is, no risk was found in the SCCS design in 7 out of 10 data sources, in 
contrast with the cohort design where no risk was found in 3 out of 7 data 
sources. 
There are some other publications comparing designs yielding different 
results. In most articles, the estimates with case only designs were lower than 
the obtained with cohort or case-control designs. Thus, Douglas et al (203) 
studied the association between exposure to proton pump inhibitor (PPI), and 
incident myocardial infarction in patients taking clopidogrel and aspirin with two 
different designs, a SCCS and a cohort study. They obtained and age-adjusted 
IRR=0.75 (95%CI: 0.55-1.01) with the SCCS, and an adjusted HR=1.30 
(95%CI: 1.12-1.50) with the cohort study. Similarly, Hebert et al (204), 
compared a case-control with a CXO design, studying the effect of BZD on 
elderly drivers. The case-control approach showed an increased rate of motor 
vehicle crashes associated with the use of BZD, OR=1.45 (95%CI: 1.12-1.88) 
whereas the CXO found no association, OR=0.99 (95%CI: 0.83-1.19). And 
Ravera et al (205), compared different designs to study the risk of motor vehicle 
accidents associated with psychtropic drugs, obtaining that the result that CXO 
did not show any statistically significant association with any drug, for instance 
for anxiolytics AOR=0.95 (95%CI: 0.68-1.31) whereas the case-control found an 
AOR=1.54 (95%CI: 1.11-2.15) for the same drug. 
Other studies however, found similar associations such as Ramsay et al, 
(123) who found similar risk estimates of pneumonia associated with the use of 
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proton pump inhibitors, in a new-users cohort (RR=3.24, 95%CI: 2.50-4.19) and 
in a SCCS (IRR=3.07, 95%CI: 2.69-3.50). Alike Andrews et al (206) who 
compared three study designs to investigate the association between autism 
and MMR vaccine, obtaining the following: Cohort, RR=0.92 (95%CI: 0.68-
1.24); the NCC, OR=0.88, (95%CI: 0.67-1.15) and the SCCS, IRR=0.94 
(95%CI: 0.60-1.47). 
7.3 STRENGTHS AND LIMITATIONS 
7.3.1- Data source 
The BIFAP database employed provided a large study sample, with 
nationwide coverage and quality standards, showing internal and external 
validity for pharmacoepidemiologic research. Population registered in BIFAP 
database are representative of the Spanish population with a similar distribution 
by age and sex (Figure 7). Moreover, results from previous studies performed 
within BIFAP (207-209) have been comparable with other scientific publications, 
proving an external validity of those data. 
The use of electronic records to ascertain the exposure, allows eliminating 
errors in measurement of drug use due to inadequate patient´s recall. Also, 
validation processes of codes used to ascertain the outcome were in place to 
ensure the inclusion of valid cases for all designs. This validation is 
recommended when a coding system is employed as outcome definition (210) 
and it is a normal practice for BIFAP database (211, 212). 
In addition, this population-based data source provided appropriate person-
time denominators and conferred good statistical power due to the large size of 
population included and followed over long periods of time. 
As limitations of the data source, similarly than in other primary care 
databases, would be the incomplete data on potential confounding variables, for 
instance, alcohol use, smoking or BMI. Also, some variables such as 
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socioeconomic status, exercise or diet are not systematically recorded. In the 
same way, as it was commented in section 7.2, some personal characteristics 
of patients such as quality of life, frailty, dependence, social networks etc, which 
may have a relevant impact on their health status, are not usually recorded in 
DBs, being therefore a major limitation of studies performed with them. 
Precisely for these reasons there is an increasing interest in 
pharmacoepidemiology to use case-only designs, to overcome such limitations 
linked to the residual confounding by personal characteristics that hardly vary 
over time. 
Finally, BIFAP only has information on prescriptions written by GPs. Over 
the counter drugs or drugs prescribed outside the primary care setting (hospital 
prescriptions) are not systematically recorded in this DB. 
7.3.2 Classification of the exposure 
The exposure was defined in all designs as a prescription of BZD or related 
drug recorded in the database; implications for this definition are the following: 
First, a prescription is not the same as dispensing or consumption. Patients 
may receive a prescription but never exchange it in the pharmacy for the 
medication, or once dispensed they may not be fully adherent, so a 
misclassification of exposure could exist. 
Secondly, the duration of prescriptions might not be precise, thus, patients 
with a treatment theoretically ended, could be still exposed and vice versa. 
Despite of this potential misclassification might be present, it would be non-
differential, affecting to cases and no cases in the same manner, and therefore 
is not expected to alter the results. 
Finally, although this medication is acquired by prescription only (PoM), 
some patients might obtain them privately and as a result, not be included in the 
primary care database. In Spain, the vast majority of population use the public 
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health system, and the percentage of patients with private prescriptions would 
be low. 
7.3.3 Outcome identification and ascertainment 
In a primary care database, the case identification depends on the selection 
of the relevant diagnostic codes used by GPs to record the event (213). In 
BIFAP the coding system employed is the ICPC-2. It is known that the 
granularity of such a system is not as great as others (ICD, Read codes, etc.) 
and this may, to some extent, reduce the specificity of the codes used. When 
this happens there may be as a result some misclassification of the outcome 
that may have an impact on the study power and on the magnitude of the true 
effect (206). Presumably, however, such a misclassification is non-differential 
according to the exposure. In order to limit that error a manual review of the 
individual clinical records of potential cases was performed, and only validated 
cases were included in these studies, strengthening the specificity of the case 
definition. 
On the other hand, the use of the outcome “hip/femur” fracture might provide 
a less comparable definition with respect to other studies which only focused on 
“hip” fractures. However, some authors (142, 214) have recommended the use 
of this broader outcome for monitoring hip fractures, even when using hospital 
records, as “there is often miscoding between fractures of the neck of the femur 
and fractures of other parts or unspecified parts of the femur”. However, this 
limitation is less important when the data are referred to population 50 years or 
older, as 90% of femur fractures beyond this age are of osteoporotic nature and 
mostly affect the neck or intertrochanteric sites (215). 
7.3.4 Confounding by indication 
This bias might be present in this investigation because as Barlett et al (216) 
already pointed out patients with pre-existing conditions that increase the risk of 
injurious falls (arthritis, depression, alcohol abuse) are significantly more likely 
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to receive a new prescription for a BZD. And, on the contrary, GPs might tend 
to avoid prescribing BZD to patients with more severe conditions. 
This confounding by indication cannot be rule out, and might explain part of 
the risk observed once the risk from baseline was removed. However, in all 
designs patients with at least one prescription of BZD or related drugs were 
included, and analyses were adjusted by a number of chronic illnesses and a 
large list of co-medications, minimizing such bias. 
7.3.5 Selection of cases/controls 
Albeit the outcome of interest requires hospitalization, a population-based 
data source was preferred than a hospital-based, avoiding the difficulty of 
finding appropriate controls in a hospital. For the NCC, cases and controls were 
selected from the same cohort study population. Controls were randomly 
sampled from the underlying cohort at the time a case occurred (hip/femur 
fracture or index date). This approach is called "risk set sampling" and it 
assures that patients selected as controls are representative of the underlying 
population, so the ORs obtained are unbiased estimates of the incidence rate 
ratios (213), allowing a better comparison across designs. 
Cases were matched to four controls, who were similar for three matching 
criteria to cases: sex, age and time of follow up within the study. In doing so, it 
was improved statistical efficiency, and the power for detecting an effect was 
increased, as well as controlling for those matching factors. Matching by follow-
up time, however, may have had an impact on the HRs estimated by duration 
effect of BDZ and related drugs, as follow-up may be somewhat correlated with 
duration of treatment. Then, HRs may be distorted to the null value as controls 
are forced to match cases on this factor. 
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7.3.6 Selection of covariates 
Co-morbidities and co-medications were searched in the database to include 
this information as potential confounders, as well as age, gender and life-style 
factors. 
The use of health care services or number of visits to the GP in the last year 
is normally used as an approximate variable or ‘proxy’ to estimate health 
condition of the study population, because subjects who consult more 
frequently are more likely to be diagnosed with any problems they have and to 
be treated (213). However, this covariate was not included in this research due 
to the extensive list of potential diseases and treatments evaluated. 
Albeit a large number of potential confounding factors were adjusted for in 
the analyses, the results may still be influenced by other potential confounders 
not included in the analyses, e.g. diet, physical activity, etc. Though it was seen 
that the main differences in the analyses were found when age was included in 
the model, and with the rest of covariates small changes were observed. 
7.3.7- Study designs 
Cohort study 
Selecting a cohort of users of BZD or related drugs, all patients were 
exposed at least once to the drug of interest. Hence, comparison between 
cohort members, was more similar than if an external cohort of non users had 
been used, minimizing this way the confounding by indication that otherwise 
would arise. 
Moreover, a "new-user" design was performed establishing as inclusion 
criteria to be six months free of the exposure of interest before the start date, 
alike "incident" cases were looked for, being twelve months without the outcome 
of interest before the start date. Prevalent users may introduce bias if risk varies 
with time, and covariates may be affected by the use of that drug (217). 
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Prevalent cases may have changed their habits and treatments because the 
disease, and reverse causality might occur. By doing this, biases from prevalent 
users or cases were avoided. 
A potential bias in cohort studies is the loss of people during the follow up. 
Many reasons can make a patient leave the study, they may die, leave the 
practice, move to another city, etc. But when the losses are related with the 
exposure, outcome or both, this can bias the measurement of effect of the 
exposure. In this research the cohort was comprised by a dynamic population, 
(BIFAP database) so losses were not specifically related with the exposure or 
the outcome, similarly affecting to all population. 
NCC study 
Using a "nested" case-control design overcomes some biases that a 
traditional case-control might present. Thus, controls were selected from the 
same source population than cases, minimizing the selection bias. Information 
on exposures were obtained before cases were diagnosed, hence it was less 
prone to bias. And selecting controls with a risk set sampling method provided 
unbiased estimates of the risk ratios. 
Other strength of this design is that allows for a more accurate 
ascertainment of the time-varying confounders, due to the proximity of the index 
date, making possible to investigate the use of co-medication one month before 
the hip/femur fracture. 
And finally, cohort and NCC approaches produced very similar findings 
(213), which make easier the comparison between those designs. 
CXO study 
The main strength of this design is to eliminate control selection bias and 
between-person confounding by constant characteristics, such chronic 
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diseases. As a case-only design, cases act as their own controls with the 
mentioned strengths that it entails (section 5.1.3). 
The CXO method assumes that the baseline risk for an exposure is 
constant, and this assumption was tested using four control periods of three 
months each starting immediately prior to the at-risk period. This consideration 
improved the precision of the effect size, by using several control time periods 
per case, and achieved greatest efficiency by using the whole year prior to the 
event (218). 
As limitation, estimates obtained from a conditional logistic model could be 
biased if the distribution of exposures in the time periods was not exchangeable 
(219), but in this study that condition was met. 
SCCS study 
Similarly than with the CXO design, the major advantage is that confounding 
by differences between patients is removed, using a within-person comparison. 
Other strengths of this design can be found in section 5.1.4. 
It has been often said, that results from this approach would be likely more 
accurate than the obtained with more traditional designs, as they removed 
selection and indication bias that otherwise would be present (134). 
A main limitation is that the occurrence of the event should not affect the 
probability of exposure. In case this happens, it can be corrected removing that 
pre-exposure time that might induce a prescription from the calculation of the 
baseline incidence rate, preventing any spurious inflation of this estimate (148); 
as it was done in this research. 
Another potential limitation would be the adjustment for more confounding 
factors such as co-medications in the analysis (220). However, in this particular 
investigation, age was the principal confounding factor, and it has shown that 
adding a broad list of co-medications barely affected the results. Once age was 
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controlled for, the estimates were indirectly adjusted for the rest of covariates as 
well. 
7.4 CONTRIBUTION OF THIS RESEARCH TO THE SCIENTIFIC KNOWLEDGE 
Findings from this investigation are consistent with other study reports (192) 
and provide evidence for the validity of the results obtained. Nevertheless, due 
to the observational nature of these data, causality cannot be guaranteed 
though evidence for causality is at least as strong here as in most other 
observational studies and should be interpreted in light of the limitations already 
discussed. 
This drug event pair has been heavily studied because of the wide use of 
BZD and related drugs and the public health impact of this increasing outcome 
nowadays. However, different results have been published worldwide. Findings 
of this research are consistent with two recently published meta-analyses (92, 
192) and suggest that the use of BZD increases moderately the risk of 
hip/femur fracture. Such increased risk is dependent on dose. 
This thesis makes an important methodological contribution to 
pharmacoepidemiological research, illustrating all similarities and discrepancies 
found between four different designs in response to a single study question, 
and employing the same data source. There is, worldwide, limited experience in 
doing that and in Spain is the first investigation of its kind. 
In this study a reciprocal association between exposure to BDZ and related 
drugs and the occurrence of hip/femur fracture has been observed. In 
pharmacoepidemiology the influence of the event on the exposure is rarely 
analysed. As has been shown, when the event determines the exposure it is 
necessary to be cautious in using designs in which current use experience is 
compared to past use within the same population. The approach used in the 
present research may be applied in further investigations. 
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In addition this is the first time that the risk at baseline has been explored, 
yielding explanations for the risk observed in a period after exposure, that 
otherwise only assumptions could have been done. 
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8. CONCLUSIONS 
1- Spain exhibited intermediate values of IRs of hip/femur fractures compared 
to other European countries, and no trend was shown over 2003-2009. 
2- The high prevalence of use of BZD and related drugs and the increasing 
trend observed in Spain compared to other European countries during the last 
decade requires a careful assessment and implementation of effective 
measures. 
3- Incidence rates of hip/femur fractures associated with exposure to BZD 
increased exponentially with age, and it was higher in females than in males 
after 50 years of age, in all exposure categories. 
4- The use of BZD and related drugs moderately increases the risk of hip/femur 
fractures and this was consistently found across the four analytical designs 
performed. 
5- Half-life appeared not to have a relevant impact on the effect while high 
doses were associated with the highest risk. 
6- The risk of having a hip/femur fracture was higher when anxiolytics and 
hypnotics were taken concomitantly. 
7- No clear trend of risk was observed with duration of use, in particular, a 
short-term effect was not observed. 
8- The hypnotics that showed the greatest risk were lormetazepam and 
clomethiazole, and among the anxiolytics, lorazepam and diazepam. 
9- The exposure was heavily dependent on the event and this may introduce an 
important bias in the SCCS design. Such bias may be corrected when the pre-
exposure period associated with an increased risk is well characterized and 
excluded from the period used as the reference. 
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10- The increased risk associated with pre-exposure can be an explanation for 
the increased risk associated with recent use in the designs performed in this 
research, although this should be further explored. 
11- Case-only designs yielded estimates higher than the obtained in the 
traditional designs, allegedly because of a better control for confounding factors 
that are difficult to measure in traditional designs. 
12- This research had not been feasible without employing an electronic 
primary care database with national coverage as BIFAP, demonstrating the 
importance of this kind of data source for pharmacoepidemiological research, 
particularly in Spain. 
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10. APPENDICES 
APPENDIX A 
List of BZD, DDD, half-life and recommended daily dose 
N05B Anxiolytics (221) 
N05BA Benzodiazepine derivatives 
ATC code Name 
Defined 
Daily Dose 
DDD 
Recom
mended 
Daily 
Dose† 
U 
Adm.
R 
Half-life* 
N05BA01 diazepam 10  mg O Long (>24) 
  10  mg P  
  10  mg R  
N05BA02 
chlordiazepoxi
de 
30  mg O Long (>24) 
  50  mg P  
N05BA03 medazepam 20  mg O Long (>24) 
N05BA04 oxazepam 50  mg O Intermediate (8-24) 
N05BA05 
potassium 
clorazepate 
20  mg O Long (>24) 
N05BA06 lorazepam 2.5  mg O Intermediate (8-24) 
  2.5  mg SL  
N05BA07 adinazolam     Short (<8) 
N05BA08 bromazepam 10  mg O Intermediate (8-24) 
N05BA09 clobazam 20  mg O Intermediate (8-24) 
N05BA10 ketazolam  15 mg  Intermediate (8-24) 
N05BA11 prazepam 30  mg O Long (>24) 
N05BA12 alprazolam 1  mg O Intermediate (8-24) 
N05BA13 halazepam 0.1  g O Long (>24) 
N05BA14 pinazepam  5 mg  Intermediate (8-24) 
N05BA15 camazepam 30  mg O Intermediate (8-24) 
N05BA16 nordazepam 15  mg O Long (24) 
N05BA17 fludiazepam 0.75  mg O Long (>24) 
N05BA19 etizolam  0.5 mg  Short (<8) 
N05BA21 clotiazepam  10 mg  Short (<8) 
N05BA56 
lorazepam, 
combinations 
     
* Half life definitions: Short (<8); Intermediate (8-24), Long (>24) 
† If there is no information on DDD, the recommended daily dose will be used to approach the DDD. 
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N05C Hypnotics and sedatives (221) 
N05CD Benzodiazepine derivatives 
ATC code Name 
Defined 
Daily Dose 
(DDD) 
U AdmR Half-life * 
N05CD01 flurazepam 30 mg O Long (>24) 
N05CD02 nitrazepam 5 mg O Long(>24) 
N05CD03 flunitrazepam 1 mg O Intermediate (8-24) 
  1 mg P  
N05CD04 estazolam 3 mg O Intermediate (8-24) 
N05CD05 triazolam 0.25 mg O Short(<8) 
  0.2 mg SL  
N05CD06 lormetazepam 1 mg O Intermediate(8-24) 
N05CD07 temazepam 20 mg O Intermediate(8-24) 
N05CD08 midazolam 15 mg O Short(<8) 
  15 mg P  
N05CD09 brotizolam 0.25 mg O Short (<8) 
N05CD10 quazepam 15 mg O Long(>24) 
N05CD11 loprazolam 1 mg O Intermediate(8-24) 
* Half life definitions: Short (<8); Intermediate (8-24), Long (>24) 
 
N05CF Benzodiazepine related drugs  
ATC code Name 
Defined Daily Dose 
(DDD) 
U Half-life* 
N05CF01 zopiclone* 7.5 mg Short (<8) 
N05CF02 zolpidem* 10 mg Short (<8) 
N05CF03 zaleplon 10 mg Short (<8) 
* Half life definitions: Short (<8); Intermediate (8-24), Long (>24) 
 
N05CM Other hypnotics and sedatives 
ATC code Name 
Defined Daily 
Dose (DDD)* 
U Half-life 
N05CM02 Clomethiazole 1,5 g O 
  1,5 g P 
* Half life definitions: Short (<8); Intermediate (8-24), Long (>24) 
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APPENDIX B 
Codes for potential confounders 
1) Well known risk factors for fracture (222) 
 
Weight, height, BMI, smoking and alcohol 
Weight 
This should be entered in kg.  
Height 
This should be entered in cm. 
BMI Calculated as weight in kilograms divided by height squared in meters.  
Categories: <18.50; 18.50-24.99; 25.00-30;>30  
Reference category: 18.50-24.99 
Smoking Enter no/yes/ex-smoker/unknown.  
Reference category: No 
Alcohol Enter non use/use/ unknown.  
Reference category: Non use 
 
Previous fractures 
ICPC codes  
L75 Fracture: femur 
L74 Fracture: hand/foot bone 
L73 Fracture: tibia/fibula 
L72 Fracture: radius/ulna 
L76 Fracture: other  
 
Glucocorticoids 
ATC code  
H02AB . Glucocorticoids 
Equivalent anti-inflammatory doses of 
corticosteroids to Prednisolone 5 mg (Fte: 
British National Formulary. BMJ Group and 
RPS Publishing BNF, London 2009) 
 
= Cortisone acetate 25 mg 
= Deflazacort 6 mg 
= Dexamethasone 750 micrograms 
= Hydrocortisone 20 mg 
= Methylprednisolone 4 mg 
= Triamcinolone 4 mg 
 
Rheumatoid arthritis 
ICPC-2 TITLE 
L88 Rheumatoid/seropositive arthritis 
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2) Risk factors immediately related to the outcome 
 
Osteoporosis and Paget´s disease 
ICPC-2 TITLE 
L95 Osteoporosis 
L99 No specific code (Musculoskeletal disease)  
 
Biphosphonates, raloxifene, parathyroid hormones and analogues, strontium 
ranelate, vitamin D and analogues and calcitonin 
ATC code  
M05BA01 etidronic acid  
M05BA02 clodronic acid  
M05BA03 pamidronic acid  
M05BA04 alendronic acid 
M05BA05 tiludronic acid  
M05BA06 ibandronic acid  
G03XC01 raloxifene 
H05AA Parathyroid hormones and analogues 
M05BX03 Strontium ranelate 
A11CC04   calcitriol 
A11CC05   colecalciferol 
 calcium+ colecalciferol 
A11CC06   calcifediol 
H05BA Calcitonin preparations 
 
3) Other drugs associated with fractures 
 
Antidepressants 
ATC code  
N06AA Non-selective monoamine reuptake inhibitors 
N06AB Selective serotonin reuptake inhibitors 
 
Antipsychotic drugs/lithium 
ATC code  
N05A Antipsychotics 
N05AA Phenothiazines with aliphatic side-chain 
N05AB Phenothiazines with piperazine structure 
N05AC Phenothiazines with piperidine structure 
N05AD Butyrophenone derivatives 
N05AE Indole derivatives 
N05AF Thioxanthene derivative 
N05AG Diphenylbutylpiperidine derivatives 
N05AH Diazepines, oxazepines, thiazepines and oxepines 
N05AL Benzamides 
N05AN Lithium 
N05AX Other antipsychotics 
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Anti-Parkinson drugs 
ATC code  
N04 Anti-Parkinson drugs 
N04A  Anticholinergic agents 
N04AA Tertiary amines 
N04AB Ethers chemically close to antihistamines 
N04AC Ethers of tropine or tropine derivatives 
N04B  Dopaminergic agents 
N04BA Dopa and dopa derivatives 
N04BB Adamantane derivatives 
N04BC Dopamine agonists 
N04BD Monoamine oxidase B inhibitors 
N04BX Other dopaminergic agents 
 
Antiepileptic drugs (anticonvulsants) 
ATC code  
N03A  Antiepileptics 
N03AA Barbiturates and derivatives 
N03AB Hydantoin derivatives 
N03AC Oxazolidine derivatives 
N03AD Succinimide derivatives 
N03AE Benzodiazepine derivatives 
N03AF Carboxamide derivatives 
N03AG Fatty acid derivatives 
N03AX Other antiepileptics 
 
Inhaled glucocorticoids 
ATC code  
R03BA Glucocorticoids 
R03BA01 Beclometasone  
R03BA02   Budesonide  
R03BA03   Flunisolide  
R03BA04   Betamethasone  
R03BA05   Fluticasone  
R03BA06   Triamcinolone  
R03BA07   Mometasone  
R03BA08   Ciclesonide  
 
Sedating antihistamines 
ATC code  
N05BB Diphenylmethane derivatives (sedating) 
 
  
Appendices 
 
224 
 
Bronchodilators 
ATC code  
 Beta-2-adrenoreceptor agonists 
R03A Adrenergics, inhalants 
R03AC Selective beta-2-adrenoreceptor agonists 
R03AK Adrenergics and other drugs for obstructive airway diseases 
R03C Adrenergics for systemic use 
R03CC Selective beta-2-adrenoreceptor agonists 
R03B Other drugs for obstructive airway diseases, inhalants 
R03BB Anticholinergics 
 
Antiarrhythmics 
ATC code  
C01B Antiarrhythmics, class I and III 
C01BA Antiarrhythmics, class Ia 
C01BB Antiarrhythmics, class Ib 
C01BC Antiarrhythmics, class Ic 
C01BD Antiarrhythmics, class III 
 
Antihypertensives 
 
ACE Inhibitors 
ATC code  
C09 Agents acting on the renin-angiotensin system 
C09A ACE inhibitors, plain 
C09AA ACE inhibitors, plain 
C09B ACE inhibitors, combinations 
C09BA ACE inhibitors and diuretics 
C09BB ACE inhibitors and calcium channel blockers 
 
Angiotensin II antagonists 
ATC code  
C09 Agents acting on the renin-angiotensin system 
C09C Angiotensin II antagonists, plain 
C09CA Angiotensin II antagonists, plain 
C09D Angiotensin II antagonists, combinations 
C09DA Angiotensin II antagonists and diuretics 
C09DB Angiotensin II antagonists and calcium channel blockers 
C09DX Angiotensin II antagonists, other combinations 
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Beta blocking agents 
ATC code  
C07A Beta blocking agents 
C07AA Beta blocking agents, non-selective 
C07AB Beta blocking agents, selective 
C07AG Alpha and beta blocking agents 
C07B Beta blocking agents and thiazides 
C07BA Beta blocking agents, non-selective, and thiazides 
C07BB Beta blocking agents, selective, and thiazides 
C07BG Alpha and beta blocking agents and thiazides 
C07C Beta blocking agents and other diuretics 
C07CA Beta blocking agents, non-selective, and other diuretics 
C07CB Beta blocking agents, selective, and other diuretics 
C07CG Alpha and beta blocking agents and other diuretics 
C07D Beta blocking agents, thiazides and other diuretics 
C07DA Beta blocking agents, non-selective, thiazides and other diuretics 
C07DB Beta blocking agents, selective, thiazides and other diuretics 
C07F Beta blocking agents and other antihypertensives 
C07FA Beta blocking agents, non-selective, and other antihypertensives 
C07FB Beta blocking agents, selective, and other antihypertensives 
 
Calcium channel blockers 
ATC code  
C08 Agents acting on the renin-angiotensin system 
C08C Selective calcium channel blockers with mainly vascular effects 
C08CA Dihydropyridine derivatives 
C08CX Other selective calcium channel blockers with mainly vascular effects 
C08D Selective calcium channel blockers with direct cardiac effects 
C08DA Phenylalkylamine derivatives 
C08DB Benzothiazepine derivatives 
C08E Non-selective calcium channel blockers 
C08EA Phenylalkylamine derivatives 
C08EX Other non-selective calcium channel blockers 
C08G Calcium channel blockers and diuretics 
C08GA Calcium channel blockers and diuretics 
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Other antihypertensives 
ATC code  
C02A Antiadrenergic agents, centrally acting 
C02AA Rauwolfia alkaloids 
C02AB Methyldopa 
C02AC Imidazoline receptor agonists 
C02C Antiadrenergic agents, peripherally acting 
C02CA Alpha-adrenoreceptor antagonists 
C02CC Guanidine derivatives 
C02D Arteriolar smooth muscle, agents acting on 
C02DA Thiazide derivatives 
C02DB Hydrazinophthalazine derivatives 
C02DC Pyrimidine derivatives 
C02DD Nitroferricyanide derivatives 
C02DG Guanidine derivatives 
C02K Other non-selective calcium channel blockers 
C02KA Alkaloids, excluding rauwolfia 
C02KB Tyrosine hydroxylase inhibitors 
C02KC MAO inhibitors 
C02KD Serotonin antagonists 
C02KX Other antihypertensives 
C02L Calcium channel blockers and diuretics 
C02LA Rauwolfia alkaloids and diuretics in combination 
C02LB Methyldopa and diuretics in combination 
C02LC Imidazoline receptor agonists in combination with diuretics 
C02LE Alpha-adrenoreceptor antagonists and diuretics 
C02LF Guanidine derivatives and diuretics 
C02LG Hydrazinophthalazine derivatives and diuretics 
C02LK Alkaloids, excluding rauwolfia, in combination with diuretics 
C02LL MAO inhibitors and diuretics 
C02LN Serotonin antagonists and diuretics 
C02LX Other antihypertensives and diuretics 
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Diuretics 
ATC code  
C03A Low-ceiling diuretics, thiazides 
C03AA Thiazides, plain 
C03AB Thiazides and potassium in combination 
C03AH Thiazides, combinations with psycholeptics and/or analgesics 
C03AX Thiazides, combinations with other drugs 
C03B Low-ceiling diuretics, excluding thiazides 
C03BA Sulfonamides, plain 
C03BB Sulfonamides and potassium in combination 
C03BC Mercurial diuretics 
C03BD Xanthine derivatives 
C03BK Sulfonamides, combinations with other drugs 
C03BX Other low-ceiling diuretics 
C03C High-ceiling diuretics 
C03CA Sulfonamides, plain 
C03CB Sulfonamides and potassium in combination 
C03CC Aryloxyacetic acid derivatives 
C03CD Pyrazolone derivatives 
C03CX Other high-ceiling diuretics 
C03D Potassium-sparing agents 
C03DA Aldosterone antagonists 
C03DB Other potassium-sparing agents 
C03E Diuretics and potassium-sparing agents in combination 
C03EA Low-ceiling diuretics and potassium-sparing agents 
C03EB High-ceiling diuretics and potassium-sparing agents 
C03X Other diuretics 
C03XA Vasopressin antagonists 
 
Hormone replacement therapy 
ATC code  
G03C Estrogens 
G03CA Natural and semi synthetic estrogens, plain 
G03CX Other estrogens 
G03D Progestogens 
G03DA Pregnen-(4) derivatives 
G03DC Estren derivatives 
G03F Progestogens and estrogens in combination 
G03FA Progestogens and estrogens, fixed combinations 
G03FB Progestogens and estrogens, sequential preparations 
 
Thyroid hormones 
ATC code  
H03A Thyroid preparations 
H03AA Thyroid hormones 
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Anti-thyroid drugs 
ATC code  
H03B Antithyroid preparations 
H03BA Thiouracils 
H03BB Sulphur-containing imidazole derivatives 
H03BC Perchlorates 
H03BX Other antithyroid preparations 
 
Disease modifying anti-rheumatic drugs 
ATC code  
Gold  
M01CB03 Auranofin 
M01CB02 Sodium aurothiomalate 
Penicillamine  
M01CC01 Penicillamine 
Antimalarials  
P01BA01 Chloroquine 
P01BA02 Hydroxychloroquine sulphate 
Drugs affecting the immune response 
L04AX01 Azathioprine 
L04AD01 Cyclosporine 
L04AA13 Leflunomide 
L01BA01/L01AX03 Methotrexate 
Cytokine modulators 
L04AA24 Abatacept 
L04AB04 Adalimumab 
L04AC03 Anakinra 
L04AB01 Etanercept 
L04AB02 Infliximab 
L01XC02 Rituximab 
Sulfasalazine  
A07EC01 Sulfasalazine 
 
Thiazolidinediones 
ATC code  
A10BG Thiazolidinediones 
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Other antidiabetics 
ATC code  
A10A Insulins and analogues 
A10AB Insulins and analogues for injection, fast-acting 
A10AC Insulins and analogues for injection, intermediate-acting 
A10AD Insulins and analogues for injection, interm-acting combined with fast-acting 
A10AE Insulins and analogues for injection, long-acting 
A10AF Insulins and analogues for inhalation 
A10B Blood glucose lowering drugs, excluding insulins 
A10BA Biguanides 
A10BB Sulfonamides, urea derivatives 
A10BC Sulfonamides (heterocyclic) 
A10BD Combinations of oral blood glucose lowering drugs 
A10BF Alpha glucosidase inhibitors 
A10BH Dipeptidyl peptidase 4 (DPP-4) inhibitors 
A10BX Other blood glucose lowering drugs, excluding insulins 
A10X Other drugs used in diabetes 
A10XA Aldose reductase inhibitors 
 
Antiemetic (metoclopramide) 
ATC code  
A03F Propulsives 
A03FA Propulsives 
A03FA01 Metoclopramide 
 
Anticoagulants 
ATC code  
B01AA Vit K antagonist 
B01AB Heparin group 
 
Opioids (including morphine) 
ATC code  
N02A Opioids 
N02AA Natural opium alkaloids 
N02AB Phenylpiperidine derivatives 
N02AC Diphenylpropylamine derivatives 
N02AD Benzomorphan derivatives 
N02AE Oripavine derivatives 
N02AF Morphinan derivatives 
N02AG Opioids in combination with antispasmodics 
N02AX Other opioids 
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Non-steroidal anti-inflammatory drugs 
ATC code  
M01A 
http://www.whocc.no/atc_ddd_index/?code=M01A 
ANTIINFLAMMATORY AND 
ANTIRHEUMATIC PRODUCTS, NON-
STEROIDS 
M01AA Butylpyrazolidines 
M01AB Acetic acid derivatives and related 
substances 
M01AC Oxicams 
M01AE Propionic acid derivatives 
M01AG Fenamates 
M01AH Coxibs 
M01AX Other antiinflammatory and 
antirheumatic agents, non-steroids 
 
Statins 
ATC code  
C10AA01  simvastatin  
C10AA02  lovastatin  
C10AA03  pravastatin  
C10AA04  fluvastatin  
C10AA05  atorvastatin  
C10AA06  cerivastatin  
C10AA07  rosuvastatin  
C10AA08  pitavastatin  
 
Proton pump inhibitors 
ATC code  
A02BC01 omeprazole  
A02BC02 pantoprazole  
A02BC03  lansoprazole  
A02BC04 rabeprazole  
A02BC05 esomeprazole  
 
Aromatase inhibitors 
ATC code  
L02BG Enzyme inhibitors 
L02BG01   aminoglutethimide 
L02BG02   formestane 
L02BG03   anastrozole 
L02BG04   letrozole 
L02BG05   vorozole 
L02BG06   exemestane 
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4) Other diseases associated with fractures 
ICPC codes  
B80 Iron Deficiency anaemia 
B81 Anaemia, Vitamin B12/folate def 
B82 Anemia other inespecify 
N07 Convulsion/seizure 
N88 Epilepsy 
A06 Syncope 
K74 Ischaemic heart disease with angina 
K75 Acute Myocardial Infarction 
K76 Ischaemic heart disease without angina 
K90 Stroke/Cerebrovascular accident 
K91 Cerebrovascular Disease 
A79 Malignancy NOS 
B72 Hodgkin’s disease/lymphoma 
B73 Leukaemia 
B74 Malignant neoplasm blood other 
D74 Malignant neoplasm stomach 
D75 Malignant neoplasm colon/rectum 
D76 Malignant neoplasm pancreas 
D77 Malignant neoplasm digest other/NOS 
F74 Neoplasm of the eye/adnexa 
H75 Neoplasm of ear 
K72 Neoplasm cardiovascular 
L71 Malignant neoplasm musculoskeletal 
N74 Malignant neoplasm nervous system 
R84 Malignant neoplasm bronchus/lung 
R85 Malignant neoplasm respiratory, other 
S77 Malignant neoplasm of the skin 
T71 Malignant neoplasm thyroid 
U75 Malignant neoplasm of kidney 
U76 Malignant neoplasm of bladder 
U77 Malignant neoplasm urinary other 
W72 Malignant neoplasm relate to pregnancy 
X75 Malignant neoplasm cervix 
X76 Malignant neoplasm breast female 
X77 Malignant neoplasm genital other (f) 
Y77 Malignant neoplasm prostate 
Y78 Malignant neoplasm male genital other 
D94 Chronic enteritis/Ulcerative colitis 
R79 (old R91) Chronic bronchitis 
R95 Emphysema/chronic obstructive pulmonary disease 
D97 Liver disease NOS 
P71 Organic psychosis other 
P72 Schizophrenia 
P73 Affective psychosis (excluding depression) 
P80 Personality disorder 
P98 Psychosis nos/other 
P99 Psychological disorders other 
P70 Dementia 
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APPENDIX C 
Additional tables from descriptive studies 
Table A1- Incidence of hip/femur fracture by sex and age for 2008 in 
different databases (per 10,000 py) 
 
MALES BIFAP CPRD NPCRD AHC THIN DKMA BAVARIAN 
0-9 2.71 2.53 4.10 4.90 2.48 0  
10-19 1.78 1.97 1.02 5.55 1.99 0.68 5.28* 
20-29 1.21 1.69 3.19 2.21 1.62 0.77 3.78 
30-39 1.47 1.04 0.00 1.92 0.80 0.71 3.48 
40-49 2.95 1.96 1.59 4.76 1.62 2.64 5.19 
50-59 4.21 2.90 2.61 4.11 3.26 7.07 8.11 
60-69 6.29 5.73 4.26 2.15 5.22 13.66 13.58 
70-79 17.82 16.73 9.93 22.70 15.65 41.06 23.53 
80+ 67.55 61.82 43.72 89.84 61.62 170.72 70.29 
        
FEMALES BIFAP CPRD NPCRD AHC THIN DKMA BAVARIAN 
0-9 1.18 1.61 2.19 2.06 1.15 0.06  
10-19 0.66 0.74 0.00 1.99 0.46 0.46 2.80* 
20-29 1.11 0.30 1.01 2.14 0.30 0.22 1.65 
30-39 0.85 0.65 0.00 0.87 0.47 0.26 1.76 
40-49 1.99 1.10 1.56 1.54 1.22 1.45 2.90 
50-59 3.16 3.87 6.01 5.44 3.95 7.43 7.17 
60-69 9.75 8.73 7.76 2.17 9.01 19.71 15.95 
70-79 45.76 33.80 32.94 25.81 37.24 72.97 45.98 
80+ 160.27 133.34 91.86 101.01 124.67 284.92 145.93 
        
* Data grouped from 0-19 years 
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Table A2- IRs and time trends: general population in all databases 
 2003 2004 2005 2006 2007 2008 2009 Slope (95% CI) V# 
BIFAP          
No. fractures 1,503 1,847 1,871 1,805 1,745 1,498 1,137 -  
Person-years 1,397,047 1,742,682 1,840,894 1,776,966 1,680,082 1,416,105 1,091,342 -  
IR per 10,000py 10.76 10.60 10.16 10.16 10.39 10.58 10.42 -0.03 (-0.15, 0.09) (-) 0.3 
Standardized IR 11.04 10.85 10.39 10.42 10.52 10.68 10.37 -0.08 (-0.18, 0.02) (-) 0.7 
CPRD          
No. fractures 3,147 3,375 3,465 3,611 3,629 3,677 3,600 -  
Person-years  3,640,845 3,847,614 3,932,917 3,972,745 3,901,072 3,830,411 3,640,820 -  
IR per 10,000py 8.64 8.77 8.81 9.09 9.30 9.60 9.89 0.21 (0.16, 0.26)* 2.4 
Standardized IR 8.46 8.60 8.56 8.77 8.80 8.94 8.89 0.08 (0.05, 0.11)* 0.9 
THIN          
No. fractures 2,880 3,018 3,126 3,060 3,142 3,189 3,101   
Person-years  3,579,571 3,647,552 3,643,259 3,675,595 3,699,299 3,713,072 3,667,410   
IR per 10,000py  8.09 8.36 8.58 8.33 8.49 8.59 8.46 0.05 (-0.17, 0.12) 0.6 
Standardized IR 8.22 8.53 8.76 8.49 8.64 8.73 8.58 0.05 (-0.03, 0.13) 0.6 
AHC          
No. fractures 55 55 78 65 65 77 -   
Person-years  106,545 114,024 120,932 127,565 133,824 142,231 -   
IR per 10,000py  5.16 4.82 6.45 5.10 4.86 5.41 - 0.00 (-0.45, 0.45) 0.0 
Standardized IR 10.27 9.01 12.71 10.11 8.48 8.80 - -0.33 (-1.39, 0.73) (-) 3.2 
NPCRD          
No. fractures 196 113 84 90 137 119 88   
Person-years  272,655 173,315 164,399 135,386 192,507 154,675 11,4214   
IR per 10,000py  7.19 6.52 5.11 6.65 7.12 7.69 7.70 0.21 (-0.20, 0.62) 2.9 
Standardized IR 6.77 6.05 4.64 5.85 5.84 7.24 7.16 0.17 (-0.28, 0.62) 2.5 
DKMA          
No. fractures 9,316 9,568 9,477 9,291 9,180 9,296 9,113   
Person-years  5,207,838 5,223,111 5,209,669 5,210,109 5,209,064 5,222,891 5,207,078   
IR per 10,000py  17.89 18.32 18.19 17.83 17.62 17.80 17.50 -0.10 (-0.20, 0.01) (-) 0.6 
Standardized IR 19.60 19.93 19.62 19.04 18.68 18.68 18.25 -0.27 (-0.38, -0.15)* (-) 1.4 
BAVARIAN          
No. fractures - - - 15,196 13,997 15,154 - - - 
Person-years$  - - - 10,387,207 10,395,597 10,415,393 - - - 
IR per 10,000py  - - - 14.63 13.46 14.55 - - - 
Standardized IR - - - 13.39 12.13 12.91 - - - 
95% CI: Confidence Interval; * p < 0.05 ; V
#  
% Variation: (Slope/2003 IR)*100 
$  
Incidence per 10,000 Insured persons in BAVARIAN, not enough data to assess time trends   
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Figure A1- Trends over the study period of sex and age-specific 
Note that the scale used in the y-axis has been accommodated to better observed the trends and vary by 
age groups.  
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APPENDIX D 
Additional tables from cohort study 
Table A3- Adjusted HRs of hip/femur fracture 
COHORT Model "A" Model "B" Model "C" 
  HR (95%)CI HR (95%)CI HR (95%)CI 
PAST 1 - - 1 - - 1 - - 
RECENT 1.36 1.19 1.56 1.35 1.18 1.55 1.35 1.18 1.55 
CURRENT 1.37 1.25 1.49 1.35 1.23 1.47 1.34 1.23 1.46 
By Duration 
Current 0-30d 1.12 0.96 1.32 1.08 0.92 1.27 1.07 0.91 1.26 
Current 31-60d 1.26 1.07 1.48 1.21 1.03 1.43 1.20 1.02 1.42 
Current 61-180d 1.24 1.07 1.42 1.19 1.04 1.37 1.18 1.03 1.36 
Current 181-365d 1.52 1.30 1.76 1.50 1.28 1.74 1.49 1.28 1.74 
Current >365 1.55 1.39 1.73 1.55 1.39 1.74 1.55 1.39 1.73 
Type of BZD by ATC 
         Current both 1.59 1.34 1.88 1.56 1.32 1.85 1.56 1.31 1.84 
Single use of anxiolytics 1.34 1.22 1.47 1.32 1.20 1.45 1.31 1.19 1.44 
Single use of hypnotics 1.36 1.18 1.55 1.33 1.16 1.53 1.33 1.16 1.52 
By Individual drugs 
         
Anxiolytics (N05BA) 1.36 1.24 1.50 1.34 1.22 1.48 1.34 1.21 1.47 
Lorazepam 1.55 1.39 1.75 1.52 1.35 1.71 1.51 1.35 1.70 
Bromazepam 1.08 0.92 1.28 1.08 0.91 1.27 1.07 0.91 1.26 
Diazepam 1.33 1.07 1.65 1.33 1.07 1.65 1.32 1.06 1.64 
Alprazolam 1.27 0.97 1.67 1.27 0.97 1.67 1.26 0.96 1.65 
Others  1.25 0.97 1.61 1.24 0.96 1.59 1.23 0.96 1.58 
Hypnotics (N05CD) 1.34 1.13 1.58 1.32 1.12 1.57 1.32 1.11 1.56 
Lormetazepam 1.45 1.22 1.73 1.43 1.20 1.70 1.43 1.20 1.70 
Flurazepam 0.80 0.26 2.48 0.80 0.26 2.49 0.80 0.26 2.48 
Loprazolam 0.42 0.13 1.29 0.42 0.14 1.31 0.42 0.13 1.29 
Others  1.06 0.57 1.98 1.04 0.56 1.94 1.04 0.56 1.94 
Hypnotics (N05CF) 1.07 0.82 1.39 1.07 0.82 1.40 1.07 0.82 1.39 
Zolpidem 1.17 0.89 1.52 1.17 0.89 1.53 1.17 0.89 1.52 
Others     0.19 0.03 1.33 0.19 0.03 1.33 0.19 0.03 1.32 
Other N05CM02 2.21 1.68 2.92 2.03 1.54 2.69 2.04 1.54 2.70 
By Half-life 
         Short  <8h 1.38 1.14 1.67 1.35 1.11 1.63 1.34 1.11 1.62 
Intermediate 8-24h 1.37 1.25 1.51 1.35 1.23 1.49 1.35 1.22 1.48 
Long  >24h 1.29 1.08 1.54 1.28 1.07 1.53 1.27 1.06 1.52 
By Dose (last prescription) 
Low dose (< 1DDD) 1.39 1.25 1.54 1.37 1.23 1.52 1.36 1.23 1.51 
Medium dose (=1DDD) 1.17 0.98 1.41 1.17 0.97 1.40 1.16 0.97 1.39 
High dose (>1DDD) 1.73 1.37 2.19 1.71 1.35 2.17 1.71 1.35 2.16 
Missing 1.33 1.16 1.52 1.31 1.14 1.50 1.30 1.13 1.49 
Model "A" : adjusted analysis by age and sex; Model "B": adjusted analysis by model A plus well known risk factors 
for fracture such as previous fractures, glucocorticoids use, rheumatoid arthritis and lifestyle factors (bmi, smoking, 
alcohol abuse); Model" C": adjusted analysis adding to model B risk factors immediately related to the outcome such 
as osteoporosis, Paget´s disease, biphosphonate, raloxifene, strontium ranelate, parathyroid hormone, vitamin D 
and analogues and calcitonin use. 
  
 
Table A4- HRs of hip fractures by doses at first and last prescription and by anxiolytics and hypnotics 
COHORT Model "Age" Model "A" Model "B" Model "C" Full Model "D" 
  HR (95%)CI HR (95%)CI HR (95%)CI HR (95%)CI HR (95%)CI 
By Dose (last Rx                               
Low dose (< 1DDD) 1.42 1.28 1.57 1.39 1.25 1.54 1.37 1.23 1.52 1.36 1.23 1.51 1.21 1.09 1.35 
Medium dose (=1DDD) 1.19 0.99 1.42 1.17 0.98 1.41 1.17 0.97 1.4 1.16 0.97 1.39 1.06 0.89 1.28 
High dose (>1DDD) 1.75 1.38 2.21 1.73 1.37 2.19 1.71 1.35 2.17 1.71 1.35 2.16 1.42 1.12 1.80 
Missing 1.35 1.17 1.55 1.33 1.16 1.52 1.31 1.14 1.5 1.3 1.13 1.49 1.18 1.03 1.35 
By Dose only anxiolytic (last Rx)                               
 Low dose (< 1DDD) 1.36 1.22 1.52 1.33 1.20 1.48 1.32 1.18 1.47 1.31 1.18 1.46 1.18 1.06 1.32 
 Medium dose (=1DDD) 1.86 1.32 2.61 1.82 1.30 2.55 1.82 1.30 2.55 1.80 1.29 2.53 1.53 1.09 2.15 
 Hight dose (>1DDD) 2.23 1.60 3.09 2.18 1.57 3.03 2.13 1.53 2.97 2.12 1.53 2.95 1.59 1.14 2.21 
Missing 1.31 1.12 1.53 1.29 1.10 1.50 1.27 1.09 1.48 1.26 1.08 1.47 1.16 0.99 1.35 
By Dose only hypnotic (last Rx)                               
 Low dose (< 1DDD) 2.15 1.67 2.75 2.16 1.69 2.77 2.04 1.59 2.61 2.04 1.59 2.61 1.52 1.17 1.98 
 Medium dose (=1DDD) 1.06 0.86 1.30 1.04 0.85 1.29 1.04 0.84 1.28 1.03 0.84 1.27 0.96 0.78 1.18 
 Hight dose (>1DDD) 1.46 1.06 2.01 1.45 1.05 2.00 1.45 1.05 2.00 1.45 1.05 2.00 1.29 0.94 1.78 
Missing 1.46 1.14 1.86 1.46 1.14 1.86 1.43 1.12 1.83 1.42 1.12 1.82 1.26 0.98 1.60 
By Dose (1st Rx)                               
 Low dose (< 1DDD) 1.42 1.28 1.58 1.39 1.26 1.55 1.37 1.24 1.52 1.37 1.23 1.52 1.21 1.09 1.35 
 Medium dose (=1DDD) 1.19 0.99 1.42 1.17 0.98 1.41 1.17 0.97 1.40 1.16 0.97 1.39 1.06 0.89 1.28 
 Hight dose (>1DDD) 1.72 1.36 2.19 1.70 1.34 2.16 1.68 1.32 2.14 1.68 1.32 2.13 1.39 1.09 1.77 
Missing 1.35 1.17 1.55 1.33 1.16 1.52 1.31 1.14 1.50 1.30 1.13 1.49 1.18 1.03 1.35 
By Dose only anxiolytic  (1st Rx)                               
 Low dose (< 1DDD) 1.37 1.23 1.52 1.34 1.20 1.49 1.32 1.19 1.47 1.31 1.18 1.46 1.19 1.07 1.33 
 Medium dose (=1DDD) 1.80 1.28 2.54 1.76 1.25 2.48 1.76 1.25 2.49 1.75 1.24 2.47 1.48 1.05 2.09 
 Hight dose (>1DDD) 2.18 1.56 3.05 2.14 1.53 2.99 2.09 1.50 2.92 2.08 1.49 2.91 1.56 1.11 2.18 
Missing 1.31 1.12 1.53 1.29 1.10 1.50 1.27 1.09 1.48 1.26 1.08 1.47 1.16 0.99 1.35 
By Dose only hypnotic  (1st Rx)                               
 Low dose (< 1DDD) 2.14 1.67 2.75 2.16 1.68 2.77 2.03 1.58 2.61 2.03 1.58 2.61 1.52 1.17 1.97 
 Medium dose (=1DDD) 1.07 0.87 1.31 1.06 0.86 1.30 1.05 0.85 1.29 1.05 0.85 1.29 0.97 0.79 1.20 
 Hight dose (>1DDD) 1.43 1.03 1.99 1.42 1.02 1.97 1.42 1.02 1.97 1.42 1.02 1.97 1.26 0.91 1.76 
Missing 1.46 1.14 1.86 1.46 1.14 1.86 1.43 1.12 1.83 1.42 1.12 1.82 1.26 0.98 1.60 
Rx= Prescription 
  
Table A5- HRs by half-life in anxiolytics and hypnotics separately 
COHORT Model "Age" Model "A" Model "B" Model "C" Full Model "D" 
  HR (95%)CI HR (95%)CI HR (95%)CI HR (95%)CI HR (95%)CI 
By Half-life                               
 Short <8h 1.38 1.14 1.66 1.38 1.14 1.67 1.35 1.11 1.63 1.34 1.11 1.62 1.09 0.90 1.32 
 Intermediate 8-24h 1.40 1.27 1.54 1.37 1.25 1.51 1.35 1.23 1.49 1.35 1.22 1.48 1.22 1.10 1.34 
 Long >24h 1.31 1.10 1.57 1.29 1.08 1.54 1.28 1.07 1.53 1.27 1.06 1.52 1.16 0.97 1.39 
By Half-life only 
anxiolytic                               
 Short <8h 1.12 0.46 2.69 1.09 0.45 2.64 1.10 0.46 2.66 0.81 0.33 1.95 0.80 0.33 1.94 
 Intermediate 8-24h 1.40 1.27 1.55 1.37 1.24 1.52 1.35 1.22 1.50 1.00 0.87 1.15 0.96 0.83 1.11 
 Long >24h 1.33 1.11 1.60 1.31 1.09 1.57 1.30 1.09 1.56 0.96 0.78 1.18 0.94 0.76 1.15 
By Half-life only 
hypnotic                               
 Short <8h 1.39 1.15 1.69 1.39 1.15 1.69 1.36 1.12 1.65 1.01 0.81 1.25 0.87 0.70 1.08 
 Intermediate 8-24h 1.38 1.17 1.65 1.37 1.15 1.63 1.35 1.14 1.61 1.00 0.82 1.22 1.00 0.82 1.22 
 Long >24h 0.76 0.25 2.37 0.76 0.25 2.37 0.76 0.25 2.37 0.56 0.18 1.76 0.56 0.18 1.74 
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APPENDIX E 
Additional tables from the NCC study 
Table A6- Model B and C with risk estimates of hip/femur fracture 
associated with BZD, and by duration and type of ATC group 
NCC Model B Model C 
  OR  (95%CI) OR  (95%CI) 
Past use (ref.) 1   1   
Recent use 1.28 1.16-1.42 1.28 1.16-1.42 
Current use 1.36 1.15-1.60 1.35 1.15-1.60 
By Duration         
Current 0-30d 1.1 0.88-1.36 1.09 0.88-1.36 
Current 31-60d 1.27 1.03-1.57 1.27 1.02-1.57 
Current 61-182d 1.18 1.00-1.39 1.18 1.00-1.39 
Current 183-365 1.48 1.24-1.76 1.48 1.24-1.77 
Current >365d 1.32 1.16-1.51 1.31 1.15-1.50 
By ATC drug         
Use of both 1.82 1.49-2.22 1.82 1.49-2.23 
Anxiolytics 1.22 1.09-1.36 1.22 1.09-1.36 
Hypnotics 1.26 1.08-1.48 1.27 1.08-1.48 
 
Model "B": adjusted by well known risk factors for fracture such as previous fractures, glucocorticoids 
use, rheumatoid arthritis and lifestyle factors (bmi, smoking, alcohol abuse); Model" C": adjusted 
analysis adding to model B risk factors immediately related to the outcome such as osteoporosis, Paget´s 
disease, biphosphonate, raloxifene, strontium ranelate, parathyroid hormone, vitamin D and analogues 
and calcitonin use. 
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Table A7- Sensitivity analysis. Model B and C with risk estimates of 
hip/femur fracture associated with BZD, by duration and type of ATC 
NCC Sensitivity analysis Model B Model C 
  OR  (95%CI) OR  (95%CI) 
Past use (ref.) 1   1   
Recent use 1.28 1.16-1.42 1.28 1.16-1.42 
Current use 1.36 1.15-1.61 1.36 1.15-1.60 
By Duration         
Current 0-30d 1.1 0.88-1.36 1.1 0.88-1.36 
Current 31-60d 1.27 1.03-1.57 1.27 1.03-1.58 
Current 61-182d 1.18 1.00-1.39 1.18 1.00-1.40 
Current 183-365 1.48 1.24-1.77 1.49 1.24-1.78 
Current >365d 1.32 1.16-1.51 1.32 1.15-1.50 
By ATC drug         
Use of both 1.83 1.50-2.24 1.83 1.50-2.25 
Anxiolytics 1.22 1.09-1.36 1.22 1.09-1.36 
Hypnotics 1.26 1.08-1.47 1.27 1.08-1.48 
 
Sensitivity Analysis: Full model but co-medication variables were measured at 30 days from index date. 
Model "B": adjusted by well known risk factors for fracture such as previous fractures, glucocorticoids 
use, rheumatoid arthritis and lifestyle factors (bmi, smoking, alcohol abuse); Model" C": adjusted 
analysis adding to model B risk factors immediately related to the outcome such as osteoporosis, Paget´s 
disease, biphosphonate, raloxifene, strontium ranelate, parathyroid hormone, vitamin D and analogues 
and calcitonin use. 
 
  
 
APPENDIX F 
Additional tables from the CXO study 
Table A8- Risk estimates of hip/femur fracture associated with BZD use, and type of BZD by ATC 
 CXO 
Cases date 
N(%) 
Contr. Date1 
N(%)  
Contr. Date2 
N(%) 
Contr. Date3  
N(%) 
Contr. Date4 
N(%) 
∑control 1-4 
N(%) 
Crude
OR 
95% CI AOR 95% CI 
Non use/past 2,493(46.1) 2,607(48.2) 2,524(49.1) 2,459(50.5) 2,338(50.8) 9,928(49.6) 1.00   1.00   
Recent use 367(6.8) 259(4.8) 268(5.2) 234(4.8) 259(5.6) 1,020(5.1) 1.88 1,62-2,18 1.69 1,46-1,97 
Current use 2,552(47.2) 2,546(47.0) 2,353(45.7) 2,180(44.7) 2,002(43.5) 9,081(45.3) 1.70 1,50-1,92 1.47 1,29-1,67 
Type of BZD used 
Both 750(29.4) 715(28.1) 659(28.0) 615(28.2) 568(28.4) 2,557(28.2) 3.62 2,77-4,75 3.03 2,30-4,00 
Anxiolytics 1,449(56.8) 1,495(58.7) 1,388(59.0) 1,293(59.3) 1,171(58.5) 5,347(58.9) 1.42 1,23-1,63 1.24 1,07-1,43 
Hypnotics 353(13.8) 336(13.2) 306(13.0) 272(12.5) 263(13.1) 1,177(13.0) 2.09 1,64-2,67 1.82 1,42-2,33 
AOR-adjusted for all co-medication 
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APPENDIX G 
Additional tables from the SCCS study 
Table A9- IRRs of hip/femur fracture with pre-exposure time risk window 
of 15 days 
 
 
Model Crude Model Adjusted by age 
Exposure   Cases Py IRR IC(95%)  IRR IC(95%)  
Past/non use 2,066 5,051,344 1.00     1.00     
Pre-Exposure 15d 646 187,471 9.28 8.43 10.23 8.32 7.54 9.17 
Current 1-30d 213 409,985 1.43 1.23 1.65 1.26 1.09 1.46 
Current 31-60d 201 362,943 1.53 1.32 1.78 1.35 1.16 1.57 
Current 61-182d 314 614,880 1.47 1.29 1.68 1.24 1.08 1.41 
Current 183-365d 246 437,601 1.76 1.51 2.04 1.38 1.18 1.60 
Current >365d 569 1,120,123 2.03 1.77 2.33 1.26 1.08 1.47 
Recent use 195 407,761 1.28 1.10 1.49 1.13 0.97 1.32 
Current use 1,543 2,945,532 1.60 1.47 1.74 1.29 1.18 1.41 
Type of BZD by ATC  
Use of Both 187 314,002 2.33 1.86 2.91 1.71 1.35 2.16 
Use of Anxiolytics 1,023 1,985,997 1.58 1.43 1.75 1.31 1.18 1.45 
Use of Hypnotics 333 645,533 1.47 1.26 1.72 1.15 0.98 1.35 
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Table A10- IRRs of hip/femur fracture with pre-exposure time risk window 
of 30 days 
      Model Crude Model Adjusted by age 
Exposure   Cases Py IRR IC(95%)  IRR IC(95%)  
Past/non use 1,898 4,941,761 1.00     1.00     
Pre-Exposure 30d 837 343,657 7.17 6.55 7.84 6.47 5.91 7.09 
Current 1-30d 213 409,985 1.58 1.36 1.83 1.40 1.21 1.62 
Current 31-60d 201 362,943 1.69 1.45 1.97 1.49 1.28 1.74 
Current 61-182d 314 614,880 1.63 1.43 1.86 1.37 1.20 1.57 
Current 183-365d 246 437,601 1.95 1.68 2.27 1.53 1.32 1.79 
Current >365d 569 1,120,123 2.27 1.97 2.60 1.42 1.22 1.65 
Recent use 172 361,158 1.37 1.16 1.60 1.21 1.03 1.42 
Current use 1,543 2,945,532 1.77 1.62 1.93 1.43 1.31 1.57 
Type of BZD by ATC  
Use of Both 187 314,002 2.59 2.07 3.23 1.91 1.51 2.42 
Use of Anxiolytics 1,023 1,985,997 1.76 1.59 1.94 1.45 1.31 1.61 
Use of Hypnotics 333 645,533 1.62 1.39 1.90 1.28 1.09 1.50 
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Table A11- IRRs of hip/femur fracture with pre-exposure time risk window 
of 60 days 
      Model Crude Model Adjusted by age 
Exposure   Cases Py IRR IC(95%) IRR IC(95%) 
Past/non use 1,706 4,744,140 1.00     1.00     
Pre-Exposure 60d 1,059 599,271 5.57 5.11 6.06 5.06 4.64 5.52 
Current 1-30d 213 409,985 1.72 1.48 2.00 1.52 1.31 1.77 
Current 31-60d 201 362,943 1.85 1.59 2.15 1.62 1.39 1.89 
Current 61-182d 314 614,880 1.78 1.56 2.03 1.49 1.30 1.71 
Current 183-365d 246 437,601 2.13 1.83 2.48 1.67 1.43 1.95 
Current >365d 569 1,120,123 2.48 2.16 2.86 1.55 1.33 1.81 
Recent use 142 303,165 1.41 1.18 1.68 1.25 1.05 1.49 
Current use 1,543 2,945,532 1.94 1.77 2.12 1.56 1.42 1.72 
Type of BZD by ATC 
Use of Both 187 314,002 2.85 2.28 3.56 2.10 1.66 2.66 
Use of Anxiolytics 1,023 1,985,997 1.92 1.73 2.12 1.58 1.42 1.76 
Use of Hypnotics 333 645,533 1.77 1.51 2.07 1.39 1.18 1.63 
 
 
